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Message from the President
Dear Colleague
It has been a great honour to represent my profession and colleagues as President of
the Irish Pharmacy Union over the past two years.
I would like to thank all of you for your support and my hope is that, with the
implementation of the Strategy Review Report, we can maintain our unity of
purpose, which is essential in these rapidly changing times.
We have had four separate briefing sessions for members over the past twelve
months to ensure that you were fully informed of the changes that happened and
their implications for our profession and business.
The Union’s Committees have worked extremely hard on your behalf and are
continuing to improve our communications and ensuring that your views are fully
reflected in Union policies and activities.
The great strength of the Union is that it belongs to you and its only role is to
promote and advance your interests through the strategies agreed by your elected representatives on national committees.
No sector or grouping controls the Union’s agenda, which is developed in the best interests of the profession as a whole
and all those involved in the business of pharmacy.
As I hand over the chain of office, I think it is vital that we all strengthen our resolve to face the changes and challenges
that lie ahead.
Finally, I would like to thank all the committee members for their enormous input over the past two years. I would
especially like to thank Darragh O’Loughlin, Vice-President and Dermot Twomey, Honorary Treasurer who have worked
tirelessly on your behalf. I would also like to acknowledge the professionalism and dedication, often well beyond the call of
duty, of the staff of the Union.
Liz Hoctor MPSI
Liz Hoctor, President, IPU
Darragh O’Loughlin, Vice-President, IPU Dermot Twomey, Hon. Treasurer, IPU
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PRESIDENT: LIZ HOCTOR
VICE-PRESIDENT: DARRAGH O’LOUGHLIN
HONORARY TREASURER: DERMOT TWOMEY
REGIONAL REPRESENTATIVES (8)
Peter Finnegan.......................................East
Damien Conaty ......................................North East
Joe Britton ..............................................North West
Tadhg O’Leary ........................................South
Niall Mulligan ........................................South East
Michelle Concannon .............................Midland
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David Carroll
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PAST PRESIDENT
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CO-OPTIONS
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NB: Up to five members may be co-opted by the Executive Committee
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Financial Statements
Irish Pharmacy Union
Financial Reports and Accounts 
for Year Ended 31 December 2009
In accordance with the Constitution of the Union, the Executive Committee submits the audited
accounts for consideration by members.
The full details of the Accounts have been circulated to members with the Summary of the 2010
Annual Report of the IPU Executive Committee.
If the Accounts are approved by the meeting after their presentation, members will be asked to
formally adopt the Accounts for the year ended 31 December 2009 and agree the election of
Auditors. In this context, the following motions will be put to the meeting: 
1. “That the Executive Committee Report and Audited Statement of Accounts of the Irish Pharmacy
Union for the year ended 31 December 2009 as submitted to this meeting, be and are hereby adopted.”
2. “That this meeting agrees to the election of Baker Tilly Ryan Glennon for a further two-year
period as Auditors for the IPU and IPU Services Ltd.”
Membership Subscriptions:
Members will be asked to approve no change to the annual subscription payable by all categories
of membership, pending the completion of the work of the Group established to review the
funding of the Union.
IPU Services Limited
Financial Reports and Accounts 
for Year Ended 31 December 2009
At this Annual General Meeting of IPU Services Ltd, members are asked to consider the Report of
the Directors and the Auditors’ Report on the Accounts.
The accounts and financial reports have been circulated to all members.
If the Accounts are approved, members will be asked to resolve, “That the Directors’ Report and
Audited Statement of Accounts for the year ended 31 December 2009 as submitted to this meeting,
be and are hereby adopted.”
Minutes of the 36th Annual General Meeting
of the Irish Pharmacy Union and IPU Services Ltd
Faithlegg, Co Waterford
25 April 2009
Present: 
The President, Ms Liz Hoctor, and 54 members.
In Attendance:
Mr Seamus Feely, Ms Ciara Enright, Ms Kate Healy, Ms Jill Lyons, Ms Roisin Molloy, Ms
Aoibheann Ní Shúilleabháin and Ms Wendy McGlashan.
Apologies:
Apologies were received from 73 members.
[A full report of the 2009 AGM is available from the IPU offices.]
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1. The President welcomed the attendance to the 36th
Annual General Meeting of the Irish Pharmacy Union.
2. On the proposal of the President all present stood in
silence in memory of deceased members including
Mr John Burke, Trustee of the Union, and all those
who had died since the 2008 AGM. 
3. Financial Reports and Accounts 2008
a. Dermot Twomey (Honorary Treasurer) presented the
Report. A motion approving the accounts was
proposed by Jack Shanahan, seconded by Ross
McEntegart, and carried. 
The motion was:
“That the Executive Committee Report and Audited
Statement of Accounts for the Irish Pharmacy Union
for the year ended 31 December 2008 as submitted to
this meeting be and are hereby adopted.”
b. The following motion was put to the meeting
proposed by Peter Harty, seconded by John Carey 
and carried:
“That this meeting agrees to the election of Baker Tilly
Ryan Glennon for a further two year period as auditors
for the IPU and IPU Services Ltd.”
c. It was announced that the Executive Committee had
agreed not to increase annual subscriptions for 2010
in light of current economic constraints.
4. IPU Services Ltd AGM
The minutes of the 2008 AGM were taken as read.
On the proposal of David O’Connell, seconded by
Peter Harty, it was resolved:
“That the Directors’ Report and Audited Statement of
Accounts for the year ended 31 December 2008 as
submitted to this meeting, be and are hereby adopted.”
This motion was carried.
5. Report of 35th AGM
The report of the 35th Annual General Meeting was
then approved as a true and accurate record. This was
proposed by Liz Hoctor, seconded by Darragh
O’Loughlin and signed by the President. The report
had been circulated to all members prior to the
meeting.
6. Report on Motions from 2008 AGM
The report on motions from the 35th Annual General
Meeting was taken as read.
7. President’s Address
Ms Liz Hoctor, President, addressed the meeting and
outlined the challenges that members now faced.
She thanked members and the staff of the Union for
their support during the year. 
8. Union Secretariat Report
The Union Secretariat Report was circulated to all
members as part of the Executive Committee report
prior to the meeting. The Secretary General, Mr
Seamus Feely, introduced the Report.
9. Group Reports
a. Pharmacy Contractors’ Committee (PCC) Report
This report was presented by Mr John Corr,
Chairman of the PCC. 
b. Community Pharmacy Committee (CPC) Report
This report was delivered by Mr Keith
O’Hourihane, Chairman of the Community
Pharmacy Committee.
c. Employee Pharmacists’ Committee (EPC) Report 
This report was presented by Mr Bernard
Duggan, Chairman of the Employee Pharmacists’
Committee. 
d. Public Relations Report 
This report was circulated in the Annual Report
and was taken as read. 
e. International Pharmacy Matters 
This report was circulated in the Annual Report
and was taken as read. 
10. Pensions Overview
This report was circulated in the Annual Report and
was taken as read.
11. Minister’s Review of Payments/Enactment of the
Financial Emergency Measures in the Public Interest
Act 2009
John Corr, Chairman of the Pharmacy Contractors’
Committee gave members an update on the
Minister’s Review of Payments under the Financial
Measures in the Public Interest Act 2009 (FEMPI).
12. 2009 AGM Motions
The 2009 Motions and action taken on them are on
Pages 8–10 of this report.
13. A.O.B
After the normal business of the AGM was
completed, the Executive Committee consented to
Eoghan Hanly, from Loughrea, raising the ongoing
problems with the administration in the HSE, the
recent move of infertility drugs from the Drugs
Payment Scheme to the High Tech Scheme without
the consent of the PCC, and his general lack of
confidence in the current health policy of the
Government. 
Marie Hogan expressed her dismay at the HSE’s
handling of the Over 70 medical card fiasco and the
distress that it was causing to many of her patients.
Eoghan Hanly then asked that a vote of no
confidence in the Government’s health policy be put
to the members.
The meeting unanimously passed a vote of no
confidence in the Government’s health policy. 
The President thanked all those who attended for
their participation and also thanked the Vice
President, Darragh O’Loughlin and Honorary
Treasurer, Dermot Twomey for the work they had
undertaken over the last year. The President also
thanked the Secretary General and staff of the IPU for
their hard work and especially Wendy McGlashan for
arranging the Annual General Meeting.
2009 AGM MOTIONS AND REPORT ON
ACTION TAKEN
The following motions, proposed in accordance with
Article 29 of the Constitution, were brought before
the 2009 AGM for consideration:
1. Proposed: Liz Hoctor
Seconded: Darragh O’Loughlin
“That this AGM appoints John Carey to be Trustee of
the Irish Pharmacy Union in accordance with Article 24
of the Union’s Constitution”
This motion was carried unanimously. 
2. Proposed: Liz Hoctor
Seconded: Darragh O’Loughlin
“That this AGM condemns the manner in which
pharmacy payments were recently reviewed and calls
on all members of the Oireachtas to repeal Section 9
of the Financial Emergency Measures in the Public
Interest Act 2009 to protect patient care, to preserve
front line pharmacy services and maintain jobs.”
This motion was carried unanimously
Action: The Union made numerous representations to
politicians from all parties, including cabinet
ministers and opposition spokespersons, on the
draconian nature of Section 9 of the Financial
Emergency Measures in the Public Interest Act 2009
(FEMPI) and called for its repeal at the earliest
opportunity. The Union also highlighted that the cuts
in pharmacy payments would have negative
implications for patient care, pharmacy services and
employment in the sector. 
However, on 1 July the Minister implemented the cuts
under Section 9 of the FEMPI. A legal challenge
against this Act was taken in July 2009. This case was
heard over two weeks in November. In December
2009, Mr Justice McMahon ruled against the plaintiff,
Haire Pharmacy Group. In the High Court challenge,
the plaintiffs argued that the Financial Emergency
8
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Measures in the Public Interest Act 2009 was
unconstitutional and the cuts in payments were
unreasonable and disproportionate when compared
to the 8% cuts imposed on other healthcare
professionals. Evidence from two leading economists
was presented to the Court to support the plaintiff’s
case; however the Judge did not accept this evidence.
An Appeal has been served in this case but no date
has been fixed for a hearing of the appeal.
Despite the Courts finding the Pharmacy Contractors’
Committee (PCC) believes the cuts are unfair and, as
part of the Ministers Review in 2010, the PCC will be
producing evidence of the impact of the cuts on
pharmacies across Ireland. A recent PwC
questionnaire, unfortunately, confirmed the PCC belief
that pharmacy income has been reduced by 30%. This
equates to a reduction of €100,000, on average. 
3. Proposed: Ger Browne
Seconded: Sheila O’Malley
“That this AGM calls on the HSE and the Department
of Health and Children to work with the Union, in the
spirit of partnership, to address issues of mutual
concern and to develop a constructive working
relationship towards advancing the shared objective of
enhancing services to patients.”
This motion was carried unanimously 
Action: The Joint Consultative Group was established
in July 2008. As part of this Group, the Union and the
HSE agreed to cooperate in the areas of
modernisation, change and flexibility. The Group is
also a forum for discussion on matters of concern for
members. This Group met three times since the AGM.
Issues raised during the year with the HSE in this
forum include:
Arrears Payments – Payment of the Arrears from the
HSE was secured during 2009 
Hardship/Psychiatric Issues – Dealt with changes to
the Hardship Scheme/ Psychiatric Scheme and the
Union continue to follow up the retrospective
changes during the JCG
Problems with Pharmacy Claims – Dealt with
ongoing issues relating the pharmacy claims
HSE/IPU Charter – The Union tabled a HSE/IPU
Charter in July 2009. Such a Charter should ensure
that the effective and fair administration of the
Community Drugs Schemes requires the HSE PCRS,
Community Pharmacy Contractors and the IPU to
recognise certain basic rights and responsibilities and
to adhere to certain procedures. The purpose of this
Charter is to set out the standard of service that each
party should receive when dealing with each other
and the reasonable expectations that each party
should have of one another. 
All these meetings are constructive and the Union
continues to communicate with officials from the
HSE and the Department to address issues of mutual
concern on a daily and weekly basis.
4. Proposed: Keith O’Hourihane
Seconded: Rory O’Donnell
“That this AGM calls on the Government to utilise the
enormous potential of community pharmacies by
expanding the role of the pharmacist so that more
services are offered to patients through community
pharmacies which will benefit patients and deliver
savings to the Exchequer.”
The following amendment was then proposed by
Keith O’Hourihane and seconded by Rory O’Donnell
“That this AGM calls on the Government to utilise the
enormous potential of community pharmacies by
funding the expansion of the role of the pharmacist so
that more services are offered to patients through
community pharmacies which will benefit patients
and deliver savings to the Exchequer.”
The motion, as amended, proposed by Keith
O’Hourihane and seconded by Rory O’Donnell, was
carried. There were two votes against.
Action: The Community Pharmacy Committee has been
involved in a number of initiatives over the past year to
promote the expansion of the role of the pharmacist in
the development of national health policies.
The Union is participating in the HSE Pharmacy in
Primary Care Group which is initially looking at
pharmacist-led MURs for chronic diseases. They now
plan to run an MUR pilot in April/May with a view to
gathering evidence for the roll out of MURs nationally.
There are now 26 GP practices and 72 pharmacies
participating in the Asthma Management
Demonstration Project. The IPU and the Asthma
Society jointly launched a health promotion in March,
encouraging patients to ask their pharmacist about
inhaler technique. The promotion was highlighted
with a radio ad on 2FM and Today FM.
The Union met with Minister John Curran in January
to discuss the delay in the roll-out of the Needle
Exchange Scheme. Most details of the Scheme have
been agreed but the HSE has yet to agree on the fees
payable to pharmacists. 
The Union met with the Irish Cancer Society in
January to discuss ways in which community
pharmacists could provide support for ICS initiatives. 
The Union continues to participate in HIQA’s
Medication Safety Forum which, in 2010, will focus on
the development of a national prescription form,
development of SOPs for pharmacies, guidelines for
codeine medicines, the roll-out of the Asthma
Management Programme, the re-launch of PIP and
the management of patient discharge.
5. Proposed: Bernard Duggan
Seconded: Fearghal O’Nia
“That, in the wake of the recent cuts introduced under
the Financial Emergency Measures in the Public
Interest Act 2009, this AGM calls on the Government
to ensure future employment opportunities for the 170
pharmacists who qualify each year in Ireland and to
adequately support pharmacy students in their pre-
registration training year in order that they may
complete their training and begin practicing the
profession of pharmacy.” 
At the AGM Mr Duggan asked that the motion be
amended as follows:
“That, in anticipation of the cuts to be introduced
under the Financial Emergency Measures in the Public
Interest Act 2009, this AGM calls on the Government
to ensure future employment opportunities for the 170
pharmacists who qualify each year in Ireland and to
adequately support pharmacy students in their pre-
registration training year in order that they may
complete their training and begin practicing the
profession of pharmacy.” 
After much debate it was agreed to amend the
motion to “That, in anticipation of the cuts to be
introduced under the Financial Emergency Measures
in the Public Interest Act 2009, this AGM calls on the
Government to ensure future employment
opportunities for pharmacists who qualify each year
and to adequately support pharmacy students in
their pre-registration training year in order that they
may complete their training and begin practicing the
profession of pharmacy.” 
The amendment was proposed by Ross McEntegart
and seconded by Tom Murray and was carried by a
majority vote. There was one vote against. 
The motion, as amended, was proposed by Bernard
Duggan and seconded by Fearghal O’Nia and was
carried by a majority vote. There was one vote
against.
Action: The EPC identified a number of different
individuals and organisations with whom they could
communicate on the issues raised in the motion.
Initially the chairperson of the EPC wrote to the
Registrar of the Pharmaceutical Society of Ireland in
June 2009 to obtain their views on the issues raised
in the motion and to identify if the PSI had
undertaken any research into the current and future
manpower situation in the sector, the current
oversupply of pharmacy graduates and the future
employment prospects of pharmacy graduates.
The PSI acknowledged the letter in July 2009
indicating that the letter would be brought to the
attention of the PSI Professional Development and
Learning Committee. The Chairperson of the EPC
wrote a follow-up letter to the PSI in January 2010
seeking an update on the consideration of the matter
by the PSI. The PSI responded in January 2010
indicating that they would revert to the EPC shortly
with a summary of their deliberations.
The EPC undertook a survey of employee pharmacists
and newly registered pharmacists in order to obtain
information on their current employment conditions
and the effect that the reduction in payments to
community pharmacists has had on these.
=
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Union Secretariat Report
(b) NUMBER OF COMMUNITY PHARMACIES
Pharmacist Owned:
Single shops 759
Chains 582 1341
Non-Pharmacist Owned:
Single shops 62
Chains 153 251 (1556)
(c) TOTAL NUMBER OF CHAINS (2 AND OVER)
Pharmacist Non-Pharmacist
Two pharmacies 106 4 220
Three 36 1 111
Four 15 60
Five 5 25
Six 3 1 24
Seven 1 7
Eight 2 1 24
Nine 1 9
Ten 1 10
Eleven 1 11
Fourteen 1 14
Fifteen 1 15
Sixteen 1 16
Twenty 1 20
Twenty-Four 1 24
Twenty -Seven 1 27
Forty-Six 1 46
Seven-two 1 72
(582) (153) (735)
1. INTRODUCTION
The last twelve months have been dramatic; for the economy generally and for the profession and business of pharmacy.
It has been an extremely busy and challenging period for the Union. I would like to thank the outgoing President, Vice-
President, Treasurer and all Committee members for their efforts over the past two years and look forward to working
with the incoming Union Officers and Committees in supporting you and responding to your needs over the next twelve
months.
2. DETAILS OF IPU MEMBERSHIP AND PHARMACY OWNERSHIP (AS AT 31 MAR 2010)
(a) MEMBERSHIP OF THE IPU
Community Proprietors 878
Industry & Wholesale 7 
Community Employees 851
Hospital 9
Army, Academic & Admin 4
Associate Members 8 (1757)
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3. PRODUCT FILE UNIT
The IPU Product File is managed by Fiona Hannigan
and her team: Ger Gahan, Eilish Barrett and Aoife
Garrigan. As well as supplying price updates and
product information for members, they provide the
following services and advice: 
■ Product sourcing
■ General queries on the IPU Product File
■ GMS pricing issues
■ Short Supply & Discontinued Lists
The IPU also provides a Drug Interaction File and
information files on drug use in Pregnancy and
Breastfeeding, produced by the School of Pharmacy in
Trinity College Dublin, linked to the IPU Product File.
These are based on the ATC classification system and
are designed to warn pharmacists of the possibility of
an interaction. A PwC survey recently found the IPU file
to be highly regarded.
The following areas are a priority in the Product File
area during 2010
■ Enhancements to the Product File to cope with
Reference Pricing, PA/PPA/DPA/EMEA numbers,
verification of products, etc. 
■ Finalisation of a contract with Trinity College Dublin
for Drug Interactions, greater automation of Product
File processes. 
■ Roll out of IPU Live Download of the IPU Product File. 
■ Product File section for both public and members
section of the IPU Web Site. 
4. ADMINISTRATION UNIT
The Administration Unit has four staff members:
Patrice O’Connor, who works part-time, looks after
reception and assists in the day-to-day running of the
office; Ciara Enright, who works part-time, is Secretary
to the Finance Committee. She maintains books of
account and advises members on a range of taxation
and accountancy problems. Wendy McGlashan is
responsible for IPU publications, including the
production of the IPU Review and co-production of the
IPU Yearbook, event organisation, general
administration and personnel matters. Roisín Molloy is
responsible for all aspects of membership and the
management of the Secretary General’s office. 
5. CONTRACTUAL AND OTHER RELATED ISSUES 
Jill Lyons, Zuzanna Zwolan and Paul Fahey deal with a
wide range of contractual and IT issues. Jill and
Zuzanna have played a key role in developing many of
the key PCC initiatives throughout the year and in the
resolution of some problems with the Health Service
Executive, Primary Care Reimbursement Service and the
Department of Health & Children. Throughout 2009
they were involved in the Haire (FEMPI) Court Case, the
Advance Payments Appeal, the Joint Consultative Group
with the HSE and the Needle Exchange Group with the
HSE. Jill also represents the Union at the PGEU
Economic Working Group. Zuzanna deals with
remuneration queries, pharmacy security and stolen
and forged prescriptions. 
The Pharmacy Contractors’ Committee also made
submissions to the Department of Health and Children,
and the Health Service Executive since the last AGM on:
■ Irish Pharmacy Union Submission on a
Payment/Reimbursement Model for the Needle
Exchange Programme in October 2009 – HSE 
■ Submission on Reference Pricing to the DoHC
Reference Pricing Group chaired by Mark Moran in
March 2010 - DoHC 
6. MEDIA AND COMMUNICATIONS
Kate Healy is responsible for the promotion and
coordination of all national and regional media
coverage for the Union. She is secretary to the Executive
Committee and assists the Secretary General in the
development and coordination of all regulatory, policy
and political activities. She is responsible for the
editorial content of the IPU Review. Kate also manages
IPU advertising campaigns and the IPU website - both
content and editorial. Aoibheann Ní Shúilleabháin
works on advertising for the Review and the co-
ordination of all communications activities as well as
liaising with the regional committees.
7. PHARMACY SERVICES
The Director of Pharmacy Services, Pamela Logan, co-
ordinates all Professional, Business and Training matters
within the Union. Pamela acts as Secretary to CPC and
details of issues covered by this Committee can be
found in the CPC report. She works with relevant
departments and agencies, both nationally and
internationally, to promote the role of the pharmacist.
Pamela also represents the Union at ICCPE, PGEU, FIP
and Europharm Forum.
8. TRAINING DEPARTMENT 
Susan McManus, Training and HR Manager, organises
and co-ordinates a range of training courses for
pharmacy staff. Janice Burke assists Susan in this
department. The Pharmacy Technicians’ Course saw 143
students graduating in March 2010. There are currently
121 students participating in Year 1 and 161 students in
Year 2 of the course. In addition, 139 students completed
the MCA Course in 2009 in Cork, Dublin, Galway, Kilkenny,
Limerick, Mullingar and Waterford. 61 students
completed the Interact course and 16 completed the
Interlink course. The FÁS Pharmacy Sales Traineeship
course is currently being run in Dublin. Susan also acts as
Secretary to the Employee Pharmacists’ Committee and
advises members on HR issues.
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9. BUSINESS SERVICES
The Business Development Manager, Darren Kelly, is
responsible for business services to members. In 2009,
seminars were organised around the country for
members, which covered issues such as employment
law, merchandising and customer service. A number
of affinity schemes have been put in place for
members on a range of services and details can be
found on the IPU website. Members are kept up to
date with current legislation through notices in the
IPU Review, Yearbook and General Memoranda. In
addition, individual advice is given to members on
request. Members who have paid their subscriptions
for 2010 will have received their IPU membership card,
“What the IPU does for you” information booklet and a
discount booklet outlining the discounts available to
IPU members. Darren also oversees the general
maintenance and upkeep of Butterfield House.
10. EXTERNAL CONSULTANTS
Gordon MRM (PR Consultants); Tom Flood (Contractual
Issues); Joe Durkan (Health Economist); Moore
McDowell (Economist); John Behan (Industrial
Relations Advisor) and Sean McHugh (Industrial
Relations Advisor); provide advice and support to the
Union as requested on an ongoing basis. Leaf
Environmental has been retained as consultants to
the Union on matters regarding environmental and
waste management issues.
11. MAILINGS TO MEMBERS
The number of mailings to members over recent years
were: 2003, 25; 2004 19; 2005, 20; 2006, 24; 2007, 47;
2008, 59; 2009, 53.
12. MAIN COMMITTEE MEETINGS
The number of  commitee meetings were:
‘09 ’08 ’07 
Executive Committee 9 10 9
Community Pharmacy Committee 6 5 3
Pharmacy Contractors’ Committee 8 6 6
Finance Sub Committee 7 7 7
All Committee Meetings 3 3
Employee Pharmacists’ Committee 3 4
13. UNION PUBLICATIONS
The following are sent to members, on a regular basis:
■ IPU Review
■ IPU Weekly Newsletter – sent to members by email
■ General Memoranda
■ Price Index List Updates
■ IPU Product File on Disk and CD
■ Yearbook & Diary
■ Wall Planner 
■ Training Course Updates 
■ Employee Pharmacists’ Committee Newsletter
■ Reap the Rewards of IPU Membership
14. PENSIONS AND INSURANCE 
AIC (Corporate) Ltd, Pharmacy Insurance Ireland and
Liberty Asset Management provide insurance and
pension services for members.
15. ENQUIRIES
Union Staff handle enquiries on a wide range of topics
and deal with questions raised by members regarding
their difficulties with companies, Government and
other agencies as well as a wide variety of
professional, business and personnel issues including:
■ Advertising
■ Banks
■ Computerisation
■ Contracts of Employment
■ Credit Cards
■ Customs & Excise
■ Dismissals; unfair, etc.
■ Dispensing, extemporaneous price list
■ Drug Donations
■ Education & Training / Training Grants
■ Employer/employee disputes
■ Employee Status
■ General Medical Services; Fees, etc
■ Health Centres
■ Health & Safety
■ Health Promotions
■ Health Screening
■ Health Services and Schemes
■ HSE
■ HSE PCRS queries
■ Industrial Relations law; general
■ Insurance
■ Internet pharmacy
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■ IPHA
■ Leave; Annual, Maternity, Compassionate, 
Public Holidays, Holiday Pay, etc.
■ Legal issues
■ Locum Lists / Situations Vacant
■ Maternity Legislation
■ Medical Translations
■ Membership
■ Methadone Treatment Scheme
■ Monitored Dosage Systems
■ Openings; pharmacy
■ Pay; National Minimum Wage, etc.
■ Part-time workers
■ Pharmacy Contract
■ Pharmacy Legislation
■ Photographic issues
■ Prescriptions, Emergency Hospital
■ Prices; including negotiations
■ Products; agents, availability, confined,
discontinued, etc
■ Professional Indemnity Insurance
■ PRSI
■ Prescriptions; Stolen, Forged, etc.
■ Psychiatric Scheme
■ Publishing Scams
■ Record Keeping
■ Redundancy
■ REPAK charges
■ Returns; for credit, etc
■ Salaries
■ Security; Pharmacy Raids, etc.
■ Sickness
■ Signage
■ Standard Operating Procedures
■ Suppliers
■ Taxation
■ Trading Terms
■ Union Posters requested on a regular basis
include:
■ Medicines & Pregnancy
■ Community Pharmacy Contractor Agreement
– Clause 9
■ Receipts (to be obtained at time of
dispensing)
■ Paracetamol
■ Ostomy Appliances (available in pharmacy)
■ Drugs Payment Scheme
■ No Smoking
■ Ask Your Pharmacist (before purchasing any
other medicines if taking prescribed
medicine)
■ Tax Relief on the Cost of Your Medicines
■ Unit Pricing
■ Unlicensed Medicines
■ VAT; IPU Scheme, etc
■ Waste Management
■ Withholding Tax
■ Wholesalers
16. SUBMISSIONS
The following submissions were made during the
year. Extracts of these are published in the appendices
to this report and all are available on the IPU website: 
■ Expert Group on Resource Allocation and
Financing in the Health Sector – DoHC – Jun
2009
■ Taxation of Locums – Revenue Commissioner –
June 2009 
■ Role of the Pharmacist – Fine Gael – July 2009
■ National Positive Ageing Strategy – Office for
Older People – September 2009 
■ Needle Exchange Programme – HSE – October
2009 
■ Supply of Veterinary Medicinal Products – IMB –
October 2009 
■ Draft Guidance on Codeine Medicines – PSI –
January 2010 
■ Draft Guidelines on Patient Consultation Area
– PSI – March 2010
17. IPU REVIEW
The IPU Review is produced in-house by Wendy
McGlashan, Aoibheann Ní Shúilleabháin and Kate
Healy.
18. CONCLUSION
Finally, I would like to thank all the staff of the Union
for their support to me and their hard work on behalf
of members. 
Seamus Feely,
Secretary General.
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Pharmacy Contractors’ Committee 
(PCC) Report 2010
The current Pharmacy Contractors’ Committee, under
the Chairmanship of John Corr, took office following
the 2008 Annual General Meeting (AGM). Tom Murray
was elected Vice-Chairman. The PCC met eight times
(in June, July, August, October, December, January,
February and March) since the AGM in April 2009. In
addition to the regular PCC meetings, there were two
joint meetings with the Executive Committee in
August. The Union also met the Minister for Health
and Children (MfHC) on two occasions last year, in
October and December.
This year the PCC’s energies have been focussed on
dealing with the Financial Emergency Measures in the
Public Interest Act 2009 (FEMPI) along with other
urgent issues which have arisen during the year. 
THE MAIN ISSUES ON THE COMMITTEE'S AGENDA SINCE
THE LAST AGM INCLUDE: 
■ Preparation for the High Court proceedings
against the HSE in relation to FEMPI;
■ Preparation of Submissions to the FEMPI Act
Consultations in 2009 and 2010;
■ Preparation of Oral Presentation to the FEMPI Act
Consultations in 2009 and 2010;
■ Communication with members on the FEMPI Act
at Regional Briefing Sessions in February and June
2009;
■ Participation in the Joint Consultative Group with
the HSE;
■ Securing payment of the Arrears taken by the HSE
from pharmacists in 2008;
■ Participation in the Methadone Group and Needle
Exchange Group with the HSE;
■ Preparation of Submission and Oral Presentation
to the Mark Moran Group on Reference Pricing;
■ Liaising with the HSE and DoHC to resolve the
Contract issue;
■ Monitoring of the Hardship Scheme/ Psychiatric
Scheme;
■ Monitoring the reduction in the cost of Medicines
under the IPHA Agreement;
■ Preparation for the Advance Payments Appeal and
issuing advice to members on this matter;
■ Providing members with advice, legal and
otherwise;
■ Monitoring all pharmacy payments;
■ Ongoing HSE PCRS Administration issues;
■ Monitoring developments throughout Europe
and Internationally.
FINANCIAL EMERGENCY MEASURES IN PUBLIC
INTEREST ACT 2009 [FEMPI ACT]
The new FEMPI Act payment structure was
implemented on 1 July and members now see the full
impact of the cuts on their income. The Act, published
in February 2009, empowers the Minister for Health
and Children to make regulations to reduce all
payments made by the State to pharmacists and, in
effect, to disregard all previous agreements and
contracts. The Union considers the legislation to be
draconian and an attack on members’ rights. 
The PCC made a submission to the FEMPI Consultation
and also made an oral presentation to officials from
the Department and the HSE. In the submission the
PCC stated that Union members are personally and
professionally committed to the provision of a high-
quality, accessible, community pharmacy service. They
also stressed that any unilateral and draconian action
on pharmacy reimbursement has the potential to
significantly undermine the very significant healthcare
contribution of community pharmacy to patients in
the State. 
However, the MfHC ignored the submission and
presentation and proceeded to implement the cuts on
1 July.
A legal challenge against this Act was taken in 2009.
This case was heard over two weeks in November. In
December 2009, Mr Justice McMahon ruled against
the plaintiff, Haire Pharmacy Group. In the High Court
challenge, the plaintiffs argued that the Financial
Emergency Measures in the Public Interest Act 2009
was unconstitutional and the cuts in payments were
unreasonable and disproportionate when compared to
the 8% cuts imposed on other healthcare
professionals. Evidence from two leading economists
was presented to the Court to support the plaintiff’s
case however the Judge did not accept this evidence.
An Appeal has been served in this case however no
date has been fixed for a hearing of the appeal.
Despite the Court’s finding the PCC believes the cuts
are unfair and, as part of the Minister for Health and
Children’s Review in 2010, the PCC will be producing
evidence of the impact of the cuts on pharmacies
across Ireland. A recent PwC questionnaire,
unfortunately, confirmed the PCC belief that pharmacy
income has been reduced by 30%. This equates to a
reduction of €100,000, on average. 
Along with campaigning against the severity of the
cuts, the PCC has also been dealing with a number of
issues that have arisen due to the implementation of
the Regulations:
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TEMPORARY CONTRACTS 
The PCC has been in continuous communication with
the HSE and the Department over recent months in
order to resolve the matter for the 485 pharmacists,
whom the HSE believe are currently operating under
temporary contractual arrangements. In March the
PCC received the CPC contract from the HSE, which
was largely in accordance with the existing contract.
There are a number of small administrative and
technical changes, which once the PCC clarified with
the HSE, they accepted. The PCC appreciates that this
matter was of great concern to the pharmacists
involved and is happy that the issue has finally been
resolved in a satisfactory manner through negotiation
and agreement between the Union and the HSE.
DISPENSING OF UNLICENSED MEDICINES (ULMS) 
The PCC was aware of the problems around claiming
for unlicensed medicines after the introduction of the
FEMPI legislation. The HSE stated that they would be
paying pharmacists the cost of the ULM minus 6.5%,
leaving pharmacists in a loss making situation. The
PCC wrote to both the HSE and the Department of
Health and Children asking for a mechanism to be put
in place whereby pharmacists will be reimbursed for
what they paid the wholesaler. In November, the HSE
confirmed that they would reimburse pharmacists the
full invoice price for all ULMs. 
DRUGS PAYMENT THRESHOLD 
The PCC dealt with a lot of queries in relation to the
Drugs Payment Threshold. The PCC issued advice on
the matter earlier this year. The advice to members
was that it is entirely a matter for each individual
pharmacist to decide for themselves what price they
charge to private patients, including sub threshold
patients. The legislation only applies to the amount
that the State reimburses to healthcare professionals
and the level of refunds that are made to patients
under the various State Schemes.
Issues arose in a small number of cases where a
patient acquires medicine in a number of pharmacies
during a particular month and subsequently makes a
claim to the HSE and some of the prices charged were
not in line with the DPS price. The HSE was issuing
letters to patients telling them that their pharmacist
had overcharged them. The PCC sought legal advice
and issued this advice to members. The legal advice
on this matter is that it was incorrect for the HSE to
imply that the patient has been overcharged in these
instances by pharmacists. In this context the PCC also
sought a redraft of the HSE letter to patients. The PCC
will continue to pursue this matter up with the HSE.
HARDSHIP ARRANGEMENT AND THE PSYCHIATRIC
SCHEME 
The Union was informed in October by the HSE that it
is intended to change the current payment
arrangements for the Hardship Arrangements and the
Psychiatric Scheme in line with the Minister for Health
and Children’s FEMPI regulations. There was no prior
notification or discussion with the Union on this
change. The PCC followed this matter up on a daily
basis to resolve the matter. Many pharmacists still
have significant amounts of money outstanding from
the HSE. The PCC believe that retrospective reductions
or changes in payment or administrative
arrangements are not acceptable and will continue to
follow this up with the HSE. 
THE PCC HAS ALSO BEEN INVOLVED IN THE FOLLOWING
MATTERS SINCE THE LAST AGM:
IPHA REDUCTIONS
The MfHC informed the Union at a meeting in
December that there would be reductions to the cost
of medicines under a new IPHA Agreement from 1
January 2010. The Union highlighted to the Minister at
that time, and in subsequent correspondence, that a
reduction in the cost of medicines would have a
knock-on effect on pharmacy income. The Union also
stated that 1 January was the worst time to introduce
such a change. Following representations from the
Union, the Department delayed the introduction of
the 40% reduction to the price of medicine until 1
February. However, despite requests to do so, the
Department refused to grant a transition period, given
the current state of the public finances. In the
circumstances, the PCC had strongly advised members
to manage their stock carefully to minimise any loss
that would occur as a result of the reduction in the
price of medicines from 1 February.
REFERENCE PRICING 
At a meeting with the MfHC in December she
indicated her intention to introduce a system of
reference pricing for certain medicines along with the
introduction of generic substitution by pharmacists in
2010. To implement these changes she established a
group chaired by Mark Moran, a member of the
Independent Body on Pharmacy Contract Pricing, to
consider various issues around reference pricing. The
PCC established a small sub group to review this issue.
This group met throughout early 2010. Members of
the Group met with Mark Moran and his group and
also made two written submission to the group on
reference pricing. 
PRESCRIPTION LEVY 
In the Budget it was announced that the Government
would be introducing a prescription levy for medical
card patients. The PCC wrote to the MfHC on a number
of occasions on this issue highlighting concerns
around the introduction of this levy and the impact it
will have on patients. The PCC are due to meet the
DoHC before the introduction of legislation
introducing the levy is finalised in May. A poster and
leaflet has been prepared for pharmacists and this will
be circulated in advance of the levy being introduced.
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JOINT CONSULTATIVE GROUP
The Joint Consultative Group met three times since
the AGM. As part of this Group, the Union and the
HSE agreed to cooperate in the areas of
modernisation, change and flexibility. The Group is
also a forum for discussion on matters of concern for
members.
Issues raised this year with the HSE in this 
forum include:
ARREARS PAYMENTS
In September 2008, Ms Justice Finlay Geoghegan of
the High Court ruled in favour of pharmacists, stating
that the HSE and the Department of Health and
Children were in breach of contract and could not
unilaterally alter the reimbursement price of medicines
under the terms of existing agreements and contracts.
This judgment was very significant and was welcomed
by both the PCC and by members. In line with the High
Court Judgment, the HSE had reinstated the payments
to members from October 2008. The PCC had lengthy
discussions at the Joint Consultative Group about the
repayment of the arrears to members and in June
2009 all arrears were paid. 
PROBLEMS WITH PHARMACY CLAIMS
During the year the Union has received many
complaints and reports from members in relation to
recurring difficulties with respect to the electronic
transmission of claims. These issues occur, in most
instances, where a pharmacy has recently transferred
from 1st Generation Electronic Claims to 2nd
Generation Electronic Claims. In many cases, a
relatively small number of members have found that
they are having difficulties in transmitting their
claims and, in other instances, their dispensary system
has allegedly reported that the file has been
transmitted successfully, when it does not appear to
have been received by the PCRS.
The PCC is continuing to try to liaise with the HSE
PCRS to ensure a proper process is in place to deal
with such issues and resolve them to the satisfaction
of all parties. However, progress has been painfully
slow and these issues will continue to be raised at the
Joint Consultative Meeting, where necessary.
METHADONE GROUP 
■ Members of the PCC have met with HSE officials
on an ongoing basis since mid 2008 to review all
issues around the Methadone Scheme. There has
been significant progress on these issues and,
while there are still outstanding matters to be
resolved, the Group has reached agreement on a
number of issues. 
■ A transfer system for patients being moved from
the Central Treatment List to pharmacy has been
agreed and is due to be implemented shortly; 
■ The HSE have also committed to appointing a
National Pharmacy Co-ordinator to help support
pharmacists dispensing methadone outside the
Dublin area.
The Union still has concerns around the level of the
Pharmacy Grant and will continue to pursue this with
the HSE.
NEEDLE EXCHANGE PROGRAM
The PCC has also been liaising with the HSE on the
implementation of a Needle Exchange Program. Once
there is agreement on this program, it is planned that
the service will be rolled out initially through
pharmacies in 65 locations across the country, where
the service is needed. The initiative is being supported
by the Elton John Aids Foundation. John Curran, T.D.,
Minister of State with responsibility for the National
Drugs Strategy, had highlighted the progress achieved
by the Union and the HSE at the launch of the new
National Drugs Strategy. 
The Union made a submission to the HSE in early
October 2009 around the implementation of the
Programme; however, the HSE has yet to respond to
this submission. The delay of over six months has,
unfortunately, led to a postponement of the
implementation of the Programme which is a great
disappointment to the PCC, the Elton John
Foundation, pharmacists and the patients who will
benefit from the Programme. The matter continues to
be pursued at official and political levels.
HSE/IPU CHARTER
The Union tabled a HSE/IPU Charter in July 2009. Such a
Charter should ensure that the effective and fair
administration of the Community Drugs Schemes
requires the HSE PCRS, Community Pharmacy
Contractors and the IPU to recognise certain basic rights
and responsibilities and to adhere to certain procedures.
The purpose of this Charter is to set out the standard of
service that each party should receive when dealing
with each other and the reasonable expectations that
each party should have of one another. The PCC will
continue to pursue this with the HSE.
CONCLUSION
The above provides a summary of some of the major
issues dealt with throughout the year. However,
officials of the Union intervened in many other
instances to resolve individual issues for members. 
The PCC is actively working with the HSE on members
behalf. Progress can be slow and discussions take
time. They are often difficult, but at all times, the PCC
continue to pursue issues on behalf of members until
a resolution is found.
John Corr,
Chairman PCC.
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Community Pharmacy Committee 
(CPC) Report 2009-10 
The Community Pharmacy Committee (CPC) is chaired by
Keith O’Hourihane with Rory O’Donnell as Vice-Chairman.
CPC’s mission statement is CPC – working to serve and
support community pharmacists in their practices and to
promote and expand their role as pharmacists by
continually developing professional, ethical, business and
technological ideals and standards.
The CPC is split into three sub-groups as follows:
Professional Development Steering Group
Daragh Connolly, Ciara Cronin, Bernard Duggan, Niamh
Murphy, Ross McEntegart, Aisling Reast.
Business and Policy Steering Group
Michael Austin, Elizabeth Lang, Barbara O’Connell, 
Rory O’Donnell.
IT Steering Group
Louise Begley, Stephen Nolan, Darragh O’Loughlin, Jack
Shanahan.
CPC has met six times since the April 2009 AGM (May, July,
September and October 2009 and January and March
2010). The Committee has dealt with a wide variety of
issues over these six meetings. The following is a summary
of the key issues dealt with during this time. 
PROFESSIONAL ISSUES 
Extended Pharmacy Services
■ Health Screening Pilot
43 pharmacies participated in the Union’s Health
Screening pilot from July 2009 until February
2010. The results will now be analysed by TCD to
provide evidence to support our lobbying for
expanding the professional role of the
pharmacist.
■ Medicine Use Reviews Pilot
The Union is participating in the HSE Pharmacy
in Primary Care Group which is initially looking at
pharmacist-led MURs for chronic diseases. They
plan to run an MUR pilot in April/May with a view
to gathering evidence for the roll out of MURs
nationally. ICCPE will provide training on MURs for
participating pharmacists.
■ Asthma Management Demonstration Project
A new initiative to facilitate the implementation
of best practice asthma guidelines in Irish
healthcare is being piloted by the Asthma Society
of Ireland in partnership with the IPU, the DoHC
and the HSE. There are now 26 GP practices and
72 pharmacies participating. Following the initial
demonstration project, which will reach up to
5,000 asthma patients, the hope is for the
initiative to be rolled out on a national level. 
■ Needle Exchange Scheme
The HSE has received funding for a pharmacy-
based needle exchange scheme from the Elton
John Aids Foundation. The scheme will initially
commence in 65 pharmacies around the country
with further expansion of the scheme over the
next three years. As part of the scheme, a
National Pharmacy Coordinator for methadone
will be appointed by the HSE. Most details of the
scheme have been agreed but the HSE has yet to
agree on the fees payable to pharmacists. The
Union met with Minister John Curran in January
2010 to discuss the delay in the roll-out of the
scheme and is continuing to push this issue at
both political and official levels. 
■ Palliative Care Initiatives
The Union has participated in a number of
initiatives under the End of Life Forum umbrella
over the past year. The Forum seeks to extend
access to palliative care to people with illnesses
other than cancer such as COPD, heart failure and
dementia. The Union’s submissions and
presentations have focused on the role of the
community pharmacist in palliative care. The
Union met with the Irish Cancer Society in
January 2010 to discuss ways in which
community pharmacists could provide support
for ICS initiatives such as bowel cancer, skin
cancer and smoking cessation. 
■ Patient Safety
The Union continues to participate in HIQA’s
Medication Safety Forum which, in 2010, will
focus on the development of a national
prescription form, development of SOPs for
pharmacies, guidelines for codeine medicines, the
roll-out of the Asthma Management Programme,
the re-launch of PIP and the management of
patient discharge.
■ Vaccination
It had been hoped that the 800 pharmacists who
completed the IPU Vaccination Training
Programme in 2009 would be able to participate
in the mass H1N1 vaccination programme. As this
has been suspended, the PSI will write to those
pharmacists, asking them to self-assess their
competence. Further practical training will be
arranged if requested. Pharmacist vaccination has
been included in the list of priorities identified by
the HSE Pharmacy in Primary Care Group.
■ Pandemic (H1N1) 2009
The Union was involved in several taskforces in
relation to Pandemic (H1N1) 2009: the European
Scientific Working Group on Influenza (ESWI), the
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Pharmacy Pandemic Preparedness Group and the
Influenza Pandemic Pharmacy Advisory Taskforce.
The Union sought to ensure community
pharmacy involvement in all aspects of pandemic
planning. 
Health Promotion
The Union ran a campaign called Ask Your Pharmacist
about Your Child’s Health in May 2009, designed to
make parents aware of some of the most common
ailments that can occur in a child’s early years. Leaflets
contained a handy guide to infectious diseases in
childhood. 
In November 2009, the Union ran a campaign to
promote the role of the pharmacist in the H1N1
pandemic. Promotional materials in pharmacies
focused specifically on H1N1 and a national advertising
campaign promoted the role of the pharmacist as an
accessible healthcare professional who can provide
expert advice on health and well being. 
The IPU and the Asthma Society jointly ran a health
promotion in March 2010, encouraging patients to ask
their pharmacist about inhaler technique. The
promotion was highlighted with a radio ad on 2FM
and Today FM. A suite of SOPs on inhaler technique
are available for download from the IPU website.
In May 2010 there will be a promotion around
European Obesity Day, in collaboration with GSK, and
the focus in the Autumn will be on Mental Health. 
In October 2009, the IPU had a stand at the Over 50s
Show in the RDS, Dublin. This year, the Union will have
a stand at the National Ploughing Championships in
Athy in September instead of the Over 50s Show.
SOPs / Guidelines
A range of Standard Operating Procedures, Guidelines
and Protocols are available in the member’s only
section of the IPU website under Professional
Assistance > Guidelines and Protocols. These simple
guidelines have been produced for you so that you
can easily draw up protocols saving you money and
time in doing it yourself. Topics covered include:
■ Dispensing Process (including a guide to SOPs); 
■ Prescription Collection and Delivery;
■ Dispensing Errors Log;
■ Dispensing EEA Prescriptions;
■ Parallel Imports;
■ Health Screening;
■ Medicines Sales Protocol;
■ Codeine Sales Protocol;
■ alli Sales Protocol;
■ Methadone Guidelines;
■ Needle Exchange;
■ Sharps Disposal;
■ Asthma Inhaler Technique;
■ Nursing Home Guidelines. 
Pharmacy Act
On 28 July 2009, the Minister for Health and Children
announced the commencement of the outstanding
Sections of the Pharmacy Act 2007 to provide for the
introduction of a Fitness to Practise regime for
pharmacists and pharmacy businesses. Also included
were Sections 63 and 64 of the Act, which relate to
the prohibition of certain economic relationships
between pharmacists or pharmacies and medical
practitioners or medical practices. These Sections of
the Act came into operation on the 1st August 2009. A
panel of solicitors with expertise in Fitness to Practise
has been listed on the IPU website to assist members
who are involved in Fitness to Practise investigations. 
■ Pharmacy Inspections
In December 2009, the Union met with the HSE,
IMB and PSI to clarify issues around inspections of
pharmacies. In January 2010, the Union sent out
an inspections checklist to assist pharmacists in
preparing for inspections of Retail Pharmacy
Businesses by the HSE, PSI and IMB. The Union
has since written to the HSE, IMB and PSI,
requesting that notice be given for routine
inspections and that electronic storage of
invoices be considered acceptable for inspection
purposes. The Union is working with the PSI on a
self audit/self assessment tool for pharmacies.
The Union met with the PSI in March 2010 to
discuss issues in relation to inspections and
fitness to practise and continues to monitor this
situation. A series of articles were written for the
IPU Review in March, April and May 2010
outlining Fitness to Practise procedures. 
Competition Act
The Department of Enterprise, Trade and Innovation is
preparing draft legislation to amalgamate the
Competition Authority with the National Consumer
Agency. The proposed legislation is expected to
include amendments to the Competition Act. The
Competition Authority wrote to the Union on 28
January 2010 confirming that their investigation into
the IPU is now closed.
BUSINESS ISSUES
Affinity Schemes
The Union has set up a number of affinity schemes to
provide better value for money for members with
companies such as Avery Berkel, Bank of Ireland,
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Compliance Doc, Design 360, Energia, 3 Mobile,
Imagine Telecommunications, PMM Merchandising
and Marketing, Pharmafit and TLC Performance. In
addition, the Union has had meetings with companies
from different business sectors such as packaging,
insurance, finance, energy assessment and retail to
provide additional services to members. Details of
these schemes can be found on the IPU website.
Buying Group Pilot
The Union is in the process of setting up a Buying
Group Pilot with Stonehouse Marketing to assist
members with front-of-shop purchasing.
Business Training
Over the past year, employment law briefings were
held in Dublin, Cork and Limerick in conjunction with
Graphite Human Resources Management.
Merchandising training was held in Donegal, Dublin,
Kilkenny, Limerick, Athlone, Galway and Sligo. A menu
of training and training providers has been developed
and is available to members from their Regional Rep.
The Union is working with PricewaterhouseCoopers to
provide workshops on business issues as per
members’ feedback at regional meetings. The Union
has also entered into an arrangement with IBEC to
provide business training to members. The CPC
Business Steering Group is planning to hold member
focus groups throughout the regions over the coming
months to identify further business issues of interest
to members.
A Pharmacy Employee Seminar was held in February
2010, covering issues such as Employment Law,
Negotiating Terms and Conditions, CV and Interview
Techniques and Income Protection.
Business Newsletters
Business Newsletters with information on
Employment Law, Purchasing and Stock Control,
Category Management, Customer Service and
Retention and Financial Information for Pharmacies
have been produced and sent to members over the
past year. Further Newsletters will cover issues such as
Health & Safety, Business Regulations and Dealing
with the PCRS.
IT ISSUES /IPU PRODUCT FILE
IPU Product File
The CPC IT Steering Group has met regularly
throughout the year to develop a strategy for the IPU
Product File so that it continues to meet the needs of
members and other users. Following meetings with all
system vendors, live downloads of the IPU Product File
are being facilitated. System vendors have also
confirmed that they have adapted their systems to
incorporate the FEMPI regulations and roll-out
commenced in February. Aegate will pilot its medicine
authentication system with two system vendors in
the coming months. The IPU Drug Interactions File,
produced for the Union by TCD, is free to all members.
Members should contact their system vendor about it
being incorporated into their dispensary system.
System Vendor Issues
The Union is working with system vendors to
facilitate the generation of a report which complies
with the HSE requested format for the Psychiatric and
Hardship Schemes. The Union is working with all
system vendors to allow for broadband transmission
of electronic orders. The IT Steering Group will
continue to monitor user requirements for pharmacy
systems and communicate these to system vendors. 
Health Information Bill
The IT Steering Group has been monitoring
developments in relation to the proposed Health
Information Bill. This Bill, when enacted, will form a
legal basis for the development of electronic patient
and health records. The Bill is expected to be
introduced during 2010.
The Health Information and Quality Authority (HIQA)
is currently developing standards in anticipation of
the Health Information Bill becoming law. The Union
is on a panel of stakeholders that participate in
workshops organised by HIQA in relation to
informatics in healthcare. 
@ipumail
The Union launched its new email service @ipumail.ie
in March 2010. Each member was provided with a
dedicated mailbox. This new service has been
developed to allow members to have easier and
instant access to all IPU services and information. The
service is completely free to members.
The existing Community Pharmacy Committee has been
in place for the past two years. The incoming Committee
will meet for the first time on 26 May 2010 following
the Union’s Annual General Meeting. I would like to take
this opportunity to thank all of the existing Committee
members and Union staff for their dedication, support
and enthusiasm over the past two years. 
Keith O’Hourihane,
Chairman CPC
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Employee Pharmacists' Committee 
(EPC) Report 2009
The Employee Pharmacists’ Committee (EPC) represents the
interests of community pharmacy employee members of
the Irish Pharmacy Union. The committee is chaired by
Bernard Duggan with Ross McEntegart as Vice-Chairperson.
The mission statement of the EPC is: “To foster an active
and dynamic Employee Pharmacists’ Committee which
actively promotes the professional and economic interests of
employee pharmacists and constructively engages with the
other committees of the Union and with other stakeholders.”
It was formed as a result of changes to the Union’s
Constitution in November 2007 and the term of office of
the first EPC will end at the AGM.
There are currently 832 members registered as employees
(accounting for 48% of members). The number of
employee pharmacists continues to increase due to a
number of factors, including the additional graduates
generated by the two additional schools of pharmacy in
Dublin and Cork, the ending of the derogation by the
Minister of Health and Children in late 2008 and the
effects of the reduction in payments to community
pharmacists introduced by the Minister in July 2009.
The EPC has met three times since the 2009 AGM (May
and November 2009 and February 2010). The EPC also
continues to have active representation on other
committees of the IPU, with an allocation of three
employee representatives on the Executive Committee and
four representatives on the Community Pharmacy
Committee. This ensures that the views of employee
pharmacists are voiced and heard on the other
committees of the Union, thus allowing for employee
input into decisions and in the development and
implementation of the policies of the IPU. During July and
August of last year the Chairperson of the EPC, Bernard
Duggan, participated in the Strategy Group along with
representatives from the Standing Committee, the
Pharmacy Contractors’ Committee and the Chair of the
Community Pharmacy Committee. During this period the
EPC issued two press releases; the first highlighting key
weaknesses in the HSE’s contingency plan prior to 1
August, with a further press release on 5 August showing
how the failure of the of the contingency plan was putting
immense pressure on employee pharmacists.
The EPC made its own submission to the “Consultation on
Fees payable to Health Care Professionals” undertaken by
the Department of Health and Children. In this submission
the EPC outlined the effect that any reduction in
remuneration would have on the service that employee
pharmacists provide to the public. It also stressed the
negative impact that any cuts would have on future
employment opportunities within the sector.
The EPC wrote to the Registrar of the Pharmaceutical
Society of Ireland in June 2009 to seek their views on the
current and future manpower situation in the pharmacy
sector, the future employment prospects of pharmacy
graduates and to ask if the Society had undertaken
research into such. The PSI acknowledged receipt of the
letter; the EPC wrote to the PSI in January 2010 to seek a
response to its’ initial request. The PSI responded stating
that the matter was considered at the PSI Professional
Development & Learning Committee in July 2009 and that
a summary of the deliberations will be sent to the EPC.
The issue of pharmacists’ salaries was raised at the AGM
and there have been a considerable number of queries to
the Union on this issue. Given the current climate within
community pharmacy, this is not surprising. The EPC
discussed this matter at length and decided that guidance
for both employees and employers would be beneficial.
The matter was then placed on the agenda of subsequent
Community Pharmacy and Executive Committees
meetings by the employee representatives on those
committees. Following on from this, salary guidelines for
Community Employee Pharmacists were approved by the
Executive Committee and are available on the IPU website.
The EPC has continued to communicate with employee
members through a regular column and articles in the IPU
Review, which have dealt with topics such as advice for
locum pharmacists and dealing with workplace pressure
and stress. The EPC has also issued two further
newsletters to community employee members. The first of
these newsletters identified the members of the EPC to
employee pharmacists so that they were aware of who
their regional employee representative is and how to get
in contact with them. It also provided information on
contracts of employment. The third newsletter updated
community employee members on the work programme
of the EPC. The new IPU website has a dedicated section
for employee pharmacists, which contains information on
a wide range of issues of relevance to community
employee members.
The EPC has continued to progress the development of
service which will provide representation for employee
pharmacists in their dealings with their employers on a
range of issues. In May 2009, the EPC considered the
discussion document entitled “Representation for Employee
Members Irish Pharmacy Union” prepared by the Union’s
industrial relations consultant, Sean McHugh of Resource.
This document outlined four possible models of
representation, with the option whereby the IPU facilitates
mediation between employers and employees being the
preferred choice. Mr McHugh then prepared a document
entitled “Mediation Proposal” which outlined how this
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option could be provided effectively to all members of the
Union. The Committee recommended that, in order to
facilitate mediation between employees and employers,
the services of a suitable external agency be sought to
carry out the mediation process. It was decided that
referral through a central point of contact at the IPU
would be the first step in the process, with the Secretary
to the EPC, Susan McManus, fulfilling this role. An agreed
set of terms for mediation, outlining rules and guidelines
for the process, would be put in place. A proposal outlining
all of the above was approved by the Executive Committee
in November 2009.
The EPC feel that the current climate within the
community pharmacy sector presents the opportunity to
introduce a structured mediation service for the resolution
of disputes on a trial basis. Although driven by the EPC,
this would be a service that would be available to all
members of the IPU. This service could be beneficial to all
parties in that it may help to achieve an early resolution of
a dispute at a local level and, at the same time, avoid
unnecessary legal costs, save time and maintain a good
working relationship. The EPC intends to launch this
service within a short timeframe.
The first IPU Pharmacy Employee Seminar was held in the
Red Cow Inn on Sunday 28 February 2010. The idea of
holding a seminar was conceived at a meeting of the EPC
in November 2009. It was felt that the holding of a
seminar which addressed issues which are currently
relevant to employee pharmacists would be beneficial.
There were four different presentations which dealt with
employment law and contracts, negotiating terms and
conditions of employment, CV writing and interview
techniques and income protection. The presentations were
made available to all members in the employee
pharmacists section of the IPU website. The EPC intends to
hold this seminar on an annual basis.
In January 2010, the President of the IPU and the
Chairperson of the EPC wrote to the newly registered
pharmacists who completed the pre-registration training
in late 2009 to invite them to apply for IPU membership,
inform them of the upcoming IPU Pharmacy Employee
Seminar and to ask for their co-operation in filling out a
survey. This survey will enable the EPC to gather
information about the current working environment of
this cohort of pharmacists. This will help the committee to
represent the interests of recently qualified pharmacists
by focusing on the issues relevant to them.
The EPC has also decided to survey community employee
members of the IPU to ascertain the current terms and
conditions of employment and to assess how the
reduction in payments to community pharmacies has
impacted on these terms and conditions and on their
working environment. 
The EPC completes its first term of office at the AGM.
Although the committee has only been in existence for a
short period of time it has achieved a considerable
amount. As the new committee takes office, it will
continue to pursue its objectives with intent and to
actively represent the interest of employee pharmacists. It
will also ensure that the IPU continues to provide services
and support to the growing number of employee
pharmacists within the community pharmacy sector. The
coming years, like those just past, will be challenging for
all in community pharmacy. It is important now, more
than ever, that employee pharmacists have a
representative body which advocates on their behalf. The
EPC will continue to be this body and it encourages the
participation of more employees at both a regional and
national level within the IPU so as to strengthen the
resolve of employee pharmacists both within the Union
and the profession.
I would like to thank all the members of the EPC for all
their work over the last two years. I would like to thank all
the staff of the IPU, in particular Seamus, Darren and
Pamela for their support and advice on all matters. I would
especially like to thank the Secretary to the EPC, Susan
McManus, for her hard work and commitment to the EPC. I
would also like to thank the President, Liz Hoctor, for all
her advice and help with the EPC over the past two years.
Bernard Duggan,
Chairperson.
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Public Relations Report 
The 12 months since our last AGM have been without
doubt the busiest period we have ever faced in relation to
Public Relations, Marketing and Communications at the
Union.
The defining issue was, of course, the dispute with the HSE
and the withdrawal of services by individual pharmacists
across the country last summer. This was one of the most
high profile disputes last year and dominated media
attention for days on end. The build up to the dispute and
the dispute itself saw intense media coverage on
pharmacy generally, on the reasons for the dispute and on
the growing anger being felt by individual pharmacists in
the face of the inequity of the cuts they were being forced
to take.
Throughout that period, the IPU PR team – Kate Healy,
Aoibheann Ní Shúilleabháin and our external advisors -
invested huge amounts of time, effort and resources in
working with journalists to help them understand what
was happening in the pharmacy profession, brief them on
developments in different parts of the country and
challenge the misleading statements being made by the
HSE and others about why individual pharmacists were in
dispute. We ran a two week advertising campaign in local
newspapers during the last two weeks of July and
organised posters and leaflets for pharmacies. The media
coverage continued into August. Briefings with politicians
and patient groups were also arranged at both local and
national levels.
Following the crisis, the Union undertook professional
opinion poll research amongst the general public, which
assessed how people had actually reacted to the dispute
and how it had affected their view of the profession.
The findings are very interesting and reflect the fact that
the public did pay attention to what was being said and to
the validity of the arguments made by pharmacists. Some
of the key findings are:
■ 81% of respondents said that they knew about the
dispute; 40% said that they knew a lot about it.
■ 52% knew that it was about how much pharmacists
are paid.
■ 48% said they knew that the HSE, Minister and Drug
companies set the price of drugs in Ireland and not
pharmacists.
■ 40% said that they supported pharmacists, while
only 8% said they supported the Minister/HSE. (The
remaining 52% were unsure).
However, the dispute was not the only issue on which the
Union focused attention last year. The Union organised
radio advertising campaigns in October, November and
December to promote the role of the pharmacist and to
encourage people to visit their pharmacy as a place to
shop in the run up to Christmas. These ads reached 72% of
adults, who heard them approximately six times. 
The Union ran some health awareness campaigns over the
past year also. In September 2009 we organised a health
promotion on the H1N1 Pandemic, where we provided
posters and leaflets to pharmacies. This focus on
campaigns which are informative to the public and which
encourage the professional use of pharmacies has
continued into 2010 with campaigns on Asthma and
Smoking Cessation. In the Smoking Cessation campaign
we secured frequent appearances on RTE 1 on The
Afternoon Show, which followed a group of three people
over their ten week efforts to quit smoking. One of the
candidates was advised and supported by a pharmacist
and he quit successfully. The Asthma Campaign ran in
March in conjunction with the Asthma Society of Ireland
on improving inhaler technique. This involved posters,
asthma attack cards and a DVD being sent to pharmacies.
It was supported by a national radio advertising campaign. 
The team also organised a Pharmacy stand at the Over 50s
Show in the RDS in October where we provided
information about the role of pharmacists. Pharmacists
were on hand to give free advice to patients and to
provide free blood pressure and BMI testing. 
Finally, we did a lot of work in terms of getting members’
feedback on our communications and, as a result, we are
working to develop better two-way communications and
the greater use of e-communications. As a consequence
we have completely re-vamped our website, have a
dedicated IPU YouTube channel, are providing all members
with an IPU based email address and are rolling out a new
electronic newsletter to replace general memorandums.
International Pharmacy Matters
companies a role in information provision. PGEU fully
supports the rights of patients to high quality
information on medicines and health related issues.
However, it fears that direct provision of information
by the pharmaceutical industry to patients may be
promotional in nature and jeopardise rational and
appropriate use of medicines. 
Counterfeit Medicines
This Directive includes proposals to require a safety
feature on each medicine pack that would allow it to
be authenticated by the pharmacist before it reaches
the patient. A number of pharmacy authentication
schemes are currently either implemented or being
piloted in Europe, including an Aegate pilot in Ireland.
For the purposes of the safety feature, PGEU would
prefer to see a comprehensive approach to medicines
rather than a risk assessment. A balance must also be
struck between an effective system and one that is
affordable. We need to avoid unnecessary increases in
the price of medicines and to consider carefully the
use of data generated by authentication systems. 
Pharmacovigilance
If adopted, this Directive will significantly strengthen
the system of pharmacovigilance in Europe. It also
recognises the role of the pharmacist in reporting
adverse drug events, expands the scope of reporting
to include medication errors and requires improved
post-authorisation safety studies. PGEU has some
concerns about the current proposals: reporting of
medication errors should be on a no blame basis; the
patient information leaflet should orient patients
towards healthcare professionals for reporting
purposes as well as the pharmacovigilance web
portal; and stronger post-authorisation requirements
should not be used as an excuse to grant premature
authorisations. 
ECJ Rulings
2009 saw the release of a landmark ruling in cases
involving rules limiting ownership to pharmacists. In
May, the European Court of Justice (ECJ) established
that legislation reserving pharmacy ownership to
pharmacists is justified. The Court stated that the
pursuit of purely economic objectives in pharmacy is a
threat to health and it is the role of the pharmacist to
ensure that professional judgment takes precedence
over economic objectives. 
The ECJ Advocate General (AG) released an opinion in
September on laws of establishment of pharmacies,
including population criteria and distances between
pharmacies. The AG found that regulations on
establishment rules ensuring a distribution of
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1. PGEU REPORT 
The Pharmaceutical Group of the European Union
(PGEU) is the European association representing
community pharmacists in 30 European countries
including EU Member States, EEA countries and EU
applicant countries. Overall, PGEU represents over
400,000 community pharmacists in Europe through
their professional bodies and pharmacists’
associations.
The IPU is represented at PGEU by Michael Guckian,
Past President, and Pamela Logan, Director of
Pharmacy Services. The Union has been very active
within PGEU over the past year, ensuring that
community pharmacy is considered in a wide variety
of EU Directives. 70% of legislation in Ireland comes
from EU Directives so it is vital that lobbying is done
at this level rather than waiting for transposition into
Irish legislation. 
PGEU 50th Anniversary
2009 was the year in which PGEU celebrated its 50th
anniversary. The occasion was marked by a reception
in the European Parliament in November and an
exhibition of posters from PGEU members, illustrating
key events in pharmacy in their countries over the last
50 years. 
Directives
There has been intense activity in the area of
pharmaceutical legislation during 2009. The three
new Directives that make up the Pharmaceutical
Package – Information to Patients, Counterfeit
Medicines and Pharmacovigilance – go to the heart of
our professional activity. The role of pharmacists in
ensuring that the medicines that reach the hands of
patients are genuine and that adverse reactions to
medicines are appropriately monitored and reported
is a key one and, with these Directives, one that is
destined to grow significantly in importance. A
delegation from the IPU went to Brussels in
November 2009 to meet with Irish MEPs and discuss
issues related to these Directives. 
Information to Patients
In 2009, proposals for this Directive were sent to the
European Parliament and Council to be studied. At
Council level, it is known that some counties are not
favourable to the proposals. Member States agree
that legislation is needed but they do not agree with
the Commission’s proposal as currently worded,
particularly the plan to give pharmaceutical
pharmacies throughout a territory could be justified
in the public interest. The final ruling is expected in
the first half of 2010. 
Policy Statements
During 2009, PGEU produced a number of policy
statements: Why Pharmacies Need Fully Qualified
Pharmacists; Community Pharmacists’ Contribution to
Ensuring Rational and Safe Use of Medicines by Older
People; Community Pharmacists’ Contribution to
Counteracting Obesity in the EU; Medicine
Authentication Technology; Cancer; Antibiotic
Resistance; and Pandemic Influenza. The policy
statements are used to ensure that the voice of
community pharmacy is heard in debates and that
the outcomes are good for health systems,
pharmacists and, most importantly, patients. 
2. REPORT ON FIP CONGRESS, ISTANBUL, TURKEY FROM
3 - 8 SEPTEMBER 2009
Introduction
The International Pharmaceutical Federation (FIP)
together with the Turkish Pharmacists’ Association
opened the 69th World Congress of Pharmacy and
Pharmaceutical Sciences on 3 September 2009 in
Istanbul, Turkey. Through its 120 member
organisations and 4000 individual members, FIP
represents and serves almost two million practitioners
and scientists around the world. FIP President, Dr
Kamal K Midha, greeted the audience of almost 3000
pharmacists, pharmaceutical scientists, academics,
researchers, students and guests who had come
together for a week of pre-satellite symposia,
workshops, lectures and meetings focused on this
year’s Congress theme – Responsibility for Patient
Outcomes – Are you Ready? 
During the Opening Ceremony, FIP President, Kamal K.
Midha, stressed the many activities that FIP had
undertaken since the last meeting in Basel, reinforcing
FIP's commitment to implement the Strategic
Objectives that support FIP's 2020 Vision. He posed
the question to the audience - FIP is ready, are you?
His words and dedication to the future of pharmacy
and pharmaceutical sciences on a global level were
echoed by the President of the Turkish Pharmacists’
Association, Mr Erdoğan Çolak, and the Minister of
Health of the Republic of Turkey, Professor Recep
Akdağ. Special guest, Dr Hans Hogerzeil, Director of
Medicines Policy and Standards at the World Health
Organization (WHO), solidified the joint efforts of the
two organisations and emphasized the progress that
has occurred in areas such as the fight against
counterfeit medicines since WHO and FIP began their
collaborative efforts. 
FIP’s mission is “to improve global health by advancing
pharmacy practice and science to enable better
discovery, development, access and safe use of
appropriate cost-effective quality medicines
worldwide.” The focus of FIP over the past year and
over the next few years is pharmacy education,
present and future workforce needs, collaborative
pharmacy practice and counterfeit medicines.
Disease Specific Initiatives by Pharmacists 
Ross Tsuyuki from Canada spoke of how increased
public demand for services has led to an increased
role for pharmacists in improving patient outcomes in
areas such as dyslipidaemia, hypertension, heart
failure and anticoagulation. In a typical cohort of 100
patients with dyslipidaemia, 64% are screened, 39%
are treated but only 8% are treated to target. In a
systematic review of pharmacist-led interventions in
dyslipidaemia, there was a mean change in LDL
cholesterol of -0.59. In a study to show the effect of a
community-based, interdisciplinary care programme
in patients with diabetes and elevated blood pressure,
BP was reduced by 5.6mmHg which extrapolates to a
reduction in stroke of 30%, in CHD events by 23% and
in mortality by 13%. Pharmacists must recognise that
their future is in patient-centred care and improving
outcomes. Governments should recognise that chronic
disease management is not a passive process. The
advantage of pharmacists is that they can be
systematic (in the application of evidence-based care)
and proactive (in identifying patients at risk).
Expanding the role of the pharmacist in primary care
is the future of our profession. 
Pharmacy Immunisation Programme
Suzete Costa from Portugal spoke of a pharmacy
immunisation programme that was introduced in 2007.
The National Association of Pharmacists (ANF)
developed a training programme for pharmacists which
covered immunisation techniques, anaphylaxis and
basic life support. The programme was based on an
American model where vaccination has been provided
in community pharmacies since 1996. A total of 1914
pharmacists from 1273 pharmacies (48% of total
pharmacies) completed the immunisation training. 
The first nationwide Pharmacy-Based Influenza
Immunisation Campaign took place during October
2008. Almost 160,000 patients were vaccinated
throughout the influenza season, which equates to
10.9% of total vaccinations at national level; the
average number of patients vaccinated per pharmacy
was 206. There was no record of any anaphylaxis
occurring. Based on the total number of influenza
vaccines dispensed in that period, the overall
immunisation coverage was estimated to be 50.4% in
patients 65 and over (the EU target is 75%) and
pharmacists’ contribution in this subgroup was
estimated between 5.5% and 11.3%. 
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Improving Adherence
Christine Bond from Scotland described the evidence
that existed for improving adherence to drug therapy.
It is well documented that one third to one half of
medicines prescribed for long term conditions are not
taken as directed. The non-adherence can be
intentional or unintentional and within these two
high level categories there are various sub-categories.
Understanding these issues is critical to developing
targeted interventions to help patients and various
approaches have been tried, many involving
community pharmacists. These are summarised in a
recent NICE Clinical Guideline and include the
opportunity for shared decision making, accepting
patient’s decisions, and asking about adherence in a
non-judgemental way. Evidence was presented
showing that Medicine Use Reviews for Asthma
decreased short-acting beta agonist use by 25% and
decreased emergency hospital admissions by 50%.  
Antimicrobial Resistance
Rachel Nugent from the Centre for Global
Development, USA, asked “What will be the global
status of Antimicrobial Resistance in 2020?” Already in
2009, resistance is a serious global problem.
Resistance is occurring across major diseases and is
rising as drug use increases. Nonetheless, incentives to
prevent drug resistance are misaligned and
inadequate. Over 30% of children with pneumonia are
not treated with the appropriate antibiotic; less than
40% of patients with acute diarrhoea are treated
according to standard treatment guidelines; only
about 50% of malaria cases are treated appropriately.
Globalisation and urbanisation will increase over the
next decade which can lead to increased transmission
of already resistant pathogen strains. Antimicrobial
resistance currently costs the USA in excess of $30
billion; most of this is due to the extra cost of care as
a result of the resistance. 
Competition, Regulation and Pharmacy
Dr Martin Henman from Ireland asked the question
“Can increased competition and regulation deliver
quality pharmacy Services?” When the new Pharmacy
Act was introduced in Ireland in 2007, the Minister for
Health and Children announced that “the new
legislation will increase competition and raise
standards in the pharmacy sector”. The theory of
competition is that markets are self-regulating and it
is in the interest of the State not to interfere in their
operation. The theory in relation to the pharmacy
sector is that pharmacy is a market for the supply of
medicines and therefore more pharmacies lead to
more choice for consumers, more competition among
pharmacies for patients, increased quality of service
and lower prices. However, in reality, patients have
their own criteria for using a pharmacy, determine
themselves whether to take their medicine and
determine whether they have a medical problem or a
lifestyle choice. 
Regulation may be needed to take account of the
special characteristics of goods. However, in reality, it
can only be easily applied to measurable activities, can
create a burden of documentation and verification,
establishes a minimum level of practice and
practitioners comply with the minimum to defend
their practices. 
Nonetheless, competition and regulation can produce
quality pharmacy services if the desired outcome is a
clear role for the pharmacist as an independent
practitioner, there is an agreed process for
collaborative care and the service is focused on the
care of the patient, the whole patient and nothing but
the patient.
The 70th World Congress of Pharmacy and
Pharmaceutical Sciences 2010 will take place in Lisbon,
Portugal from 28 August – 2 September 2010. The
theme of the conference will be “From Molecule to
Medicine to Maximising Outcomes – Pharmacy’s
Exploratory Journey”. Members are encouraged to
attend this conference to meet and share experiences
with pharmacy colleagues from all over the world. 
3. 18TH GENERAL ASSEMBLY OF EUROPHARM FORUM
The 18th General Assembly of the Europharm Forum
was held in Budapest on 10 October 2009. 57 people
attended the meeting representing 19 countries and a
range of observer organisations. The IPU was
represented by the Director of Pharmacy Services.
Europharm Forum Priorities
Europharm Forum is a joint network of national
pharmacy associations and the WHO Regional Office
for Europe. The mission of Europharm Forum is to
improve health in Europe according to priorities set up
by WHO and to strengthen the position of
pharmacists by showing their value to people involved
in health issues. 
The Forum’s Vision to Practice 2020 is based on six key
principles:
■ Practice adapted to new public expectation;
■ Practice close to patients;
■ Provide up-to-date and evidence-based therapies
and services;
■ Ensure quality based on Good Pharmacy Practice;
■ Secure a competent workforce (education,
training);
■ Provide integrated care in a collaborative practice.
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To achieve this vision, Europharm Forum translates
WHO and FIP strategies into the European context
and supports PGEU activities in order to inspire
National Associations and practicing pharmacists to
implement good practice. 
Executive Committee
The Executive Committee is composed of: 
■ Th(Dick) Tromp (The Netherlands), President;
■ Balázs Hankó (Hungary), Vice-President;
■ Lidija Petrusevska-Tozi (FYR Macedonia); 
■ Ingunn Björnsdottir (Iceland);
■ Gerald Alexander (UK);
■ Carin Svensson (Sweden).
The Statutes of Europharm Forum were amended to
permit membership of National Associations whose
activities cover all aspects of professional practice; the
previous Statutes stated that the governing body of
National Associations must have a majority of
pharmacists. An amendment was also made to permit
future proposed changes to the Statutes to be done in
a more timely matter. 
Future of Europharm Forum
A consultation with members was carried out in April
2009 in Copenhagen where the issues facing
Europharm Forum were discussed. It was agreed at
the consultation that Europharm Forum needed to
improve its focus and improve the synergies between
FIP, PGEU and other organisations working within
pharmacy practice and to reduce the overlap and
duplication of efforts so that maximum outcome may
be achieved. 
It was proposed that an Advisory Group be set up to
review the challenges facing Europharm Forum in
2010 and make recommendations for its future. It was
also agreed that the fee structure would be reviewed.
In the meantime, activity levels will be kept as high 
as possible. 
Collaboration with Other Organisations
PGEU would like to commit to an agreement between
both organisations as the Forum can provide
professional evidence to support PGEU’s lobbying. 
FIP considers Europharm Forum to be the ‘arms and
legs’ of FIP in Europe and sees the Forum’s role as
implementing FIP strategy in Europe. FIP has
broadened its scope with other organisations such as
United Nations, World Bank, WHO Geneva and other
global donors. FIP is willing to support Europharm
Forum in having access to these organisations. 
WHO Copenhagen (Europe) acknowledged the
importance of Europharm Forum in assisting WHO to
improve health in Europe and offered to assist the
Forum in communications with WHO Geneva (Global). 
Observatory
In May 2009, Europharm Forum launched a new
initiative, the Observatory, to provide members with
easy and reliable access to information on
developments and experience within pharmacy
practice. This instrument provides a result of quality
superior to that of a Google search. National
Associations and their members can access the
Observatory through www.europharm.pbworks.com 
Reports
During 2009, Europharm Forum produced two reports
through its working groups: The Role of the
Pharmacist in Fourteen National Pandemic Influenza
Preparedness Plans in Europe; An Analysis and A
Framework for a Guide on Counterfeit Medicines for
Pharmacists. 
The 19th Annual Meeting of the Europharm Forum will
take place on 1 October 2010 in Copenhagen, Denmark.
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Report of IPU Strategy Review Group
The IPU Executive Committee established the Strategy
Review Group for the purposes of revising the Strategy for
the IPU in the period 2010 to 2012. Following input from
members, the HSE and others, the IPU 2010–2012 Strategy
was presented to members at regional forums in March.
The Strategy is available on www.ipu.ie 
The Executive Committee has overall responsibility for the
implementation of the Strategy. After considering the
report from the Strategy Review Group and feedback from
individual members, the Executive Committee has
established action plans and timescales for the
implementation of the new strategy. Updates on these
plans will be provided at six monthly intervals.
2010 AGM Motions
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The following motions, proposed in accordance with
Article 29 of the Constitution, are brought before the
meeting for consideration:
1. Proposed: Liz Hoctor
Seconded: Darragh O’Loughlin
“That this AGM calls on the HSE and the Department
of Health and Children not to introduce the
Prescription Levy for patients on the Medical Card
and Long-Term Illness Schemes but instead to work
with pharmacists to ensure more cost-effective use
of medicines through structured medicine use
reviews for patients, where appropriate.”
2. Proposed: Rory O’Donnell
Seconded: Paul Fahey
“That this AGM calls on both the Minister for
Enterprise, Trade and Innovation and the Minister for
Health and Children to ensure that any exemption
that may be granted in the new Competition Act to
the Irish Medical Organisation should also apply to all
representative bodies for healthcare professionals.”
3. Proposed: Noel Stenson
Seconded: Morgan Power
“That this AGM calls on the Minister for Health and
Children to exercise caution if she decides to
introduce Reference Pricing and to ensure that the
supply of vital medicines to patients is maintained
and the viability of community pharmacy is not
further undermined.”
4. Proposed: Stephen Nolan
Seconded: Rory O’Donnell
“That this Union calls upon the Minister for Health
and Children and the HSE to implement the
recommendations of the Joint Committee for Health
and Children, published in their Report on Primary
Medical Care in the Community, that the role of the
pharmacist be expanded to provide additional
healthcare services to patients.”
5. Proposed: Bernard Duggan
Seconded: Catriona O’Riordan
“That the Employee Pharmacists’ Committee of the
IPU calls on the Minister for Health and Children to
ensure that funding is provided for the one year
practical intern training completed under the
supervision of a practicing tutor pharmacist in line
with similar practical training funding already
provided to other Primary Healthcare Professionals
such as GPs and Nurses.”
6. Proposed: Fearghal O’Nia
Seconded: Catriona O’Riordan
“That this Union calls upon the Minister for Health
and Children to amend Section 14 (1) (f) of the
Pharmacy Act, 2007 which prohibits pharmacists who
become bankrupt from registering with the
Pharmaceutical Society of Ireland.”
7. Proposed: Joe Carroll
Seconded: Brian Walsh
“That this Union calls upon the Minister for Health
and Children to proactively engage with the
Pharmaceutical Industry and the Irish Medicines
Board to encourage the deregulation of appropriate
medicinal products from prescription only to
pharmacist supervised sale.”
8. Proposed: Joe Carroll
Seconded: Ultan Molloy
“That this Union calls upon the Minister for Health
and Children to ensure that Medical Card holders,
who are experiencing huge delays in having their
cards renewed because of HSE structural
reorganisation, are not placed in a position of
financial hardship by having to pay for their
medicines while their cards are expired.”
9. Proposed: Richard Collis
Seconded: Edward MacManus
“That this AGM endorses the IPU in its work to
support IPOS purchasing pharmacists and calls on
the Union to continue its endeavours in working
towards a fair, equitable and timely resolution of all
outstanding issues between stakeholders.” 
10. Proposed: Ultan Molloy
Seconded: Padraig Loughrey
“That this AGM urges the Irish Pharmacy Union to
consider exploring new avenues of working in
partnership with the three third level institutions
offering degree courses in Pharmacy in Ireland.”
Appendices
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Appendix I
EXTRACT OF SUBMISSION BY THE IPU TO THE EXPERT GROUP ON RESOURCE ALLOCATION AND FINANCING IN THE HEALTH SECTOR 
19 June 2009
1. INTRODUCTION
The IPU welcomes the opportunity to make a
submission to the Expert Group on Resource Allocation
and Financing in the Health Sector and show how
community pharmacies can deliver on Government
healthcare priorities and achieve true value for money.
2. ROLE OF THE PHARMACIST
The wide-ranging professional role of the pharmacist is
poorly appreciated by the State – notwithstanding the
fact that non-dispensing services prevent the
emergence of a large volume of demand in other parts
of the Irish healthcare system, such as A&E. In 2007, for
example, in the area of minor ailments alone,
pharmacists provided free consultations on 15 million
occasions. In the Review of the Pharmacy Sector 2007,
PricewaterhouseCoopers (PwC) estimated the value of
pharmacist-prevented demand to be €460 million. The
Exchequer was the main beneficiary. 
3. GOVERNMENT HEALTHCARE POLICY
Governments throughout the western world are
developing the role of the pharmacist in primary care in
response to changing demographics, health policies
and life expectancy. In many European Member States,
the health authorities recognise that many services,
which up to now were not provided at all or were only
provided by other healthcare professionals including
GPs and hospitals, can be provided in a more timely and
cost effective manner through community pharmacies.
The authorities in these countries realise that
community pharmacy is an untapped professional
resource which, if used to its full potential, can relieve
pressure in GP surgeries and Accident & Emergency
facilities in a cost effective manner as well as saving
patients time and money.
The Tallinn Charter, which was signed in June 2008 by
all Ministers for Health and Finance under the umbrella
of the World Health Organisation’s Regional Office in
Europe, highlights that health systems should integrate
targeted disease-specific programmes into existing
structures and services in order to achieve better and
sustainable outcomes. It goes on to say that health
systems need to ensure a holistic approach to services,
involving health promotion, disease prevention and
integrated disease management programmes, as well
as coordination among a variety of providers,
institutions and settings, irrespective of whether these
are in the public or private sector, and including primary
care, acute and extended care facilities and people’s
homes, among others. The Charter also highlights that
effective primary care is essential, providing a platform
for the interface of health services with communities and
families and for inter-professional cooperation and health
promotion. In the Charter, the Member States commit to
promoting shared values of solidarity, equity and
participation through health policies, resource allocation
and other actions, ensuring due attention is paid to the
needs of the poor and other vulnerable groups. 
In Ireland, there are a number of Government policies
that advocate that healthcare services should be
delivered through primary care where possible. 
The Department of Health & Children’s Policy
Framework for the Management of Chronic Diseases
entitled Tackling Chronic Disease, published in April
2008, points to the need for an integrated approach to
tackle both the prevention and management of chronic
diseases. The framework sets out the principles which
should be applied for effective and efficient
management of chronic conditions. Broadly, the aims of
the policy are:
■ To promote and to improve the health of the
population and reduce the risk factors that
contribute to the development of chronic disease
(disease prevention programmes); and
■ To promote structured and integrated care in the
appropriate setting that improves outcomes and
quality of life for patients with chronic conditions
(disease management programmes). 
In the Minister for Health’s foreword, she says that
“Much of this care [of chronic diseases] can and should
take place within the primary care setting.” The report
goes on to recommend that future primary care
contracts should include enabling provisions with
respect to the management of chronic conditions. 
The Joint Committee on Health and Children published
a report in April 2007 on the Adverse Side Effects of
Pharmaceuticals. One of the recommendations in this
report was that the role of the pharmacist in
community health should be expanded and provision
made for regular medication reviews for all patients.
Another recommendation was that there is a need for
public information campaigns to improve public
attitudes to the proper use of medicines including:
■ advising patients that many medical problems are
self-limiting and they should not always demand
or expect prescriptions when they visit doctors;
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■ encouraging compliance with courses when a
prescription is given;
■ disposing safely of unused pharmaceuticals in
collaboration with pharmacists; 
■ raising awareness of the dangers of self-prescribed
medicines including internet, counterfeit and
imported medicines; and 
■ promoting awareness of adverse drug reactions
among patients and of the desirability and the
means of reporting them to the Irish Medicines
Board.
In her budget speech on 14 October 2008, the Minister
for Health and Children said: “We must promote
wellness and disease prevention to allow people to live
healthily and independently. We must ensure that if
people need a service, it is provided in their own homes
and communities through primary care.”
The Consumer Strategy Group Report from the
Department of Enterprise, Trade and Employment,
published in 2006, called for pharmacists to be given
the power to substitute generically.
In February 2009, the Barry Report on Economies in
Drug Usage in the Irish Healthcare Setting
recommended that medicine use reviews should be
considered in an attempt to improve compliance and
health outcomes as well as reducing wastage
associated with prescription medicines.
Over the coming months, the Health Service Executive
(HSE), as part of a review of the existing contract
between pharmacists and the State, will be considering
with the Union the nature of the role that could be
played by pharmacists in the delivery of healthcare
services. The IPU hopes to take this opportunity to
expand the professional role of pharmacists to develop
additional pharmacy services for patients in the
community. The objective behind many of these
initiatives is to assist Government in delivery of its
health policies by enhancing healthcare services that
patients receive in the community so that patients are
less likely to end up in hospital or in nursing home care.
Extending pharmacy services can deliver on both these
fronts, allowing the HSE to deliver its core activities in a
more efficient and effective way.
4. EXTENDED PHARMACY SERVICES
Patients need better services and health outcomes and
Government continues to seek better value for money.
In this context, the Union has been advocating the
introduction of the following cost-saving initiatives:
a. Medicines Use Review
b. Minor Ailments Scheme 
c. Structured Health Promotion Services
d. Health Screening Services
e. Generic Substitution
a. Medicines Use Review
The objective of any review of expenditure on
medicines must be done with a view to ensure better
health outcomes for patients and to maximise value for
money. A strategic approach should be adopted
therefore which addresses the wider issues of usage,
compliance and support for patients. 
In Ireland, once a medicine is dispensed, there is no
structured follow-up on drug compliance or wastage. In
this context, the Union is proposing that a one-on-one
medicines use review should be undertaken by a
pharmacist with a patient who is on a complicated
medication regime. A pharmacist will review a patient’s
medication to identify any problems that might have
arisen. Most likely these would be elderly patients or
those who suffer from chronic conditions who would
be on many medications. The purpose of this
intervention would be to improve compliance, reduce
leakage to secondary care and reduce wastage of
medicines.
There is a considerable body of international evidence
to suggest that pharmacist interventions, through
medicines management initiatives, lead to better
outcomes for patients and quantifiable savings. In
Australia, for example, the Government provided
funding for pharmacists to provide domiciliary
medication reviews which resulted in a net saving of
AS$100 per review for each patient. In the USA, it is
estimated that non-adherence, including wasted or
unused medicines, additional medical consultations
and hospital admissions, costs over US$100 billion. 
b. Minor Ailments Scheme
The primary aim of a Minor Ailment Scheme is to
enable medical card patients to receive treatment of
common illnesses free of charge direct from their local
community pharmacy. The basis of the GMS Scheme is
to provide full pharmaceutical services for persons who
are unable, without undue hardship, to provide such
services for themselves and their dependants. This
raises an issue of parity of access to such medicines. 
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Many of the GMS products are available to those who
can afford them over the counter without having to
visit a GP to obtain a prescription. However, in order to
receive these medicines free of charge, medical card
patients must visit their GP to get a prescription for
these non-prescription items. The IPU has proposed
that GMS eligible patients should not have to go to
their GP to receive treatment for specified minor
ailments that can be treated by the pharmacists from
the agreed list of GMS reimbursable items which are
exempt from prescription supply. 
This enhanced role for pharmacists has been
introduced in Scotland and Northern Ireland with
considerable success. It is estimated that in Northern
Ireland up to 39% of GP workload in the winter can be
spent dealing with minor self-limiting ailments which
could be treated by the community pharmacist. The IPU
believes that pharmacists are in an ideal position to
treat routine ailments. Such a scheme would facilitate
more prompt treatment of ailments thereby improving
the quality of life for patients, alleviating pressures on
GP surgeries, facilitating patients during out-of-surgery-
hours and also preventing unnecessary use of Accident
and Emergency and out-of-hours GP services.
c. Structured Health Promotion Services
With 636,000 people visiting community pharmacies
every week in Ireland, pharmacists are in an ideal
position to communicate health promotion messages.
The pharmacist has an important role to play in health
promotion, both as a source of education to patients
and as a means to improving lifestyle. The Union
initiated a number of its campaigns in recent years in
conjunction with patient groups. The Union is seeking a
more structured health promotion role for pharmacists
with the support of the HSE.
In March 2005, the Union ran a campaign called Ask
about Your Medicines, designed to encourage patients
to ask their pharmacist for more information about
their medicines. In 2006, the Union focused more on
the management of chronic diseases in our health
promotions, looking at heart disease, smoking cessation
and diabetes. The main aim of the campaigns was to
make people aware of the risk factors associated with
these diseases and to encourage them to adopt a
healthier lifestyle with a view to preventing heart
disease and diabetes, rather than waiting for it to occur
and then treating it.
In 2007, the Union’s health promotions focused on the
safe use of pain relievers and treatment of minor
ailments. In 2008, we looked at inhaler technique in
asthma, medicines in the elderly and problems
associated with overuse of antibiotics. In 2009, our
health promotion in February gave advice on health
service entitlements and our May promotion focused
on ailments in children. 
d. Health Screening Services
Pharmacists are well placed to delivery screening
services in the pharmacy. Examples would include blood
pressure and cholesterol screening as well as giving
people an indication of whether they are at risk of
developing diabetes. Pharmacists could advise at-risk
patients on diet, exercise and other lifestyle issues as
well as referring patients to a GP where necessary.
Approximately 60% of the disease burden in Europe is
accounted for by 7 leading risk factors comprising high
blood pressure, tobacco, cholesterol, overweight, poor
diet and physical inactivity.
In the Tackling Chronic Disease Report, it is estimated
that 80% of cardiovascular disease and Type 2 diabetes
as well as 40% of cancer could be avoided if major risk
factors were eliminated. The WHO estimates that 86%
of deaths and 77% of disease burden are caused by
chronic disease; they represent the significant majority
of GP consultations and hospital admissions. It is
estimated that, in Ireland, three quarters of the
healthcare expenditure is allocated to the management
of chronic diseases. In the UK, it is estimated that 5% of
in-patients with a long term condition account for 42%
of all acute bed days. 
Despite this, the OECD has estimated that only 3% of
total healthcare expenditure goes towards population-
wide prevention and public health programmes. It
follows that there should be greater emphasis on
prevention and a greater reorientation towards primary
care and more health promoting services to achieve
this. Data from the USA has shown that chronic disease
management programmes can achieve a 50%
reduction in unplanned hospital admissions as well as a
50% reduction in bed day rates for these conditions. 
The treatment of Type2 Diabetes, the most common
form of diabetes prevalent in Ireland, costs the health
service €580 million each year. This could be
significantly reduced through investment by
Government in the prevention of diabetes and
diabetes-related complications. Pharmacists have the
necessary skills to play a key role in this area in an
informal and accessible environment. 
e. Generic Substitution
In Ireland the pharmacist must dispense the medicine
that is written on a prescription. As part of the proposal
for expanding the professional role of the pharmacist,
the Union is advocating for pharmacists to be enabled
to dispense an alternative medicine, where it is safe to
do so. In this way the pharmacist would be able to offer
less expensive generic alternatives. This is called generic
34
A N N UA L  R E P O RT  2 0 1 0  
substitution. Pharmacists have the right to do this in
many other countries such as Denmark, Germany,
Finland, Netherlands, Poland, France, Italy, Portugal,
Spain and Sweden. 
The Pharmaceutical Care Management Association in
the USA calculates that for every 1% increase in generic
utilisation, there is a 0.5% drop in overall drug
expenditure. In Finland in 2003, generic substitution by
pharmacists occurred on 14% of all prescriptions leading
to savings of €40 million which represents 5% of the
total medicines bill.
The National Centre for Pharmacoeconomics estimated
that in 2007 on the GMS Scheme alone, 20% of the
ingredient cost was spent on proprietary medicines
where an equivalent generic was available. It is
estimated that there are potential savings of €30
million on the GMS Scheme. The Union believes that
this is a conservative estimate and that greater savings
could be achieved through a pharmacist-led generic
substitution scheme. The Union has made a number of
submissions calling for generic substitution but the
Department of Health and Children and the HSE have
not as yet taken up this proposal. 
f. Other Community Pharmacy Services
There are a number of other extended community
pharmacy services which the Union would like to see
introduced into community pharmacies, for example,
monitored dosage systems, services to
residential/nursing homes, extended methadone
services, pharmacy based needle exchange, vaccination
clinics, community based palliative care services,
pharmacy based warfarin clinics and chronic diseases
management services. The Union would be happy to
furnish the Expert Group with further details of these
services if required. 
4. CONCLUSION
Community pharmacists, as the experts in medicines
and as independent healthcare professionals, are
recognised as a valuable resource capable of delivering
more on Government healthcare priorities in a timely
and cost effective manner which would provide true
value for money. With the shortage of funding for the
HSE in the current economic climate, it makes sense to
look for new ways to deliver healthcare services to
patients. The forthcoming merger of PCCC and the
National Hospitals Office in September 2009 provides
an ideal opportunity for the HSE to move a significant
number of healthcare services out of secondary care
and into primary care. Community pharmacies provide
the perfect location for some of these new primary care
services to be delivered to patients. 
Appendix II
EXTRACT OF SUBMISSION BY THE IPU TO THE REVENUE COMMISSIONERS ON TAXATION OF LOCUMS (PREPARED BY BAKER
TILLY RYAN GLENNON, ACCOUNTANTS TO THE IPU)
26 June 2009
We have been retained by the Irish Pharmacy Union (IPU) to
make representations to your office regarding the tax
treatment of locums retained from time to time by
pharmacies. By way of background we note that various
District Tax offices have issued documentation to
pharmacies requesting PAYE to be applied forthwith to all
payments made to locums. 
We also note that at a meeting with the IPU last year, you
advised the IPU that in Revenue’s view an
employer/employee relationship existed in relation to ALL
locum appointments regardless of the many commercial
arrangements possible in practice and irrespective of the
fact that in some cases the locums themselves were being
seconded through the medium of limited companies which
had obtained VAT and PAYE registration in the normal way.
1. EMPLOYED V SELF EMPLOYED STATUS
Trading through medium of limited company
The formation by any individual of a limited company
has for many years being seen as synonymous with the
establishment of a business structure appropriate to
and reflective of trading rather than employment
activities. A company is a separate legal entity from that
of its shareholders and employees and from a general
legal perspective cannot be “employed” by another
company.
In our view when a locum sets up a company, obtains
VAT and employer registration for tax purposes and
then arranges for the company to issue invoices for the
secondment of staff to a pharmacy (i.e. the locum), an
employer/employee relationship does not exist
between the company and the pharmacy and
consequently PAYE should not be deducted at source
from payments made. 
It is appreciated that Revenue may well be concerned
with situations where such an arrangement is abused –
for example where a locum seconded by a limited
company is on site for a protracted period – however
this should not change the correct application of
general law in this area.
Multiple appointments
On behalf of the IPU we have engaged extensively with
locums and note that a significant number have
between 5 and 12 concurrent appointments at any one
time. By their definition locum appointments are short
lived and are obtained very much through word of
mouth on an ad hoc basis. Formal employment
contracts are not used and locums do not obtain any of
the benefits of employees. 
As Revenue is aware a key distinguishing feature
between an employee and self employed person is the
number of clients or appointments that that person
has at any one time. In general principles it is submitted
that when a person has multiple appointments of this
magnitude and is required through his or her own
devices to source through their own resources a large
number of such appointments in order to earn even a
modest income they should clearly be regarded as
being in business on their own account.
It would be submitted that in excess of 4 concurrent
appointments as a locum should be regarded as
evidence of self employment. It will be noted that this
is consistent with Revenue’s own views as expressed
through their technology systems that any more than 4
employments at any one time is not possible.
UK experience
The Irish Revenue approach is at odds with the UK
stated practice in this area which makes a clear
distinction between:
a. Locums retained on a seasonal or daily basis and
who perform statutory requirements only such as
dispensing of medicines – these are regarded as
self employed and payments are not subject to
deduction of PAYE at source; and
b. Locums who take on a full range of the employed
pharmacist duties such as staff supervision, etc. –
these will generally be employees. 
The UK Revenue does not, in summary, adopt a blanket
“one solution fits all” approach and quite sensibly in our
view recognises the range of commercial arrangements
which can be in place in practice. 
We submit that a similar practical approach by Irish
Revenue is required in a manner that assures Revenue
that appropriate safeguards will be put in place to
prevent abuse and we would be happy to meet with
you and discuss this matter as soon as possible. 
2. PRACTICAL DIFFICULTIES ARISING TO EMPLOYED LOCUMS 
As indicated above it is not unusual for many locums to
have as many as 12 live appointments at any one time.
There is an understandable reluctance by locums at the
end of a specific appointment with a pharmacy to
request a P45 as this is seen as a signal that they are no
longer available for further assignments. 
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The Revenue’s system of allocating part of the standard
rate cut off point and tax credits is however only
capable of dealing with 4 live employments at any one
time. This means that the emergency system of
deducting tax is applied to any locums with an excess
of 4 appointments at any one time. This is an ongoing
source of some considerable hardship to locums. 
In addition there are considerable delays between
requesting transfer of tax credits etc to a new
appointment and issuing of the appropriate certificates
to employees. A procedure whereby Revenue officials
were permitted to contact “employers” directly on
receipt of instruction from locums as to the particular
details applicable to that appointment would be of
assistance but it appears that this is not possible. The
effect of this is that by the time the official
documentation arrives with the employer from
Revenue the locum in question has already been paid
with tax deducted under the emergency tax system. 
3. CONCLUSION 
We suggest that a meeting is held with your office as
soon as practical to address both the substantive and
practical issues arising. On behalf of the IPU we look
forward to a constructive engagement with Revenue to
bring about an equitable resolution of the matters
outlined in this submission.
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Appendix III
EXTRACT OF SUBMISSION BY THE IPU TO FINE GAEL ON THE EXPANSION OF THE ROLE OF THE PHARMACIST WITHIN
PRIMARY CARE
9 July 2009
1. INTRODUCTION
The IPU welcomes the opportunity to make a
submission to Fine Gael on the expansion of the role of
the pharmacist within primary care. 
2. ROLE OF THE PHARMACIST
The primary role of the pharmacist is to improve health
outcomes by safely dispensing medicines and advising
patients on how to get the optimum benefit from
them. Pharmacists are able to counsel patients on the
correct use of their medication and can intervene when
a patient requests advice or visits the pharmacy for any
reason. However, there is considerable scope to develop
the current level of professional services delivered by
community pharmacies into a more comprehensive,
structured and organised service to the community. 
3. EXTENDED PHARMACY SERVICES
Patients need better services and health outcomes and
Government continues to seek better value for money.
In this context, the Union has been advocating the
introduction of the following cost-saving initiatives:
■ Medicines Use Review
■ Minor Ailments Scheme 
■ Structured Health Promotion Services
■ Health Screening Services
■ Generic Substitution
There are a number of other extended community
pharmacy services which the Union would like to see
introduced into community pharmacies, for example,
monitored dosage systems, services to
residential/nursing homes, extended methadone
services, pharmacy based needle exchange, vaccination
clinics, community based palliative care services,
pharmacy based warfarin clinics and chronic diseases
management services. The Union would be happy to
furnish Fine Gael with further details of these services if
required. 
4. CONCLUSION
Community pharmacists, as the experts in medicines
and as independent health professionals, are
recognised as a valuable resource capable of delivering
more on Government healthcare priorities in a timely
and cost effective manner which would provide true
value for money. With the shortage of funding for the
HSE in the current economic climate, it makes sense to
look for new ways to deliver healthcare services to
patients. The forthcoming merger of PCCC and the
National Hospitals Office in September 2009 provides
an ideal opportunity for the HSE to move a significant
number of healthcare services out of secondary care
and into primary care. Community pharmacies provide
the perfect location for some of these new primary care
services to be delivered to patients. 
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Appendix IV
EXTRACT OF SUBMISSION BY THE IPU TO THE OFFICE FOR OLDER PEOPLE ON THE NATIONAL POSITIVE AGING STRATEGY
24 September 2009
1. INTRODUCTION
The IPU welcomes the opportunity to make a
submission to the Office for Older People on the
National Positive Ageing Strategy to show how
community pharmacists can assist Government in
creating an environment in which the independence
and dignity of every older citizen is assured. In particular,
community pharmacists, working in conjunction with
other health professionals, are in a position to provide
the service and support which enables older people to
live healthy and fulfilling lives for as long as possible at
home in their own community. 
2. ROLE OF THE PHARMACIST
Pharmacists are in a unique position to contribute to
the care of older people and to alleviate the workload of
other healthcare professionals in tackling related issues.
In recessionary times, it makes sense to use an existing
resource, community pharmacy, to its maximum
potential. People need no appointment and they have
ready access in a familiar, informal environment to
expert knowledge about medicines in particular and
healthcare generally. Community pharmacists are close
to their patients and their carers, know their personal
and family history, their social environment and their
overall medications. However, pharmacists are the most
under-utilised resource in the health service and there
is considerable scope to develop the current level of
professional services delivered by community
pharmacies into a more comprehensive, structured and
organised service to the community in general and
older people in particular. 
3. GOVERNMENT POLICY
It is Government policy that “every older person would
have adequate support to enable them to remain living
independently in their own homes for as long as
possible”. The Government provides funding to support
this policy and a key area supported by this funding is
the Home Care Support Package. The Health Service
Executive (HSE) has responsibility for the delivery of
home care support at local level; to date, community
pharmacies have had no input into this scheme. 
The main priority of the Home Care Support Package is
older people living in the community or those who are
in-patients in acute hospital at risk of admission to
long-term care. Home Care Packages are also available
to those older people who have been admitted to long-
term care and who can, with support, return to the
community. In addition, Home Care Support Packages
are available for young, chronically sick people and
others who could continue to live at home provided
they had adequate support. 
The IPU is advocating the expansion of the role of the
community pharmacist to allow for the development of
additional pharmacy services for older patients. The
objective behind many of these initiatives is to assist
Government in delivery of its health policies by
enhancing healthcare services that patients receive in
the community so that patients are less likely to end up
in hospital or in nursing home care. The HSE is looking
to make considerable savings whilst ensuring that
patients’ needs are accommodated. Extending
pharmacy services can deliver on both these fronts,
allowing the HSE to deliver its core activities in a more
efficient and effective way.
Despite the efforts of competent and dedicated
healthcare professionals, many healthcare systems are
being pushed to a crisis stage because of unrelenting
pressures related to cost, quality and access.
Demographic aging, the introduction of new medical
technology and people’s growing expectations
concerning healthcare services all play a role in this
development. Since people are living longer,
combinations of serious and chronic illnesses are also
becoming more and more prevalent. Without major
changes, the current paths of healthcare systems in
many countries will become unsustainable in the next
decade. We need to ensure that older people remain in
good health for as long as possible by introducing a
more patient-centred care system and stimulating
more personal responsibility. New levels of
accountability, tough decisions and collaborative hard
work on the part of all stakeholders will be required to
transform the Irish healthcare system into a national
asset.
4. EXTENDED PHARMACY SERVICES
Older patients need better services and health
outcomes and Government continues to seek better
value for money. In this context, the Union has been
advocating the introduction of the following cost-
effective services:
■ Medicines Use Review
■ Monitored Dosage Systems
■ Minor Ailments Scheme 
■ Structured Health Promotion Services
■ Health Screening Services
■ Generic Substitution
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There are a number of other extended community
pharmacy services which the Union would like to see
introduced; for example, services to residential/nursing
homes, vaccination services, community based palliative
care services, pharmacy-based warfarin clinics and
chronic diseases management services. 
5. CONCLUSION
Community pharmacists, as the experts in medicines
and as health professionals, are recognised as a
valuable resource capable of delivering more on
Government healthcare priorities in a timely and cost
effective manner, which would provide true value for
money. With the shortage of funding for the HSE in the
current economic climate, it makes sense to look for
new ways to deliver healthcare services to patients.
Community pharmacies provide the ideal location for
some new primary care services to be delivered to
patients with a particular focus on older people. In
particular, older people and those who are chronically ill
need timely access to medications and advice on their
safe and effective use. This is important from a
reassurance perspective, giving them the confidence to
continue to live independently in their own
communities. The existence of a relationship between
these individuals and their community pharmacist
provides the ideal framework to deliver primary care
services, which would result in positive outcomes being
achieved in a cost effective manner. 
Appendix V
EXTRACT OF IPU SUBMISSION ON A PAYMENT/REIMBURSEMENT MODEL FOR THE NEEDLE EXCHANGE PROGRAMME
October 2009
The Union is making this submission to the Health Service
Executive (HSE) on behalf of its members who have agreed
to provide a Needle Exchange Programme to patients on
behalf of the HSE. The Union believes that there is no
reason, legal or otherwise, why the Union and the HSE
cannot negotiate under the Community Pharmacy
Contractor Agreement 1996, where the Minister has
always had the final decision on fees. A process was also
set out by the HSE on 28 April 2008 which would provide a
fair and independent means to address discussions on a
pricing structure for the Needle Exchange Programme. The
Union has set out below the issues that the HSE should
take into account when considering a pricing structure for
the Needle Exchange Programme.
1. SERVICE OUTLINE
The IPU agrees to support and advocate for the roll
out of a Needle Exchange Programme through
community pharmacy on the basis that:
■ The Needle Exchange Group, with officials from
the HSE and the IPU, will continue to meet to
assess the progress of the programme;
■ The position of National Pharmacy Coordinator
will be filled by an appropriate candidate before
the roll out of the programme;
■ The HSE will provide support to all community
pharmacy contractors providing Needle
Exchange;
■ The HSE will, through ICCPE, provide face-to-face
training on Needle Exchange to all pharmacists
in the 65 locations already specified;
■ A distance learning pack will be provided by
ICCPE to assist in the training of other pharmacy
staff;
■ The HSE will provide information for people
participating in the programme;
■ All staff working on the premises should be
aware that a Needle Exchange Programme is
being operated and should be covered for
Hepatitis B immunisation by the HSE;
■ The HSE will provide a protocol on the
management of needle stick injuries;
■ The HSE will provide stickers to be displayed in
participating pharmacies; 
■ The HSE will provide clean injecting equipment
locally and a safe disposal system for the return
of used injecting equipment;
■ The HSE will provide sharps bins and set up
collection services for pharmacies providing the
Needle Exchange Programme;
■ The HSE will, in conjunction with the IPU in the
Needle Exchange Group, address any areas of
concern that arise for pharmacies participating
in the programme in a timely manner.
2. PRICING STRUCTURE
There is a considerable workload for community
pharmacists involved in the operation of the Needle
Exchange Programme and this should be
acknowledged by the HSE. Factors to be taken into
account when considering a pricing structure should
include, but are not limited to:
■ The impact on the pharmacy’s staff;
■ The impact on other pharmacy customers;
■ Added administrative burden on community
pharmacies providing the service;
■ The training needed for pharmacy staff working
in participating pharmacies;
■ The extra time and counselling needed for this
patient cohort;
■ The labour-intensive nature of provision of
Needle Exchange Programme.
The Union would suggest that the pricing structure
for the Needle Exchange Programme to be rolled out
through community pharmacy be based on the
model currently operating in Scotland. The payment
structure in the Scottish model is based on a
combination of an annual retainer fee paid to each
pharmacy participating in the scheme and a payment
per transaction with the patient. The annual retainer
is paid to the pharmacy immediately upon
agreement to provide the service and regardless of
number of patients. The Union would ask the HSE to
bear in mind that the costs for operating a pharmacy
in Ireland are significantly higher than costs in
Scotland. The pharmacy sector in Ireland is also
deregulated unlike the highly regulated sector in
Scotland and this should be reflected in a higher
retainer fee than £1,000, which is the average
currently payable in Scotland. 
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A transaction would be regarded as either the patient
handing over used needles to the pharmacist or the
pharmacists providing clean needles. In some
instances there would be two transactions with the
patient handing over the used needles and the
pharmacist giving the patient clean needles. These
interactions may not always take place at the same
time. There may be a time lapse of hours or days. In
light of this the Union would expect separate
transaction fees to be paid for collection of used
needles and for issuing of clean needles. 
Given the nature of the work, the commitment
required and the administrative burden involved, the
Union suggests that a fee of €5 per transaction
would be appropriate. Obviously where a pharmacist
has taken in used needles and issued clean needles
to the patient then this should attract two fees
whereas if a pharmacist only accepts the used
needles or alternatively only issues clean needles a
single fee would be applicable. It is important to
acknowledge this difference and the need for a fee
for both interactions with the patient aspects of the
patient interaction. This would also address the
administrative burden on a pharmacist who would
have to fill out paper work for both interactions.
3. WIDER PATIENT CARE ISSUES
The patients who will be participating in the Needle
Exchange Programme are particularly vulnerable and
susceptible to many health problems. By operating
the Needle Exchange Programme through
community pharmacy, patients who may not have
any contact with a healthcare professional will now
be attending the pharmacy on regular basis. The
pharmacist is then able, where appropriate, to
engage these patients in wider health promotion
tailored to this specific cohort of patients. These
frequent visits will put the pharmacist in a key
position to maintain a relationship with the patient
and to address any issues of concern. 
4. REVIEW OF THE NEEDLE EXCHANGE PROGRAMME
It is imperative that there is a review of operation of
the Needle Exchange Programme after the initial roll
out of the programme. The IPU would see this review
taking cognizance of the following: 
■ Adequacy of the training course material (both
face to face and distance learning);
■ The work load for pharmacies providing Needle
Exchange;
■ The number of pharmacies providing Needle
Exchange;
■ The locations of the pharmacies providing
Needle Exchange;
■ The level of remuneration (the annual retainer
and the transaction fee) for the provision of
Needle Exchange.
A review should take place six months after the roll
out of the Needle Exchange Programme.
Appendix VI
EXTRACT OF IPU/PHARMACHEM SUBMISSION TO THE IRISH MEDICINES BOARD ON THE SUPPLY OF ANTIPARASITIC
VETERINARY MEDICINAL PRODUCTS TO COMPANION ANIMALS IN IRELAND
30 October 2009
1. INTRODUCTION
The Irish Pharmacy Union (IPU) is the representative
body for pharmacists including pharmacist owners of
community pharmacies. There are approximately three
hundred pharmacies actively involved in supplying
veterinary medicines and providing professional advice
on their safe and effective use. Many of the other 1200
or so pharmacies supply pet medicines to a limited
extent. Pharmachem is the association of veterinary
pharmacists whose objective is to maximise the supply
of veterinary medicines through pharmacy. The IPU and
Pharmachem welcome the establishment of a Working
Group within the Irish Medicines Board (IMB) to look at
the classification of methods of supply of veterinary
anthelmintic and antiparasitic products to companion
animals in Ireland and are pleased to be able to make a
submission on matters pertaining to pharmacy.
2. ROLE OF THE PHARMACIST
Pharmacists spend four years as undergraduates
reading pharmacy to B.Sc. degree level where a
veterinary module is included. These years are spent
preparing to dispense prescriptions and to counsel on
the safe and effective use of medicines. On graduation,
pharmacists spend one year under the supervision of a
tutor pharmacist further developing their dispensing
and counselling skills. It is only then that a pharmacist
assumes professional responsibility. A further three
years continuous dispensing experience is required
before a pharmacist may be a Supervising Pharmacist
recognised by the Department of Health and Children,
the Health Service Executive and the Pharmaceutical
Society of Ireland under the Pharmacy Act 2007. 
Prescriptions are dispensed under a written Code of
Ethics published by the Pharmaceutical Society of
Ireland. As custodians of medicines in the community,
pharmacists provide a means of cross-checking and
support to the prescriber as dispensing is fraught with
problems and risks to public health. Pharmacy provides
a critical role in terms of checks and balances to protect
public health and safety. The attention to detail and the
quality of training is apparent in that pharmacy is the
only section of the Health Service that is working well
and operates efficiently and effectively, particularly with
regard to access, professionalism and quality from a
client’s perspective. Given the pharmacist’s training and
accessibility, the IMB should ensure that pharmacy
retains a strong role in the distribution of veterinary
medicines and vaccines; this is very much in keeping
with the 2004 Directive and its preamble.
3. SUPPLY ROUTES FOR VETERINARY MEDICINES
In September 2009, the Working Group established by
the IMB issued a note Avenues to Explore with
Stakeholders to assist stakeholders with submissions. It
is intended to use their proposed format in this
submission.
What is your opinion on the suitability of the existing
methods of supply for authorised antiparasitic
medicines for companion animals?
The routes of distribution available to the IMB to
designate animal remedies to are stipulated in Part 1 of
Schedule 1 of S.I. 786 of 2007 “European Communities”
(Animal Remedies) (No.2) Regulations 2007. These are,
as abbreviated in Part IV of the schedule, VPO-1, VPO,
POM, POM(E), PS, LM, and CAM. 
Currently the “Prescription Only” (POM) route is the
usual designation. Licence applicants have the
opportunity to indicate their preferred route of
distribution. By choosing POM, companies make a
commercial decision to confine their products to
Veterinary Surgeons, thereby creating a monopoly. If
companies were to apply for a route other than POM,
they may be exposed to negative commercial
sentiment for other products. There is a perception that
the pharmaceutical industry is afraid to upset the
veterinary profession and therefore restricts the
majority of medicines to prescription-only status.
Only a veterinary practitioner may prescribe POM
animal remedies in Ireland. Article 43 (1) states that a
person shall not prescribe an animal remedy unless he or
she is a registered veterinary practitioner…... This means,
for instance, that a vet must prescribe spot-on
treatments for dogs. However, it does not follow that
prescriptions are presented for dispensing because
Article 28 (6) (a) allows: Notwithstanding Paragraph
(4)(b), a registered veterinary practitioner need not write
a veterinary prescription in respect of an animal remedy
prescribed for a companion animal, other than an equid,
if he or she offers a veterinary prescription to the owner
or person in charge of the animal and the offer is
declined.
The effect of this exemption is to undermine the
prescription imperative introduced for non-companion
animals resulting in few, if any, prescriptions being
issued by veterinary practitioners for POM
antiparasitics; the products are supplied directly from
the veterinary practice. This may be contrasted with the
UK where the Marsh Report 2001, followed by the
Competition Authority, found that antiparasitics were
unnecessarily restrictive in their availability and
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directed vets to write prescriptions and allow clients the
opportunity to purchase them at the source of their
choice. Since then, many have been de-regulated to a
non-POM status. Irish legislation should facilitate non-
veterinary practitioner supply of these animal remedies.
As stated, Article 43 confines prescribing to vets. This is
unnecessarily restrictive as Directive 2004/28/EC, Article
1.21, defines a veterinary prescription as any prescription
for a veterinary medicinal product issued by a
professional person qualified to do so in accordance with
applicable national law. We would strongly advocate
that the Department of Agriculture allow pharmacists
to prescribe certain animal remedies by amending
Article 43.
Currently, any animal remedy which is centrally licensed
by the European Medicines Agency (EMEA) is likely to
be designated POM. Stronghold (Pfizer), for instance, is
confined to prescription control and must stay in that
category, irrespective of the availability of safety data of
similar molecules or analogues being available through
other routes of distribution. While these products,
categorised as POMs, restrict availability and access in
the Republic of Ireland, consumers can freely and legally
purchase them in Northern Ireland or the UK, further
undermining the single market philosophy of the
European Union.
POM designations are in place to protect public health,
consumers, animals, the environment – the criteria laid
down in Schedule 1, Part II, Section 3, of the regulations.
Prescription control is essential for many therapeutic
categories, e.g. antibiotics, antihypertensives, etc. One
may question whether ectoparasitics fulfil these
criteria. Many similar licensed products for humans are
used to treat scabies and lice infestations in babies,
children and adults and are available as over-the-
counter products.
It is our opinion that the current use of the available
routes of distribution is too restrictive and, in practical
and operational terms, creates a monopoly for
veterinary practitioners. Legally, if antiparasitic
veterinary medicinal products are designated POM,
Licensed Merchants’ personnel are entitled to dispense
veterinary prescriptions for such medicines, thus
bypassing all professional advice and final warnings for
the end user. The Department of Agriculture has yet to
issue guidelines or protocols for Licensed Merchants to
dispense prescriptions but has specified that the level
of training expected is level CTV 3 to 4. The Responsible
Person in Licensed Merchant outlets currently
completes a three day course without an examination.
The Department of Agriculture has previously
acknowledged that the standard of this training will
have to be raised.
If you think that the method of supply of a specific
product(s) should be amended, what are the reasons
for this?
Pharmacists are the custodians of medicines for society.
Pharmacy allows access to medicines and certain
products which otherwise could be too dangerous as
ordinary items of commerce. The methods of supply
and standards are set by the Pharmaceutical Society of
Ireland governing Retail Pharmacy Businesses under a
Code of Practice. Placing veterinary medicines and
vaccines in POM(E) or PS categories ensures
professional sale and supply in a competitive
environment to animal owners. The routes of supply
include: POM(E), PS, LM and CAM.
POM(E) (Prescription Only Medicine (Exempt)) 
This method is used for animal remedies which, by
therapeutic classification, would be expected to be
POM but, because they do not require veterinary
diagnosis, can be otherwise supplied. The criteria are
laid down in Schedule 1, Part II, Section 4, which are the
same as POM criteria, Section 3 (excluding (b) and (d))
[See Appendix 1]. POM(E) confers a level of importance
to a veterinary medicine in that only a veterinary
practitioner or a pharmacist can personally supply to
the end user. Medicines always require advice to be
given at the time of supply, including details on
administration, reconstitution, storage after a container
is opened and, ultimately, disposal of used containers
and residual material. POM(E) provides for efficient
access to medicines, particularly from pharmacists 
who, by definition, are always available six to seven 
days a week. 
Stronghold should be rescheduled to POM(E), retaining
its E.U. status, but exempted under Paragraph 4. Only a
vet or a pharmacist personally can supply it to the
companion animal owner. This also applies to all other
centrally licensed antiparasitic veterinary medicinal
products. An animal remedy containing an active
substance which has been authorised for use in animal
remedies for less than five years should also be POM(E),
Paragraph 3(f), Appendix 1.
PS (Pharmacy Only Sale) 
This is the ideal route of supply for spot-on antiparasitic
treatments. Paragraph 5 of Schedule 1 lists the
conditions for PS. PS sales are conducted by a
pharmacist or under the supervision of a pharmacist. A
pharmacist is always available to answer questions and 
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advise on the correct use of medicines including animal
remedies:
a. potential risks to the person administering the
animal remedy: Spot-on treatments and sprays
should not come into contact with the user before
or after application. Advice at the point of sale
regarding proper skin protection e.g. wearing
gloves, safeguards the animal owners.
b. possible contra-indications with other commonly
used animal remedies: Many animals are on
concurrent medication or may be given an
anthelmintic simultaneously. A pharmacist is
qualified to advise on poly-pharmacy and the
avoidance of duplication.
c. the method of administration or use or the handling
or preparation prior to use: Spot-on treatments are
usually supplied in pipette formulations. If an
owner is unfamiliar with these preparations,
inadvertent spillage may occur, resulting in under-
dosing. 
d. storage conditions, in particular unusual conditions,
both prior to and during use: If the preparation is
not used at the correct temperature, its bio-
availability by percutaneous absorption may be
affected. 
e. unusual conditions for safe disposal of used, or,
unused, material including containers: Used
containers should be disposed of correctly in order
to avoid contamination of other animals, owners,
children or the environment.
f. the correct dose can be difficult for owners to
calculate: Advice from pharmacists and qualified
pharmacy staff will ensure correct dosing and
compliance.
LM (Licensed Merchant) 
This route allows self-selection of animal remedies. We do
not consider it appropriate for ectoparasitic treatments,
particularly Spot-on treatments, to be available by this
route of distribution. However, anthelmintics are available
by this route for food producing animals as exempted in
accordance with the criteria set down in the EU Directive
2006/130/EC9, negotiated by Department officials in
comotology proceedings. If they can safely be chosen and
administered without professional input, as the
Department thinks, they should be available to companion
animal owners; if they are safe for food producing animals,
they are safe for pets and LM is probably appropriate. POM
for anthelmintics is never justified.
CAM (Companion Animal Medicine) 
This category should be reserved for products with less
potential for harm such as pyrethroid insecticides. 
The IMB should use scientific and legal criteria only when
considering licence applications for animal remedies.
What impact would the proposed amendment have
for animal health and welfare and for the safe and
effective use of the product? 
The use of the POM(E) and PS routes of supply would
allow ready access to antiparasitic veterinary medicinal
products through 1500 community pharmacy
businesses throughout the country. They would continue
to be available through veterinary practitioners.
Consumers would benefit from access to quality
information and advice on the safe and effective use of
these products. Consumers would also benefit from
price competition between suppliers in the market. 
Do you have evidence to support your position?
Changing from one route to another changes the risk
potential for any product. In the UK, VMD
pharmacovigilance data is available since deregulation
of the sector [See Appendix 2]. Comparing it with
similar IMB data, where Frontline has remained on
prescription, should reveal a similar level of adverse
reactions, thus underlining the safety of the
antiparasitic sector in general.
4. CONCLUSION
Irish pharmacy is an underutilised resource. Restrictive
practices, such as little or no access to veterinary
prescriptions for dispensing POMs, or inappropriate
routes of distribution, such as POM instead of POM(E)
or PS, exclude pharmacists from practice. Irish pharmacy
operates under the Pharmacy Act 2007, has a
countrywide network of pharmacies with nearly 4000
highly educated registered pharmacists. This resource
has been paid for by the State through the three
schools of pharmacy. 
If the IMB wishes to see the health of companion
animals improve by increasing the use of antiparasitics,
then wider access will inevitably facilitate that
improvement. If the IMB has concerns about the welfare
of the animals or the safety of the user, then POM(E) and
PS, where the pharmacist is always available, can only
contribute positively. If there is a requirement for
diagnosis, where an animal might have a problem, then
that animal will inevitably referred to the vet.
The current regulatory framework should be utilised to
maximise the potential of pharmacists for the benefit
of owners of companion animals and the animal health
industry. The IPU and Pharmachem recommend that
the POM(E) and PS routes of supply should be the main
method of supply of veterinary medicinal products to
companion animals in Ireland. The IMB should
recognise pharmacists’ expertise and utilise it for the
benefit of animal welfare. We are available to meet
with the IMB to discuss the issues raised in this
submission and any other related matters.
45
Appendix VII
EXTRACT FROM IPU SUBMISSION TO THE PSI ON DRAFT GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY OF
NON-PRESCRIPTION MEDICINAL PRODUCTS CONTAINING CODEINE
15 January 2010
1. INTRODUCTION
The Union welcomes the opportunity to make a
submission to the Pharmaceutical Society of Ireland
(PSI) on its draft guidance for pharmacists on the safe
supply of non-prescription medicinal products
containing codeine. 
2. PHARMACY POLICY ON CODEINE SUPPLY
The Union agrees that a pharmacy policy addressing the
supply of medicines containing codeine should be in
place. Over the past few years, the IPU has produced a
number of Medicines Sales Protocols, designed to assist
pharmacists and their staff in the appropriate sales of
non-prescription medicines to the public. Indeed, in early
December 2009, the IPU and the Irish Pharmaceutical
Healthcare Association (IPHA) jointly produced a
protocol to assist pharmacists in the sale of medicines
containing codeine. This protocol was sent to all
members of the Union and can be downloaded from the
IPU website. A copy of the protocol is attached to this
submission and the PSI is welcome to send it to all
pharmacists on the PSI register. 
3. STORAGE OF CODEINE MEDICINES
The Union agrees with the draft guidance that any
medicinal product containing codeine must not be
accessible to the public for self selection and that
codeine medicines must be stored in an area of the
retail pharmacy business where patients cannot self-
select the product. The Union believes that this area
would be behind the counter. This would ensure that all
sales of codeine medicines would be under the
supervision of the pharmacist, as recommended by the
IPU/IPHA Codeine Sales Protocol. This is also in line with
the guidelines from the Royal Pharmaceutical Society of
Great Britain (RPSGB), following their consultation in
March 2007, in which they highlighted that ‘restrictions
should not preclude methods of display which allow
patients to better view pharmacy medicines’. It is not
practical to store codeine medicines in the dispensary. It
is equally important that they should be placed in the
patient environment, i.e. behind the counter, to
facilitate patient choice, supported by the advice and
supervision of the pharmacist, according to the Codeine
Sales Protocol. 
4. SUPPLY OF CODEINE MEDICINES
The Union agrees with the draft guidance that the
appropriateness for the supply of codeine medicines
should be determined before each sale and that the
duration of treatment should be no longer than 3 days.
The IPU spearheaded a public awareness initiative, in
conjunction with other organisations, in August 2007
highlighting the safe use of pain relievers and the
problems associated with their overuse or abuse. In
particular, people were advised to speak to their
pharmacist on the appropriate use of codeine. The
campaign recommended that people always follow the
instructions which accompany the medicines and not
use them for longer than stated on the pack, unless
advised to do so by their doctor. The campaign
highlighted that taking medicines which contain
codeine for longer than instructed or misusing them
can lead to physical and psychological dependence. The
leaflets distributed during the campaign gave
information on how and when to use products
containing paracetamol, aspirin, ibuprofen and codeine.
Posters in the pharmacy encouraged people to ask their
pharmacist about pain relief. Pharmacists were
provided with a Medicines Sales Protocol to use for all
OTC sales. Local pharmacists around the country gave
local media interviews. The Union would welcome the
opportunity to run such a campaign again in
association with the PSI. 
5. SUSPECTED ABUSE AND/OR MISUSE
The Union supports the proposal that patients should
be facilitated in accessing services which will assist in
the management of codeine addiction. Indeed, in
September 2005, the IPU, in partnership with the
Health Promotion Unit of the Department of Health
and Children, ran a Drugs Awareness Campaign. Posters
in pharmacies encouraged patients to ask their
pharmacist about drugs misuse and abuse and leaflets
gave details of how to access services. The Union would
welcome the opportunity to run such a campaign again
in association with the PSI.
The Union does not believe that an audit or monitor of
the sale and supply of codeine medicines is necessary
as, if pharmacists comply with the Codeine Sales
Protocol, any issues of abuse/misuse will be addressed. 
6. PHARMACOVIGILANCE
The Union regularly reminds members to ensure that
any suspected adverse reactions should be reported to
the Irish Medicines Board via their online reporting
system and will continue to do so.
7. ADVERTISING OF CODEINE MEDICINES 
The Union agrees that advertising of codeine medicines
should be prohibited. 
A N N UA L  R E P O RT  2 0 1 0
46
A N N UA L  R E P O RT  2 0 1 0
8. CONCLUSION
In conclusion, the Union welcomes the intent of the
draft guidance from the PSI on the safe supply of non-
prescription medicinal products containing codeine. The
Union accepts that it is desirable that medicines
containing codeine should not be available for self
selection by the public. However, it is not necessary to
locate the medicines in the dispensary in order to
achieve the objectives of the guidance nor is it practical
from a pharmacist’s perspective in relation to the
efficient workflow in a pharmacy or from the patient’s
perspective in relation to choice of medicines. The
Union looks forward to working with the PSI on the
production of final guidance to incorporate the issues
addressed in this submission. 
47
Appendix VIII
EXTRACT OF IPU SUBMISSION TO THE PSI ON DRAFT GUIDELINES ON PATIENT CONSULTATION AREA 
30 March 2010
1. INTRODUCTION
The Union welcomes the opportunity to make a
submission to the Pharmaceutical Society of Ireland (PSI)
on its draft guidelines on Patient Consultation Area. 
2. TIMING OF THE GUIDELINES
IThe Union wishes to express its concern at the delay in
producing these draft guidelines for consultation. The
Regulation of Retail Pharmacy Business Regulations
2008 (S.I. 488 of 2008) came into force on 29 November
2008. These regulations introduced the requirement to
have a consultation area in a pharmacy, with a
derogation for existing pharmacies until 1 November
2010. The consequences of this are that many pharmacy
owners, in preparation for the end of the derogation,
have already installed a consultation area in their
pharmacies. It is unreasonable to expect pharmacy
owners to now adapt existing consultation areas when
they have expended considerable money to have one
installed promptly to comply with the regulations
during the 17 month period in which there were no
guidelines. Indeed, newly opened pharmacies and
existing pharmacies, during this period, have had their
consultation areas approved by the PSI during
inspections. The Union would therefore advocate that
any existing consultation areas, especially those that
already have PSI approval, should not have to undergo
any changes. Any future consultation areas being
installed should be bound by the new guidelines. 
3. COST OF PROVIDING CONSULTATION AREA
The PSI draft guidelines quote Scotland as one of the
countries which has a requirement for a consultation
area in pharmacies. Community Pharmacy Scotland
commenced its consultation process over seven years
ago and is still working towards having consultation
areas in all pharmacies. Pharmacies were entitled to
apply for a government grant to assist with the
installation, minimum guidelines were imposed and
recognition was given to those pharmacies who
structurally could not install a consultation area at all or
one that would fully comply with the guidelines. 
Community pharmacists in Ireland have already seen
significant increases in the cost of providing a
pharmacy service, not least with a six-fold increase in
PSI fees in recent years while, at the same time, their
payments have been reduced by Government by in
excess of 30%. Now they face an additional cost in
providing a consultation area within the pharmacy.
Such expense is beyond the reach of many pharmacies
in the current economic climate. The Union believes
that pharmacies should be given a grant towards the
cost of the installation of the consultation area, similar
to the grant of €6,370 that the HSE pays to
pharmacists who are involved in the Methadone
Treatment Scheme. The PSI should consider the
precarious nature of the funding model for many
pharmacies at present and should not enforce any
policy that would have a detrimental effect on the
ability of pharmacies to continue to provide a full level
of service to patients. 
4. PRACTICALITY
The PSI must consider the scope to provide a
consultation area in the average Irish pharmacy. Some
pharmacy owners have reported that they will find it
challenging, and in some cases impossible, to install a
consultation area within their pharmacy due to
limitations in space. Many existing pharmacies would
struggle to install a consultation area without major
structural work or refit taking place. The PSI must adopt
a flexible approach to these pharmacies. In some cases,
the only suitable place may be adjacent to a storeroom.
The prohibition of an entry through the consultation
area is not practical in these and other cases and should
be replaced with a stipulation that some system should
be in place to prevent disturbance during a
consultation.
Other practical considerations should be applied; for
example, a temporary designation of a given area of the
pharmacy or a partitioned counter space should be
acceptable to meet legislative requirements. 
5. WHEELCHAIR ACCESS
Many existing pharmacies, through no fault of their
own, are not wheelchair accessible. This could be due to
planning limitations or restrictions. Therefore, it does
not make sense that the consultation area must be
wheelchair accessible for all pharmacies. The guidelines
should state that, where possible, the consultation area
should be wheelchair accessible. 
6. LOCATION OF CONSULTATION AREA
The guidelines state that the consultation area should
be close/adjacent to the dispensary. Whilst this would
be practical for single pharmacist stores, it should not
be a blanket requirement for all pharmacies as some
have multiple pharmacists employed and this should
be reflected in the guidelines. 
7. SAFETY AND SECURITY
Whilst we acknowledge that it is useful to have an area
in the pharmacy where pharmacists can talk to their
patients in private, there is a concern amongst the
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profession about the safety and security of the
pharmacist being in a relatively enclosed space with an
unstable patient. Whilst we recognise that this issue is
addressed in the guidelines, there is a concern that
pharmacists are leaving themselves open to allegations
from patients that inappropriate behaviour occurred
whilst in the consultation area. Consequently, the
consultation area should not be so secluded as to
facilitate such allegations. Equally, a pharmacist must
be able to decide if it is appropriate or not to engage
with the patient in the consultation area, or if the
consultation is best carried out in the public area of 
the pharmacy. These issues should be recognised in 
the guidelines. 
8. SUPERVISION
The draft guidelines imply that a second pharmacist be
made available to ensure supervision of the pharmacy
whilst the consultation area is being utilised. This is
impractical as there may be only one pharmacist on
duty in many independent pharmacies. Whilst it may
be a reasonable requirement should a pharmacy decide
to use the consultation area for planned Medicine Use
Reviews or other such activities, it is envisaged that
most private consultations with patients would take 
a matter of minutes. This should be clarified in the
guidelines.
9. CONCLUSION
In conclusion, whilst the Union accepts that all
pharmacies should have a consultation area, the Union
would expect that the PSI be cognisant of the
practicalities from a pharmacist’s perspective in relation
to the installation of a consultation area in pharmacies
that have been in existence for many years, the costs
incurred, and the safety and security of the pharmacist.
Equally, it would be totally unreasonable to expect
every pharmacy to have a private consultation area by
next November that would comply with the guidelines
and this needs to be recognised. 
It is worth noting that when the Pharmacy Bill was
passing through the Seanad in 2007, Senator Mary
Henry stated that she hoped that “existing pharmacies
will not be closed down simply because they are unable
to fulfil this requirement (of having a consultation area).”
She went on to suggest that “They should be required to
do so when they are being reconfigured or being built.”
The Minister for Health and Children replied that “one
must be pragmatic and sensible in the manner in which
one seeks to apply this provision”. The Union would hope
that the PSI would follow this advice.
The Union looks forward to working with the PSI on the
production of final guidance to incorporate the issues
addressed in this submission. The Union is available to
meet with the PSI to discuss the issues raised above or,
indeed, any other relevant issues. 
Appendix IX
EXTRACTS FROM SPEECH BY MS LIZ HOCTOR MPSI, IPU PRESIDENT’S DINNER, 11 NOVEMBER 2009
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Liz Hoctor, IPU President, highlighted that change is
constant at the IPU Annual President’s Dinner which took
place in Dublin on 11 November. 
She said that in April 2008, after discussions with the IPU,
the HSE set out a process for advancing change and for
negotiating a new contract, which would include
negotiations on payment models. This process also
envisaged the establishment of an independent body to
determine fees after discussions between the parties had
concluded. This approach was and is broadly acceptable to
us subject only to agreement on the terms of reference and
membership of the independent body. 
“In response to a deepening financial crisis, FEMPI; Financial
Emergency Measures in the Public Interest Act was born.
Section 9 of this legislation gives the Minister for Health and
Children extraordinary power in relation to payments to
health care professionals. A power that the Taoiseach said
would not be used in either an unfair or a disproportionate
manner; however, I am afraid that the resultant actions spoke
louder than those words. April 2009 saw cuts of about 8%
being imposed on other healthcare professionals; however, on
18 June 2009; a cut of 34% was imposed on pharmacists.” 
“As pharmacists on Main Street, not Wall Street, we analysed,
we took stock and we considered the options. Our ability to
provide a professional patient-centred healthcare service had
been undermined by the unfair and disproportionate nature
of the Minister’s cut. Then on 1 August, in an unprecedented
move, more than half the country’s pharmacists withdrew
services under Government schemes for the first time in the
history of the profession.” 
Ms Hoctor said that she wanted to commend her colleagues
for their courage and to thank them for continuing to fulfil
their professional obligations to their patients, often in the
face of bullying and of underhand tactics. She also thanked
members for agreeing to resume normal services when they
were asked to do so by the Executive Committee. She said:
“The Executive Committee made this call for a number of
reasons. Their primary concern was to ensure that patients’
lives were not put at risk in the face of the collapsing
contingency plans. Secondly, the Minister gave a commitment
to monitor carefully the actual outturn in savings, €133
million, and to report the savings in a transparent way, so
that the savings objective achieved is neither more or less and
to conduct a review of the Regulations before June 2010.” Ms
Hoctor reminded the guests that on 12 August, Minister
Harney stated in a radio interview that the 2010 review
would be thorough, honest and robust. Only time will tell if
this is to be the outcome. Thirdly, the High Court agreed to
an early hearing of the challenge to the Regulations; that
hearing concluded yesterday and we now await the decision
of the Court. 
Ms Hoctor called on all political parties to recognise that real
and lasting change will only ever be truly accepted when it
is introduced in a spirit of partnership. “It is in the national
interest and it is in patients’ interests that we put systems in
place to ensure that positive relationships can be developed so
that our common agenda of meeting patients’ needs can be
met,” she said. 
Ms Hoctor urged other representative organisations to work
together on the early repeal of the so-called Emergency
legislation. 
Speaking on the impact of the cuts, the President said: “We
are now seeing pharmacies close and others teetering on the
brink. There is a huge personal cost to these closures for all
involved; the staff who are losing their jobs; the patients who
are losing their local pharmacy and the pharmacist who sees
his or her business failing because of Government imposed
cuts. 
There is a sad irony to all of this. A recent ESRI report called for
more and better use to be made of the professional skills of
pharmacists. Noting that Ireland has a high number of
pharmacists per head of population, it recommended that the
role of pharmacists in primary care be extended into areas
such as health screening and chronic disease management in
community pharmacies - yet that very resource is now under
threat.”
Ms Hoctor said: “As a Union, we are already responding to
changes. We have had a preliminary discussion with the
Minister on the future of and on developing the role of
pharmacists and pharmacy services. We agree with the
Minister that there are many community based health
services where pharmacists can have a greater role. This year
alone, our Community Pharmacy Committee has developed
and rolled out a national Health Screening Pilot, where
pharmacists are screening patients’ blood pressure, cholesterol
and blood glucose with the aim of referring those who may
need treatment to their GP. 
Over nine hundred pharmacists have availed of another
Union initiative and are now trained to provide a vaccination
service, such as the seasonal flu or H1N1 or next holiday’s
travel vaccination. We look forward to developing more
services, which we believe will meet patients’ needs in an
efficient and effective manner in community pharmacy.
Medicines are at the core of pharmacy. On a daily basis,
pharmacists address the overuse, underuse and misuse of
medicines because, let’s face it “medicines don’t work in
people who don’t take them properly”. We are uniquely
positioned and qualified to make sure that our patients get
the best possible return on the investment they are making in
their medication; an investment in time, energy and money
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that can be considerable. Such a positive outcome can be
achieved in partnership with the patient, the prescriber, the
pharmacist and the HSE.”
She continued: “In a crisis, be aware of the danger - but
recognise the opportunity.” This Union and we its members
recognise that there are opportunities to develop an agenda
of positive change and we are more than capable of
delivering such an agenda. 
This is not to say that the challenges we face as pharmacists
and as a Union are to be underestimated. As health care
professionals we must stay united, because solidarity will
make us stronger, reconciliation will bring us closer and our
belief in ourselves and our common cause will carry us
forward. The challenge is there for me and it is there for you.
Our patients and our communities depend on us as surely as
we depend upon each other. We simply cannot afford not to
stay the course, to stick by each other and to stand up for
what we care for and what we believe in.”
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Appendix X
SOME KEY LETTERS AND RESPONSES RECEIVED THROUGHOUT THE YEAR
Topics
■ Financial Emergency Measures in the Public
Interest Act 2009
■ Unlicensed Medicines
■ Fees for Pharmacists and Pharmacies
■ Prescription Charges
■ IPHA Reductions
■ Reference Pricing
■ Competition Act
■ Administrative Issues with the HSE/PCRS
FINANCIAL EMERGENCY MEASURES IN THE PUBLIC
INTEREST ACT 2009 
Financial Emergency Measures in the Public Interest Act
2009 – Letter 1
From IPU President to Members of the Oireachtas
[23 June 2009]
As President of the Irish Pharmacy Union, the
representative body for community pharmacists in
Ireland, I am writing to you on behalf of the hundreds of
thousands of patients who depend on our committed and
professional service as well as the 16,500 people
employed in community pharmacies in Ireland. The
service we provide to our patients as well as the jobs and
livelihood of our members and staff is now seriously
threatened. 
The Minister for Health and Children announced on 18th
June measures, which she states will save the Exchequer
€55m in payments to pharmacists in 2009 and €133m in
a full year. We understand that the Minister has written
to you regarding the proposed cuts. In fact, the cuts are
much greater that the Minister has stated. Furthermore
the Minister offers no costing or account of what these
figures will mean, either for patient care or for
pharmacists’ jobs and livelihoods. It is a one dimensional
and flawed calculation. 
The briefing note accompanying this letter deals with the
issues in detail and answers the Minister’s assertions. 
The proposed cuts will, when implemented, amount to
€169m in a full year and not €133m as stated by the
Minister. The significance of this much higher figure is
that it will virtually wipe out the net profit of our
businesses. It will mean the loss of up to 5,000 jobs and
the closure of many pharmacies. 
Undermining the capacity of pharmacists to serve the
community makes a mockery of a model of community
based health care. It makes nonsense of Government’s
policy to preserve jobs. A reduction in services will hit poorer,
older and more vulnerable patients most. The loss of every
single job represents an estimated cost per person of
€20,000 in terms of Social Welfare contributions and lost
income to the State.
The Minister has seriously miscalculated both the basis
for and the consequences of her proposed actions. Our
position is a responsible one. We know we have to play
our part in reducing costs and we are ready and willing to
do so; indeed, we already offered to take an 8% cut in our
fees. We would ask you not to stand by while pharmacy,
pharmacists and patient care are decimated by a flawed
calculation of savings that will cost more in their
consequences than they will ever yield in their delivery.
We ask you to please urgently engage with the briefing
note we are sending you now and to strongly support our
reasoned position.
Financial Emergency Measures in the Public Interest Act
2009 – Letter 2
From IPU President to Chairman, Joint Committee on
Health and Children
[24 June 2009]
As President of the Irish Pharmacy Union, the
representative body for community pharmacists in
Ireland, I am writing to you regarding the cuts in
payments to pharmacists that were announced by the
Minister for Health and Children on 18th June.
The cuts amount to a 34% reduction in payments for
delivering an essential front line health service and this is
due to be implemented on July 1st. 
Pharmacists are extremely worried about the
consequences of these cuts on patient care, pharmacy
services and the 16,500 people employed in pharmacies
around the country. 
I have attached a copy of a letter and briefing note that
was sent to TDs and Senators yesterday, which explain
the impact of the cuts and I would ask you to consider
this. 
Given the seriousness of the situation and in an effort to
find a resolution to the matter, I would welcome an early
opportunity to set out our position before the Joint
Committee on Health and Children. 
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Financial Emergency Measures in the Public Interest Act
2009 – Letter 3
From IPU President to Members of the Oireachtas 
[15 July 2009]
Re: Pharmacy Payments and Cost Savings
You will have received a letter from the Minister for
Health and Children on 10 July trying to justify the
unsustainable cuts she announced under the Financial
Emergency Measures in the Public Interest Act 2009. 
Contrary to the Minister’s repeated assertion, the cuts are
in fact much greater than has been stated. Furthermore,
the Minister asserts figures as facts while failing to sit
down with pharmacists and clarify how her figures are
arrived at.
More importantly, the Minister’s figures offer no costing
or account of what these figures will mean for patient
care or for pharmacists’ jobs and livelihoods.
It is a one dimensional and flawed calculation. 
Because the Irish Pharmacy Union agrees with the
Minister that these matters are best discussed based on
facts, we are again setting out clearly what the facts are.
Here are a few that will be of interest to you:
■ The Minister insists that the cuts will generate
savings of €133 million in a full year from the
pharmacy sector. The Union has asked to see how
this figure was arrived at. We believe this figure is
inaccurate. The Union, along with its external
economic advisors, have run financial models that
show the effect of what the Minister proposes will
result in a loss of €169 million in a full year. This
equates to a 34% cut in payments to pharmacies in a
full year. 
In the interest of transparency, fairness and good
government it is essential that the Minister and/or
her advisors sits down with the Irish Pharmacy Union
to clarify how she arrived at these figures.
■ The 34% cut in payments to pharmacies is hugely
disproportionate to that being applied to other
healthcare professionals who have had their fees cut
by 8%.
■ The cuts will disproportionately affect smaller
pharmacies and pharmacies with high volumes of
medical card dispensing. These are the pharmacies
that are providing services where they are most
needed by those with medical cards. In her letter of
10th July the Minister wrote, “the state cannot be
responsible for different levels of overheads and fixed
costs among pharmacists”. If the issue was one of
economic efficiency we would agree with her. In fact
the real issue is about patients’ care in deprived
communities. These are people and not statistics.
Ironically the cost of their ultimate care will be made
higher and not lower by a shorted sighted cut that
undermines care in the community and pushes
vulnerable patients up through the health system
first to GP’s surgeries and A&E at an ultimately much
greater cost.
■ The Minister states that pharmacists’ income from
State sources doubled since 2002. Figures from the
HSE show that pharmacies were paid €213 million in
2002 in fees and mark-up across all schemes and in
2008 this figure was €421 million. The Minister failed
to inform you that, since 2002 the number of items
that were dispensed by pharmacies rose from 40
million to 65 million. In other words, the output from
pharmacies has increased dramatically over that
period, as have the costs of providing the service. The
Minister tried to create the impression that
pharmacies are being paid more for delivering the
same level of service. This is not true. Pharmacies had
to cover the cost of providing this hugely increased
service, including employing more pharmacists and
technicians in order to provide the service required by
patients.
■ The Minister states that those subject to the pension
levy have not seen their salaries double since 2002.
This is not comparing like with like and is “spin”. The
Minister again is trying to give the impression that
pharmacy income generated from the State goes
directly into the “pocket” of pharmacists. Again this is
simply not true. This is the “income” that is used to
provide premises, pay the salaries of pharmacists,
technicians, medicines counter assistants,
administrative personnel and other costs incurred by
a pharmacy, which allows it to provide services to
patients on behalf of the State. These services include
dispensing and double checking of prescriptions and
reducing demand in Accident and Emergency Units,
hospital admissions and other out of hours’ services.
■ The Minister makes many assumptions in her letter
as to projected incomes for 2009 and 2010; however,
she has not shown how these figures were arrived at.
■ The Minister has not responded, or indeed seems to
care, that the cuts she has implemented have the
potential to cost 5,000 Irish taxpayers their jobs or to
show how the State will be able to afford to keep
these people on jobseeker’s benefit or allowances
going forward. The Union estimates it will cost the
Exchequer at least €72 million on an annual basis.
Thus the savings, as stated by her Department, of
€133 million would only amount to €61 million, yet
she will not talk to the Union on its proposals for
savings of the order of €83 million, which would
preserve jobs in the sector. This, you will agree, is
tantamount to fiscal recklessness. 
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■ The Minister makes much play of the €640 million
she says it costs to get €1 billion worth of medicines
to patients. This is factually incorrect. According to
2008 figures, it costs €182m to ensure the medicines
are delivered on time to pharmacies and hospitals. It
is important that the system should work efficiently,
so that there is not a delay in patients receiving their
medicines. Community Pharmacies are then paid
approximately €398m for providing pharmacy
services to patients on the community drugs
schemes. If the Minister wants a lower quality of
service and is happy for patients to be left waiting for
essential and often life saving medicines, then indeed
she is on the right track.
These cuts are excessive and disproportionate and must
be immediately revised in the interests of services and
patients. Significant savings can still be made without
damaging patient care and causing further job losses,
that is, if the Minister is willing to engage with the Union.
It is regrettable that the Minister at this difficult time for
the economy is still trying to force through an agenda for
reasons that have never been credibly explained and is
not prepared to engage in any form of constructive
engagement aimed at resolving matters.
If, as the Minister states her agenda is, “to discuss these
matters on the basis of fact” she should have no problem
meeting with pharmacists to explain how the facts upon
which she rests her case are in fact arrived at.
Financial Emergency Measures in the Public Interest Act
2009 – Letter 4
From Secretary General to Chief Executive, HSE
[14 August 2009]
I have been asked by the Executive Committee to express
their grave concern about the approach being adopted by
the HSE to the reinstatement of contracts to pharmacists
who were involved in the recent dispute. 
Prior to the ending of the dispute, the Union had been
assured that the pharmacists’ contracts would be there
for them when they returned to normal service. It now
seems that the HSE is intent on taking a bureaucratic and
legalistic approach to the matter. This is entirely
unacceptable and creates a great deal of doubt in the
minds of our members about the agenda that is being
pursued and therefore has the potential to lead to further
problems. The events that occurred over recent weeks
should be treated as a temporary disruption of service.
The HSE should accept either the notification that the
Union has issued to the Department (copy attached) or a
similar notification from each individual contractor. This
would facilitate pharmacists to continue to provide
services under their existing contracts. This would be a
sensible way to proceed and avoid any unnecessary
conflict arising at this time.
I would ask you for an assurance that the HSE will adopt
this reasonable approach. 
Financial Emergency Measures in the Public Interest Act
2009 – Letter 5
From President to Chief Executive Officer, HSE
[28 August 2009]
Community Contractor Pharmacy Agreement
I am writing on the instructions of our members and with
their authority. I refer to recent events and to letters sent
to certain of our members dated 13 August, 21 August and
24 August, 2009. 
It is not accepted that there is currently no contractual
relationship in place between the HSE and certain
individual community pharmacy contractors as claimed in
the letter dated 24 August, 2009. In certain cases,
individual members served termination letters pursuant
to Section 9(8) of the Financial Emergency Measures in
the Public Interest Act 2009 which letters may or may not
have been valid. However, regardless of their validity or
otherwise, it is beyond doubt that explicit statements
were made by, or on behalf of, the HSE and the Minister
for Health which amount to a waiver of any termination
notices in an effort by the HSE and the Minister to ensure
that pharmacists resumed or continued to provide
normal services to the public. 
Our members are relying on those statements and
representations, as is the Union. Without prejudice to the
foregoing, when urging, indeed pleading, that each
individual community pharmacy contractor resume or
continue to provide normal services, the statements and
representations by or on behalf of the HSE and/or
Minister were to the effect that such service would be in
accordance with the terms of the existing contracts. The
intent and effect of the explicit representations by or on
behalf of the Minister for Health and/or the HSE was to
encourage our members to continue or resume the
provision of services as they had done previously, i.e. in
accordance with the terms of their individual contracts. 
It is beyond doubt that the HSE welcomed what it
described as the decision by pharmacies “to resume
normal services”. The Union’s recommendation to
members that they continue to provide services and our
members’ agreement to do so was in reliance on the
foregoing and not otherwise and the HSE is estopped
from resiling from that position given that our members
resumed or continued to providing normal services (the
term used by the HSE).
“Normal services” can have only one meaning, namely the
services provided up to that point pursuant to the
standard form contract negotiated between the Union
and the Minister, i.e. the “community pharmacy contractor
agreement for provision of services under the Health Act
1970” as entered into by individual members of the IPU. 
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Our members continue to provide services to patients just
as they have always done and they are continuing to do
so in accordance with the terms of the community
pharmacy contract. Each of our members concerned
stands over their rights in this respect as does the Union.
The HSE is aware that, as we speak, our members are
dispensing under the GMS and community drug schemes
and providing a full range of services on behalf of the
State in the normal way as per the requests from the HSE
and Minister. In that context, and with respect, it is
disingenuous for the HSE to claim in correspondence to
certain of our members that there is no contractual
relationship in place between them and the HSE. 
For the reasons outlined in this letter, our members and
the Union maintain that the original individual contracts
remain in force. In the alternative and without prejudice
to the foregoing, members dispensing under the State
drug schemes are doing so on the basis of a contractual
relationship incorporating exactly the same terms as
those of their previous contract, namely the standard
community pharmacy contractor agreement. The IPU
which is authorised and instructed to represent its
members has agreed no other contract with the Minister
and/or HSE on behalf of members. Nor have any
individual members agreed or entered any alternative to
the community pharmacy contractor agreement. That is
their and our position, notwithstanding any
correspondence individual members may have to return
to the HSE in order to ensure continuity of payment
under the various schemes. On behalf of our members we
confirm that they shall continue to provide services to
patients in a professional manner as they have done
heretofore. 
If the HSE fails or refuses to pay any of our members, i.e.
reimburse them in the normal way, for work done on
behalf of the Minister pursuant to the various State drug
schemes, the HSE will be acting unlawfully and the
individual members concerned will suffer immediate and
extremely serious loss for which the HSE is liable. Failure
to pay any of our members in circumstances where the
HSE is perfectly well aware that they are providing a
service to the community on behalf of the State, in
response to explicit requests by the Minister and HSE that
they do so, would be cynical, reprehensible and unlawful
and would give rise to litigation. I trust this will not arise
and that the HSE will honour its obligations to pay our
members in the normal way. 
The Union accepts that, for the time being, payments to
individual pharmacists shall be reduced in accordance
with the terms of SI 249 of 2009 (until a successful
challenge to same and/or the underlying legislation). 
UNLICENSED MEDICINES 
From Secretary PCC to Assistant National Director,
Contracts, HSE
[28 September 2009]
The Union has had a number of calls from members who
have dispensed unlicensed medicines to patients through
either the GMS Scheme or the Drugs Payment Scheme.
These medicines are usually purchased for a specific
patient when the need arises and are usually not bought
from the pharmacist’s main wholesaler. 
The members concerned have submitted their claims,
along with the invoice, for these medicines to the HSE
and have been told by the HSE that they will be paid the
amount on the invoice less 6.5%, in line with the
Regulations. The members who have contacted us about
this matter have been charged the invoice price by the
wholesaler and will now be reimbursed a lower amount
leaving them in a minus situation. 
I appreciate that the HSE PCRS are implementing the
Regulations on the Minister’s behalf; however this leaves
members a situation where they are at a loss when
dispensing unlicensed medicines to patients who
urgently need these drugs. 
I would appreciate if you would address this matter
urgently and advise me how these members can reclaim
the full amount they have paid for these medicines.
FEES FOR PHARMACISTS AND PHARMACIES
Fees for Pharmacists and Pharmacies – Letter 1
From Secretary General to Assistant Secretary, Department
of Health and Children
[15 October 2009]
I have been asked by the Pharmacy Contractors’
Committee (PCC) to write to you regarding The Union
changes to the payment structure for the Hardship
Scheme / Non Medical Card Item Scheme. 
Under this scheme, which currently operates through
local HSE offices, GMS patients can access unlicensed
medicines which are not available to them through the
regular Medical Card Scheme. Most of the medicines
dispensed under this scheme are complex medicines
which are vital for the patients concerned. These
medicines are not always available through a
pharmacist’s main wholesaler and pharmacists routinely
spend many hours and numerous phone calls trying to
source these products for their patients. 
For the past ten years, pharmacists were paid a DPS fee
and mark up. In some areas, where there was agreement
between the pharmacist and the local HSE official, a
patient care fee of €60.52 was paid on high cost items.
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While the Committee acknowledges that the HSE is no
longer purposing to reduce the invoice price by 6.5%, it is
now proposing to get rid of the mark up and the patient
care fee for this scheme with no prior notice to
pharmacists. The purposed payment of a fee of €3.50 to
€5 is totally inadequate to cover the costs associated
with administering the scheme.
Pharmacists are currently already at a loss from the
withholding of payments since 1 July 2009. The local HSE
offices had been advised not to pay any claims until a
decision on payments had been made. Pharmacists have
been sourcing and supplying these medicines to their
patients in good faith for the past three months unaware
that, not only would their payments be delayed, but their
payments would be changed without warning. 
In some areas pharmacists have written approval for the
payment they will receive for a particular product and the
Union would expect that these agreements between the
individual pharmacist and the HSE will be honoured. 
Given the complexity of the medicines involved and the
extra work that goes into sourcing the products on behalf
of the patients, the Union would see the retention of a
mark up as crucial to the viability of the scheme and to
guarantee the supply of these medicines to patients. 
The Union raised this matter with the Minister for Health
and Children at our meeting last week and stressed that
any changes need to be discussed with the Union before
they are implemented to ensure that patients will
continue to be able to access these medicines. 
Given the urgency of the matter, the Union would request
an urgent meeting with officials from the Department
and HSE to discuss the matter. 
Fees for Pharmacists and Pharmacies – Letter 2
From Secretary General to National Director Integrated
Services - Performance and Financial Management, HSE
[20 November 2009]
I wish to refer to previous correspondence regarding a
number of issues, including the contractual position of
almost five hundred of our members.
The contract matter has been raised with the Minister
and the HSE on numerous occasions. Despite
commitments received at various times over the past
three months that the issue would be resolved “shortly”,
this has not happened and no good reason has been put
forward for the delay.
Secondly, the HSE have recently attempted to alter
payment arrangements for both the Hardship and
Psychiatric Schemes, without any discussion or
agreement with this Union. They have also sought to
apply the new payment and administrative arrangements
retrospectively, which is not acceptable. 
Thirdly, pharmacists facilitated the HSE in the distribution
of Tamiflu in July last, without any agreement or payment
arrangements. The matter has not been satisfactorily
resolved and the HSE is now seeking to impose
administrative arrangements on pharmacists
retrospectively which, again, is not acceptable. 
The Union has made its views known to the HSE on all of
these issues, most recently at a meeting on 5 November,
when it was assured that the HSE wished to resolve these
issues and would respond the following week. However,
none of these issues have been resolved.
In the circumstances, I would like to have an urgent
meeting with you to discuss these issues. I would be
available at any time on Monday or Wednesday next
week. Perhaps your office could get in touch with me on
01-493 6401 or 087-917 0174 to arrange a suitable time. I
can assure you that the meeting will not take longer than
an hour.
Fees for Pharmacists and Pharmacies – Letter 3
From Secretary General to Minister for Health and Children
[19 January 2010]
At our meeting in December, the Union raised the
ongoing delay facing pharmacists participating in the
Hardship and Psychiatric Schemes. Unfortunately the
matter is still unresolved. 
Many pharmacists have been supplying medicines to
patients under both these schemes for over 6 months
without payment. In some areas pharmacists have been
paid the cost of the medicines but no fee or mark up has
been paid. Where there have been payments made
pharmacists have not been given any paperwork and are
unaware of what claims have or have not been paid. In
other areas no payments at all have been made leaving
pharmacists with unpaid claims of thousands of Euro. 
Despite numerous requests, the HSE have failed to clarify
the payment structures for these schemes. The Union has
been requesting a meeting with the HSE to discuss the
situation however to date a meeting has not taken place.
The situation is unacceptable and needs to be resolved
without delay and we would ask you to intervene and
raise the matter urgently with the HSE.
Fees for Pharmacists and Pharmacies – Letter 4
From Secretary General to Mr P Burke, HSE PCRS
[25 January 2010]
I wish to refer to your letter of 21 January 2010.
I wish to express the Union’s disappointment that,
despite commitments given by the HSE to revert to us on
the Hardship and Psychiatric Schemes within a week of
our meeting on 5 November 2009, it has taken the HSE
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over two months to respond. It is also disappointing that
the fundamental issues raised at that meeting in 
relation to:
■ changing scheme arrangements retrospectively; 
■ significant delays in making payments; 
■ inadequate payment levels; 
■ the lack of communications; and 
■ the lack of engagement;
have still not been addressed.
Hardship Arrangements
I welcome the HSE’s intention to publish a list of
medicines reimbursable under this arrangement;
however, it is not clear whether this list will include codes
and prices for these medicines. 
The administration required for the Hardship
arrangement is excessive and the proposed payments are
completely inadequate. These issues need to be
addressed immediately. It is unacceptable that
pharmacists are still waiting to get full payment and, in
some cases, any payments, months after they have
dispensed medicines to patients. The PCRS list of Claims
Paid is inadequate and it is not possible for pharmacists
to reconcile payments being received with the claims they
have submitted.
DPS Refund Claims
You will appreciate that it is a matter for each individual
pharmacist to determine prices for their private patients
and clients. It is not clear from your letter what precisely
is being proposed or how it can be implemented on a
practical basis. This issue needs to be discussed further.
HSE (Unified Claims Form) Receipts
It is not clear what is proposed in your letter in relation to
the Unified Claim Form and how it differs from current
arrangements. Again this issue requires further discussion
and clarification.
Reimbursement for Psychiatric Drugs
The FEMPI Regulations did not cover this scheme or the
Hardship Arrangements. It may be the desire of the HSE
to bring payments under this scheme into line with the
recent payment changes but this is not mandated by
regulation. Furthermore, there was no communication
from the HSE of their intention to change this scheme
until November 2009, four months after the introduction
of the regulations, and this communication was
confusing and was not sent to every pharmacist. 
As was raised at the JCG meeting in November, the HSE
cannot implement price changes or administrative
arrangements retrospectively. This issue is not addressed
in your letter. Many pharmacists have not been
submitting their claims, pending clarification from the
Local HSE Offices, and many members have been told by
HSE personnel that they do not know what payment
arrangements will apply, or when payments will be made.
This scheme applies to a very vulnerable cohort of
patients and these issues should be resolved without any
further delay.
The issues outlined above need to be resolved
immediately and a meeting between the Union and the
HSE is required urgently. The Union will make itself
available on either Wednesday or Thursday of this week
for such a meeting. It would be helpful if the issues set
out in this letter are considered in advance of the
meeting so that progress can be made on these matters. 
Fees for Pharmacists and Pharmacies – Letter 5
From Secretary General to National Director Integrated
Services - Performance and Financial Management, HSE
[4 March 2010]
I am writing to you on behalf of our members who
participate in the Hardship and Psychiatric Schemes 
(“the Schemes”). 
The reimbursement arrangements on these schemes
were changed without notice to pharmacists and this has
given rise to long delays in making payments. Following
several meetings with HSE officials, some of these
administrative issues are now being resolved. 
The HSE has reported to reduce payments to pharmacists
under the Schemes in line with the Health Professionals
(Reduction of Payments to Community Pharmacy
Contractors) Regulations 2009. However, these
Regulations do not apply to the Schemes. In addition, the
HSE is seeking to apply the reduction retroactively to
claims as far back as July 2009 and all pharmacists were
only officially notified of these changes in January of this
year. 
Firstly, as the Schemes are not affected by the
Regulations, the HSE is not entitled to unilaterally reduce
payments under the Schemes. Furthermore, payments to
pharmacists under these Schemes are approved in
advance by the local HSE office. In some instances this
agreement is verbal, while in other cases a written form is
issued by the HSE. In all instances however there is an
agreement in place between the pharmacy and the HSE
prior to the dispensing of the relevant products by the
pharmacy. The pharmacy has reasonably relied upon the
terms of this pre-approval in performing its part of the
agreement and dispensing the respective product. The
retroactive application of the reduction in payments is
not only inappropriate, but the failure by the HSE to pay
the agreed amount is a breach of the terms of the
agreement between the pharmacy and HSE. This breach
entitles the pharmacy to seek legal redress. 
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I would ask you to intervene to resolve this matter and I
would welcome an early opportunity to meet to discuss
these matters with you.
PRESCRIPTION CHARGES
Prescription Charges – Letter 1
From Secretary General to Minister for Health and Children
[17 November 2009]
I wish to refer to the publicity over the past few days in
relation to consideration being given to the introduction
of prescription charges.
The Union set out its preliminary views on this matter, as
well as its views on the DPS threshold and Reference
Pricing, in a letter to the Department on 15 October last.
The Union accepts that there is considerable wastage in
the system and has been highlighting this fact for a
number of years. The Union believes that this issue can be
addressed in other ways that may have less impact on
patient welfare and would welcome an opportunity to
discuss this matter with you in advance of any decision to
impose such charges being taken by the Cabinet. The
Union would also be prepared to participate in a multi-
disciplinary group to address this matter, as proposed by
the Irish Medical Organisation yesterday, should it be
decided to proceed on that basis.
I look forward to hearing from you.
Prescription Charges – Letter 2
From Secretary General to Minister for Health and Children
[23 November 2009]
Co-Payments
I wish to refer to my previous correspondence and the
recent media reports on the possible imposition of
prescription charges. 
We understand that the initiative is aimed primarily at
reducing wastage in the system, which the Union has
been highlighting for a number of years, rather than
depriving any patients of vital medication. The imposition
of such a charge will also produce revenue for the
exchequer but it is assumed that this is secondary to the
key objective. The Union believes that before any such
charges are imposed, the implications of so doing and
associated risks need to be carefully considered. 
The imposition of a co-payment on patients will impact
most heavily on those who can least afford to pay for their
medication. This may well mean that many patients may
decide not to get their medication in a timely fashion and,
consequently, may end up in hospital or in A&E
departments. The imposition of such an arrangement
would also be difficult and costly to administer. 
Rather than taking the charges approach, this issue could
also be effectively addressed through focused medicine
use reviews which would address not alone the issues of
over use but also the under use and misuse of medicines.
The Union proposals in this regard were submitted to the
Department some years ago and envisaged that a one-
on-one medicines use review would be undertaken by a
pharmacist with a patient who is on a complicated
medication regime. Initially such reviews would focus on
elderly patients or those who suffer from chronic
conditions who would be on many medications. The
purpose of this intervention would be to improve
adherence, reduce leakage to secondary care and reduce
the current level of wastage in the system. 
The Union has also been advocating for the payment of a
higher fee for not dispensing medicines than is currently
being paid. The elimination of unnecessary dispensing of
medicines requires a considerable and costly intervention
from pharmacists and the Union believes that there is
scope to achieve additional savings through this
mechanism. Equally, the non dispensing fee currently
remunerates pharmacist intervention in the areas of
under use and abuse of medicines. The current level of fee
does not adequately cover the costs of pharmacists’
intervention in such matters. An increased level of fee
would have the potential to yield additional savings to
the exchequer as it would enable the pharmacist to
devote more time and energy to discussing such issues
with the patient.
Finally, if it is decided to proceed with such charges then
the manner of implementation should be discussed and
agreed with the Union in advance of its introduction. It is
important that such charges do not impose any
additional administration or costs on pharmacists. Many
of the patients affected by such a charge will be elderly or
seriously ill and in some instances may not be in a
position to attend the pharmacy personally. It is the view
of the Union that such charges should be collected
directly from patients by the HSE and, if introduced,
should be made mandatory. You will appreciate that it is
vital that no further costs are imposed on the profession
given both the impact of recent cuts and the impact of
the downturn in the economy on other pharmacy activity. 
Prescription Charges – Letter 3
From Secretary General to Registrar and CEO, PSI
[16 December 2009]
I wish to refer to the recent announcement by the
Government to introduce prescription charges.
The Union had previously pointed out to the Minister other
ways in which wastage in the pharmacy system could be
addressed without having to introduce a prescription
charge. It is regrettable that the Government has now
decided to introduce a prescription charge, especially given
the fact that these charges are being abolished in other
jurisdictions for good public health reasons. 
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Nevertheless, as the Government has indicated its
intention to proceed with a charge of 50 cent per item for
medical card patients, the Union would like to highlight
to the PSI a number of ethical and professional issues,
along with patient care issues, which may arise for
pharmacists administrating this charge on behalf of the
Government. 
■ There is a high risk that the charge will reduce
compliance; therefore the Union would advocate for
exemptions for specific patient cohorts. Many
patients affected by such a charge will be elderly,
chronically ill, people with addiction problems and
mental health problems. In some instances, patients
may not be in a position to attend the pharmacy
personally to pay the charge;
■ If a patient is on a number of items, then the cost to
that patient will increase; this will again lead to
compliance issues and long term cost issues and
consequences for the health service;
■ Where a patient is on a phased dispensing regime,
the charge needs to be imposed once a month and
not for each individual dispensing;
■ Certain patient cohorts would have their medicines
changed on a weekly/daily basis (palliative care
patients) and there will need to be a mechanism put
in place for these patients;
■ If a patient refuses to pay or is not in a position to
pay the 50c fee for whatever reason and the
pharmacist knows that they need the medication,
what approach should the pharmacist adopt in these
circumstances in order to comply with their
professional obligations and avoid breaching ethical
and legislative provisions. 
iven the short time frame for the introduction of the
charges, the Union would appreciate your comments on
the above issues as soon as possible.
A copy of a recent letter to the Department is also
attached for your information which also raises some of
the same issues.
Prescription Charges – Letter 4
From Secretary General to Assistant Secretary DoHC
[17 December 2009]
I wish to refer to my previous correspondence on this
issue and the recent announcement by the Government
to introduce prescription charges.
The Union has previously highlighted other ways in which
wastage in the system could be addressed without
having to introduce a prescription charge. It is regrettable
that these alternative proposals were not acted upon
given the fact that these charges are being abolished in
other jurisdictions for good public health reasons.
Nevertheless, as the Government has indicated its
intention to proceed with a charge of 50 cent per item for
medical card patients, it is important that both sides work
together and agree on the manner of implementation in
advance of its introduction in April 2010. I look forward to
meeting with you to discuss the matter further.
In advance of these discussions, I set out some of the
issues and questions that need to be addressed:
■ There is a high risk that the charge will reduce
compliance; therefore the Union would advocate for
exemptions for specific patient cohorts. Many
patients affected by such a charge will be the elderly,
chronically ill and people with addiction and mental
health illnesses. In some instances, patients may not
be in a position to attend the pharmacy personally to
pay the charge;
■ Where a patient is on a phased dispensing regime,
the charge needs to be imposed once a month and
not for each individual dispensing;  
■ Certain patient cohorts would have their medicines
changed on a weekly/daily basis (palliative care
patients). Consideration needs to be given on how to
deal with these circumstances;
■ The implementation of the fee for patients in
residential and nursing homes as well as Hospital
Emergency Scheme prescriptions needs to be
considered;
■ How will the charge be administered for multi-
preparation and combination packs;
■ How does the pharmacist deal differing pack sizes
e.g. 1 x Zocor 60 mg (50 cent) versus 3 x Zocor 20mg
(€1.50);
■ How will the €10 threshold apply to a household
where there are children over 16 with a medical card;
■ How will the €10 threshold be applied where there is
an elderly patient being cared for by a relative who is
on carers allowance/disability allowance and also has
a medical card;
■ How will the HSE deal with situations where patients
will be due refunds from the HSE due to the €10
threshold being breached through no fault of their
own e.g. a patient has to go to different pharmacy.
■ There are also issues around the professional and
ethical responsibilities of pharmacists in cases where
a patient needs the medication but refuses to pay
the charge; that also needs to be addressed.
The implementation of these arrangements will be both
difficult and costly to administer. This will involve
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pharmacists devoting more time and energy to discussing
issues such as compliance with their patients. To cover
these and other costs pharmacists should be allowed to
retain 30% of the fee and the non dispensing fee should
not be less than €5. 
I look forward to discussing these issues with you early in
the New Year.
IPHA REDUCTIONS
IPHA Reductions – Letter 1
From Secretary General to Chief Executive, IPHA
[16 December 2009]
Re: Reduction in the Cost of Medicine
I wish to refer to the recent announcement by the
Government of their intention to reduce the cost of
medicines. Pharmacists are genuinely concerned about the
impact of any price reduction on the value of their existing
stock. I would ask your Association to consider this matter
in your talks with the Department to ensure that the
transition from the old pricing arrangements can happen
smoothly and ensure continuity of supply to patients.
I enclose a copy of a letter that the Union has sent to the
Department on the matter.
IPHA Reductions – Letter 2
From Secretary General to Assistant Secretary, DoHC
[16 December 2009]
Re: Reduction in the Cost of Medicine
I wish to refer to our meeting on 3 December and the
recent announcement by the Government of their
intention to reduce the cost of medicines.
I have been asked by the Pharmacy Contractors’
Committee to seek an implementation date of 1 March for
any reduction in the cost of medicines to give pharmacies
time to work stock purchased at existing price through
the system.
January is the worst month of the year for such a change
to be implemented because of the potential effects on
both stock availability and, more critically, patient access
to medicines. During the Christmas and New Year period
there is increased hospital discharge rates, reduced access
for patients to GP services, a reduced wholesaler delivery
to pharmacies, an increased level of urgent prescriptions
and unpredictable patterns of patient demand, which all
routinely put pressure on the supply system. 
It is essential that there is continuity of supply of
medicines for patients during this critical time. The Union
is requesting that pharmacies are reimbursed at the same
rate in January and February and pharmacists will absorb
losses that will arise from 1 March onwards on old stock. 
The Union would also request that members have access
to the list of products well in advance of the
implementation date to make sure that they are in a
position to manage their stocks which continuing to
ensure that they retain an adequate supply for their
patients.
REFERENCE PRICING
Reference Pricing – Letter 1
From Secretary General to Mr Mark Moran, Department of
Health and Children
[17 December 2009]
I wish to refer further to your request to the Union to
make a short submission on the various options and
components of a reference pricing system. The Union
believes that by working together a system of reference
pricing can be introduced within a reasonable time frame
and can work to the benefit of all parties. The Union has
commenced research in this area and we envisage work
to be completed by mid-February 2010. We would hope to
have a bilateral meeting with you at that time to discuss
issues in some detail. In the meantime, and to facilitate
discussions on the 14th January, we set out some preliminary
views and identify some issues for consideration:
■ The strategic objectives of a Reference Pricing System
need to be clearly identified and could include;
• An improvement in the status and quality of
health for the general population;
• An improvement in the status and quality of
health for specific cohorts and specific
individuals;
• An enhanced role for the pharmacist in the
provision of care within the general health care
system;
• Financial benefits and cost savings for both the
State and individual patients; 
• New and improved remuneration and payment
structures for pharmacists, both to reflect their
increased workload and to allow for investment
in future practice development; and
• Ensuring continuity of supply of vital medicines
to patients;
■ Pharmacy led substitution must be an essential part
of any Reference Pricing System if it is to work for all
stakeholders;
■ Possible savings and costs to the health authorities
from a Reference Pricing System;
■ Demands and costs placed on pharmacists in terms
of time, facilities and information systems;
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■ Pricing and reimbursement policies and their impact
on pharmacists and other stakeholders;
■ The need for a public information campaign to
address possible fears and concerns of patients. Such
a campaign would promote public awareness of
reference pricing while providing assurance to
patients to accept substitution and reference pricing
in the case of their own medicines:
■ Identification of key performance indicators to
facilitate ongoing review and evaluation of any
system that may be introduced.
The Union is happy to participate in discussions with the
Group on 14 January 2010. We would welcome a bilateral
meeting with the Group following the completion of our
analysis and research. 
We look forward to working with you on this matter.
Reference Pricing – Letter 2
From Secretary General to Mr M Moran, DoHC
[31 March 2010]
I wish to refer further to our letter of 17 December 2009
and our meeting on 14 January 2010 regarding the
proposal to introduce a reference pricing and generic
substitution system. 
The economic advice available to us suggests that, due to
the complex inter-relationship of all State Scheme
funding, the impact of reference pricing cannot be
assessed in isolation. Furthermore, in order to have a
meaningful input into the economics of reference pricing,
more information on the approach and type of reference
pricing system that may be recommended would be
required. We are available to meet within the next few
days to discuss this matter further if you are in a position
to provide further details of the proposals that you will be
submitting to the Minister.
In the meantime, we attach a paper from economist Joe
Durkan and put forward some additional views for your
information and consideration.
The Union welcomes the commitment given by the
Minister in response to a Dáil question last February to
introduce pharmacist led generic substitution. We believe
this is essential in terms of ensuring that a reference
pricing system works for all parties. 
We also note that, in response to that Parliamentary
Question, the Minister indicated that the reference price
could be limited to the lowest priced product within a
reference group. The Union considers that the reference
price needs to be given very careful consideration. It is not
at all obvious that opting for the cheapest price is
necessarily the best approach as it may lead to a relatively
small number of suppliers as some players exit the
market. It is important also that the price is set at a level
that does not totally erode the viability of pharmacies,
which has taken significant hits over the past year. 
In this context, the initial reference price should not be
substantially reduced overnight but on a gradual basis
over time. It is noted that Michael Barry, from the Centre
for pharmacoeconomics, has previously expressed a view
that reference prices are generally set at 20-30% below
the branded price. If this was to be the recommendation
then this would have very significantand serious
implications for the pharmacy sector.
Furthermore, it is vital that the Minister take cognisance
of the significant additional costs for pharmacists
implementing a reference pricing system. Patients taking
a particular medication will need advice, counselling and
reassurance from their pharmacist whenever any generic
substitution takes place to allay their concerns about
changes in their medication regime. This extra
professional input is crucial from a patient safety and
welfare perspective. A patient who is uncertain of their
medication, or who distrusts it as a result of a change in
branding or appearance, is less likely to take that
medication correctly, leading to the risk that their
condition will worsen. However, the necessary pharmacist
input comes at a significant cost in terms of time,
resources and expertise, which any substitution/reference
pricing regime must take account of and this needs to be
evaluated and assessed.
In addition, in setting a reference price, it needs to be
borne in mind that the Irish market is a relatively small
market. Changes should not inadvertently create a
situation that leads to shortages in the supply of
medicines which will be difficult to overcome if
competition in the market is diminished. Patients and
pharmacists in the UK are currently struggling with
severe medicines shortages due to the low cost of
medicines. Medicines such as Femara, a cancer treatment,
and Cipralex, an antidepressant medicine, have been
unavailable to patients in the UK over the past few
months. An emergency Government summit, involving all
stakeholders, was recently held to look at ways to address
this situation that has arisen due to changes in
Government policy in the pharmaceutical market. This is
not a situation anyone would like to see in Ireland and, if
it was to occur, it could lead to an increase in the number
of high priced unlicensed medicines in use in Ireland.
Any reference pricing system should provide appropriate
incentives to pharmacists to drive the types of efficiencies
sought by the Minister as has happened in other
countries. Such incentives should include the realisation
and retention by pharmacists of buying efficiencies. 
You indicated at our last meeting that you did not have a
role to play in examining the impact of a reference pricing
system on community pharmacists, whose professional
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input will be vital in terms of delivering such a pricing
system. As was indicated to you at that meeting, we do
not believe that you can introduce such a system in
isolation from reviewing and reforming the current
method of reimbursing pharmacists. A move to a generics
system not alone changes the relationship between
pharmacist and patient but also fundamentally alters the
economics of the pharmacy sector and the relationship
between pharmacists and Government. 
In the context of developing a new payment model,
issues of concern to the Minister can also be addressed. In
this context, it is worth noting that the recent ESRI report
predicted significant increases in dispensing over the next
9-10 years, which have clear implications for public
expenditure and also for the capacity of pharmacists to
deliver these services.
The Minister acknowledged, at a meeting last year, that
the introduction of a reference pricing system would have
a knock-on effect on pharmacy income. It is our firm
belief that this issue and the long-term implication of
increased medicine consumption on public expenditure
can be best addressed in the context of a new payment
model for pharmacists. Discussions with the Union on
this fundamental change need to commence as a matter
of urgency and we will be taking the matter up directly
with the Minister.
In the event of introducing a system of reference pricing,
it would be vital to ensure that it does not have negative
long-term consequences that could jeopardise the
sustainability of this part of the healthcare system and
cause major irreversible structural changes in the
pharmaceutical market and supply chain. It is important
therefore that the issues set out in this letter are
addressed and that reference pricing is introduced on a
gradual basis.
Finally, the Union and its members are committed to
working with the Minister on this initiative. Pharmacists
can bring their considerable professional knowledge and
skills as well as their business experience into play in
managing the overall cost of medicines. The Union looks
forward to continuing engagement with yourself and, in
due course, with the Minister on the matter. In the
meantime, we would ask that you ensure that our views
on this and all aspects of reference pricing, including
those set out in our letter of 17 December 2009 are
brought to the attention of the Minister. 
COMPETITION ACT
From Secretary General to Minister for Enterprise, Trade &
Innovation
[29 March 2010]
Review of the Competition Act 2002 
I would like to take this opportunity to congratulate you
on your new role as Minister for Enterprise, Trade and
Innovation, following the recent Cabinet reshuffle. The
Irish Pharmacy Union (IPU) looks forward to working with
you in your new role. 
In this context, I understand that your Department is in
the process of reviewing the Competition Act 2002 as
part of the legislation to give effect to the amalgamation
of the National Consumer Agency and the Competition
Authority. We have had previous correspondence with
your predecessor on this matter. In particular, we
forwarded a legal opinion, produced by Michael Collins
S.C., on whether section 4 of the Act was applicable to
negotiations between the IPU and the HSE/Department
of Health & Children. The opinion addressed two issues:
1. Whether, as a matter of competition law, it is correct
that if the IPU negotiates on behalf of its member
pharmacists on the price which pharmacists will be
reimbursed for the pharmaceutical products covered
by the Community Drug Schemes and on the
dispensing fee, such negotiation is, by its very nature,
a breach of section 4 of the Competition Act 2002;
and
2. Assuming that such negotiation would constitute a
breach of section 4, whether there is any legal reason
as to why the IPU could not be given the same
statutory exemption apparently envisaged for the IMO. 
It is the opinion of Mr Collins S.C. that section 4 of the
Competition Act 2002 does not apply to the negotiations
as described above. “Negotiations by the IPU with the HSE
on the price at which pharmacists are reimbursed for drugs
under the CDS and on the dispensing fee do not have the
effect of preventing, restricting or distorting competition
between pharmacists and accordingly there is no breach of
section 4.” 
The opinion of our Senior Counsel is in line with the
opinion of the previous EU Commissioner for Competition
who is on record as stating that “the fixation of fees for
pharmacy services would only be problematic from the
point of view of EC competition law if it was not the Irish
State which had the final word in fixing the price”.
However, if there is still a belief that by engaging in
negotiations on behalf of its members with the HSE, the
IPU is acting in breach of section 4, Mr Collins S.C. states
that: “there would be no legal objection to creating an
exception to section 4(1)” 
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stating that, in relation to Article 81(1): “the process
whereby the IPU negotiates with the HSE would not
produce an appreciable effect on inter-State trade so that
Article 81(1) should not be engaged.” 
We submit, in accordance with the legal opinion provided,
that section 4 of the Competition Act does not prevent
negotiations taking place between the IPU and the
Department of Health & Children or the HSE. However, if
the Department has a different view on this matter and
the Government intends to amend the Competition Act
to allow the Irish Medical Organisation to engage in
collective bargaining on behalf of its members, there is no
reason why such an amendment cannot be extended to
the IPU. 
I would welcome your views on the matter and the
opportunity to meet with you to discuss this matter
further. I look forward to hearing from you soon. 
ADMINISTRATIVE ISSUES WITH THE HSE/PCRS 
From Secretary General to National Director Integrated
Services, HSE
DPS reimbursement letter sent to patients
It has come to our attention that the HSE is contacting
some patients, who are due a refund under the DPS, with
a letter which informs the patient, 
“that the total due to be refunded does not equate to
the amount(s) claimed on your application minus your
€100 payment. This is because the prescription claim
forms which you have submitted did not have the
correct price calculated by the pharmacy.” (Emphasis
added)
There is no “correct” price for products sold to private
patients below the €100 threshold, as there are no set
prices for these products. The statement underlined
above is not only inaccurate but could be damaging to
the business and reputation of the pharmacist involved. 
In order to avoid further damage to the business and
reputation of any of our members so referenced, directly
or indirectly, in your letter, the IPU insists, on a without
prejudice basis to any other action that may become
necessary, that you direct your local offices to amend
their letter to read as follows,
Dear [Sir/Madam]
Please find enclosed calculation of the refund payment
due to you under the Drug Payment Scheme (DPS). We
apologise for the delay in processing your application –
your refund cheque will be posted to you shortly. You
will see that the total due to be refunded to you does
not equate to the amount(s) claimed on your
application minus your €100 payment. This is because
the HSE can only refund clients for money spent over
the €100 threshold at set prices.
The Minister for Health and Children signed regulations
into law on the 1st July 2009 which reduced the
reimbursement prices of drugs under the DPS. The HSE
can only refund clients on the basis of these reduced
prices. 
The medicines dispensed to you and the corresponding
prices as set by the Minister are listed on the attached
calculation sheet. If you wish to query the difference in
price you may discuss this with the undersigned
and/or with your local pharmacist.
To avoid having to pay out money for your
prescriptions over the €100 threshold you should carry
your DPS card with you and show it to the pharmacy
staff when giving in your prescription.
Yours sincerely,
In order to avoid any further action being taken by any of
the pharmacies referred to, directly or indirectly, in the
letter the HSE has previously sent, we require your
confirmation within seven days that the steps above have
been or are in the process of being carried out.
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Appendix XI
A SELECTION OF PRESS RELEASES ISSUED TO THE NATIONAL MEDIA DURING THE YEAR ON VARIOUS MATTER
1. PHARMACY CRISIS
18 June 2009
■ Pharmacists condemn Minister for undermining
pharmacy services and jobs
■ Warning that up to 5,000 pharmacy jobs could be lost
Front line health services will be seriously damaged by
the Minister for Health and Children’s decision to cut
payments to pharmacists for providing medicines and
advice to patients on the community drugs schemes
by 36%, according to the IPU, the representative body
for 1,900 community pharmacists. 
IPU President, Ms Liz Hoctor, stated; “These cuts
announced today amount to a 36% reduction in the
current level of payments to pharmacists. These
massive cuts are utterly disproportionate and totally
unsustainable. These cuts compromise patient services
and up to 5,000 jobs in pharmacies could be lost as a
direct result of this Government decision. 
“Although pharmacists are not responsible for rising
health costs and have always provided value for
money, we had indicated to Government that we were
willing to accept a cut equivalent to 8% of our fees in
the national interest. This was in line with cuts being
proposed in other parts of the health service.” 
Ms Hoctor described the small increase in the fees for
dispensing medicines and providing advice to
medical card patients as a fig leaf – “it’s a clumsy
attempt to mask the true extent of the cuts”, which
amount to 36% of pharmacists’ payments from the
HSE. She also said the cuts will wipe out pharmacists’
margins and their capacity to deliver and sustain
services through the negotiation of trading terms.
The dispensing fee per item now being proposed is,
on average, 33% lower than the rate put forward by
the Minister’s own Independent Body late last year.
“No amount of spin or distortion of fact will hide the
devastating reality of these cuts, which is an overall cut
of 36% for delivering the State’s community drugs
schemes.”
Ms Hoctor continued: “This Minister seems
determined to destroy one of the few parts of the
health service that has managed to continue to deliver
effective patient care in an otherwise very
dysfunctional health service. The irrational nature of
this decision again highlights the lack of leadership
and vision in either the Department of Health and
Children or the Health Service Executive and their
scant regard for patient services.’
Ms Hoctor said that “The Minister for Health and
Children has used Section 9 of the Financial Emergency
Measures in the Public Interest Act 2009 in a vindictive
fashion to circumvent a High Court Judgment, which
found that the HSE had acted unlawfully by cutting
pharmacists’ payments in March 2008.” Ms Hoctor
said: “Section 9 of the Act should be repealed at the
earliest opportunity if it is to be used in this cynical
fashion”.
The Union will be communicating with its members
on the matter and will also be seeking an urgent
meeting with the Minister.
30 June 2009
Irish Pharmacy Union criticises ‘incomplete’ report
President of IPU says pharmacists prevented by
government from offering patients cheaper generic
medicines
The Irish Pharmacy Union, the representative body for
1,900 community pharmacists in Ireland, has
criticised the Competition Authority for failing to
address key issues around the cost of medicines in
Ireland. The IPU is responding to a new report by the
Competition Authority entitled “Retail-related
Import and Distribution Study” published today.
In particular, the Union states that the Competition
Authority ignored the fact that pharmacists are
currently prevented from offering patients the choice
of a cheaper generic medicine by a clause in an
agreement reached between the large
pharmaceutical manufacturers in this country and
the State. 
President of the Irish Pharmacy Union, Ms Liz Hoctor
described the report as incomplete and unbalanced.
“There is a glaring omission from the Competition
Authority’s report and that is the fact pharmacists are
currently prevented from offering the patient the
choice of cheaper generic medicines, where it is safe to
do so. Pharmacists in other European countries have
been enabled to do this to save costs not just for the
State but also for patients. Irish pharmacists are
prevented from offering the patient a cheaper generic
by a clause in an agreement between the large
pharmaceutical manufactures and the Government.
The price of medicines is set by this agreement.
Pharmacists here have no say in this.”
Ms Hoctor also pointed out that the Competition
Authority’s report also fails to acknowledge that 76%
of the medicines dispensed on the community drugs
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schemes by Ireland’s pharmacists are dispensed with
no mark up. These are medicines dispensed to
medical card patients.
In relation to the profit margins earned by
pharmacists, Ms Hoctor said: “The average pharmacy
in Ireland earns a net profit margin of 6.6%. We are
transparent in relation to this. This has been verified a
report on the community pharmacy sector published
by PricewaterhouseCoopers in January 2009. This is
hardly excessive.”
In relation to the cuts to pharmacists payments, Ms
Hoctor said: “The Government is now moving to make
a 34% cut in payments to pharmacists for providing
medicines and advice to patients on the community
drugs schemes. This cut is excessive and unsustainable
and will damage pharmacy services, undermine
patient care and lead to up to 5,000 job losses in
pharmacies across the country. This is extremely
worrying.”
IPU Press Release
1 July 2009
■ Over 700 pharmacists give notice to the HSE of
their withdrawal from drug schemes 
■ Irish Pharmacy Union calls on the Minister for
Health and Children to enter talks to avoid a
medicines crisis 
The Irish Pharmacy Union has been informed by over
700 individual pharmacists that they have written to
the Health Service Executive (HSE) giving 30 days
notice of their intention to discontinue providing
services on the community drugs schemes. The
means that to date effectively half of all pharmacies
across the country will cease dispensing medicines
on behalf of the HSE under the Medical Card Scheme
and the Drugs Payments Scheme effective from 1st
August next. Many other pharmacists are also
reviewing their position. The pharmacies involved are
from all parts of the country, but in particular from
Donegal, Sligo, Leitrim, Cavan, Roscommon, Galway
and Kerry. The Irish Pharmacy Union (IPU), the
representative body for community pharmacists in
Ireland, is today calling on the Minister for Health
and Children to enter talks with its members as soon
as possible to avoid a medicines crisis. 
Liz Hoctor, President of the Irish Pharmacy Union
said: “I have no doubt that each pharmacist did not
take this decision lightly. However, the Minister for
Health and Children has dropped a bombshell on the
pharmacists by imposing a 34% cut in payments for
providing medicines and advice to patients under the
community drugs schemes. This cut is excessive and
unsustainable. These cuts will damage pharmacy
services, patient care and lead to up to 5,000 job losses.
Ms Hoctor also said: “Pharmacists are calling on the
Minister for Health and Children to engage with us
immediately on how savings can be achieved without
having a catastrophic impact on pharmacy services,
patient care and employment. We recognise the
seriousness of the country’s economic situation and
back in March made proposals to the Minister which
would save the State €83m. Our proposals included
enabling pharmacists to offer patients the choice of a
cheaper generic medicine where it is safe to do so and
the acceptance of an 8% cut in pharmacy fees which is
in line with cuts imposed on all other healthcare
professionals. However, our proposals, which are
practical and reasonable, were ignored by the Minister
and instead a 34% cut in payments was announced.”
Ms Hoctor continued, “Ireland has one of the most
liberal pharmacy markets in Europe. The Minister
seems determined to push small independent
pharmacies out of business and to hand the
community pharmacy sector on a plate to a small
number of large international players. It would be a
great shame to decimate a sector that has over the
years provided a personal and professional service that
is highly valued by patients.”
Section 9 (8) of the Financial Emergency Measures in
the Public Interest Act 2009 states “A health
professional who does not wish to continue to render
services to or on behalf of the health body concerned
on the basis of a payment regime fixed in a regulation
made under subsection (1) may give 30 days’ notice to
that effect to the health body and, on the expiration of
those 30 days, shall be relieved of any obligation to
render those services notwithstanding any contractual
or other term with regard to notice.”
1,521 pharmacists currently hold a contract with the
HSE for the provision of medicines to patients on the
community drugs schemes.
IPU Press Release
Sunday 19 July 2009
Pharmacists Respond to HSE Contingency Plans 
for Drug Supply
The Irish Pharmacy Union, the representative body for
pharmacists in Ireland said that it had grave concerns
about the HSE's contingency plan for the supply of
medicines after 1st August, published today.
A spokesman said that what had been dubbed Phase
One of the contingency plan is totally inadequate in
terms of meeting the medicines needs of patients. The
Union called for the immediate publication of Phase
Two of the plan, which it hoped would be more
comprehensive. The Union wrote to the Minister for
Health and Children over three weeks ago seeking to
resolve the matter. To date, the Minister has not responded. 
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HSE Press Release
Sunday, 19 July 2009
HSE publishes Phase 1 of alternative pharmacy locations
Expression of interest invited from pharmacies in
Northern Ireland
As part of the ongoing programme to lower medicine
prices, the rates payable to pharmacists for providing
medicines under the State Drugs Schemes (e.g.
Medical Card, Long Term Illness Scheme, etc.) are
being reduced. As a result, some pharmacists have
advised the HSE that from 1st August 2009 they will
stop filling prescriptions under these Schemes. The
HSE is putting in place alternative arrangements to
ensure that everyone who requires medicines under
the State Drugs Schemes can continue to access
them.
Based on the information currently available, HSE
operated pharmacies are being set up in the
following locations:
■ St Patrick's Hospital, Summerhill, Carrick-on-
Shannon, Co Leitrim 
■ Aras Naomh Chaolain, Knock Road, Castlerea, 
Co. Roscommon 
■ Donegal Community Hospital, Donegal Town, 
Co. Donegal 
■ Dungloe Community Hospital, Dungloe, 
Co. Donegal 
■ Carndonagh Community Hospital, Convent Road,
Carndonagh, Co. Donegal 
■ Falcarragh Community Hospital, Falcarragh, 
Co. Donegal 
■ St Marys Hospital, Castlebar, Co Mayo 
■ Mercy Road, Ballina, Co Mayo 
■ Arus Deirbhle, Belmullet, Co Mayo 
■ Cherryfield House, Coolgrane, Killarney, Co Kerry 
■ 19 Denny Street, Tralee, Co Kerry 
■ Listowel Community Hospital, Listowel, Co Kerry 
These pharmacies represent Phase 1 of the HSE
Pharmacy Contingency Programme. Additional
pharmacies may be added as more information
becomes available on the existing pharmacies that
will be withdrawing service. These locations are
currently being fitted for operation by 1st August
2009. Arrangements are also being made to enable
hospitals to dispense higher than usual volumes 
of medicines.
Last week the HSE, through advertisements in
newspapers in Northern Ireland, invited expressions
of interest from border county pharmacy contractors
with the Health and Social Care Board of Northern
Ireland to dispense medicines to HSE clients from 1st
August 2009.
The HSE’s Chief Pharmacist (Contracts Office) Kate
Mulvenna said; “It will not be possible to replace every
pharmacy which withdraws service on a like for like
basis so patients and clients may have to travel further
than normal to have their prescription filled. We would
encourage family, friends and neighbours to assist
vulnerable people who may have transport difficulties
to secure their medication.
Community pharmacists are an important part of our
health services and we hope that local pharmacists
will continue to provide these services. We are doing
everything possible to make sure patients and clients
can have their prescriptions filled, should their usual
pharmacist withdraw services, by either directing them
to participating pharmacists in their area or to
alternative arrangements that we have put in place.
Our advice to people who are concerned is that the
first thing to do is to ask their pharmacists if they will
be withdrawing services from 1 August 2009 or if they
will be continuing to provide a service to them.”
During the coming weeks the HSE will provide
information on pharmacies which have confirmed
that they will continue to participate in the Schemes.
This will be done through the HSE Infoline 1850 24
1850, advertisements and our website: www.hse.ie.
HSE Statement 
Tuesday, 21 July 2009 
Termination of State Drug Scheme Contracts by
Pharmacists 
The HSE today formally acknowledged the
termination of contracts by 800 pharmacists who
have given the Executive written notice that they will
be withdrawing from the State Drug Schemes. Letters
issued by the HSE to these pharmacists today
acknowledges receipt of communication from
pharmacists that constitutes termination of the
Community Pharmacy Contractor Agreement with
the HSE when the 30 days notice period expires on
1st August 2009.
In the letter, the HSE appealed to pharmacists to
facilitate patients and clients in having their
prescriptions filled in other locations by providing
clients with their records, such as repeat prescriptions
and dispensing records, on request. In addition,
pharmacists who have chosen to terminate their
contract have been asked to give Drug Payment
Scheme patients details of the payments they have
made up to the termination date of the contract. 
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The HSE stressed the importance of pharmacists
providing a list of patients who require extra
supports to their local HSE Primary Care Pharmacist
so that these patients’ needs can be factored into the
HSE’s ongoing contingency plans. Yesterday, as part of
Phase 1 of its contingency arrangements, the HSE
announced details of 12 new pharmacy locations
which the HSE will be setting up in the West of the
country from 1 August. 
The HSE’s Chief Pharmacist (Contracts Office) Kate
Mulvenna said; “We are asking pharmacists who have
chosen to terminate their contract to assist us in
ensuring minimal disruption to patients who need
access to their medications. By handing over
prescription records to their clients, on request, and by
identifying to the HSE patients who may require extra
supports, pharmacists can help ensure that their
clients can continue to access their medications.
“Our advice to people who are concerned about where
they can get their medication after 1st August is to ask
their local pharmacist if they will be withdrawing
services or if they will be continuing to provide a
service to them. If they are withdrawing services,
individuals can ask for their records and transfer to
another pharmacy in the locality or to a HSE
pharmacy which we will be setting up in locations
around the country, as required. Further information
on which pharmacists will be continuing to operate
the schemes after 1st August will be made available to
the public in the coming days,” she said.
Requests from pharmacists for reinstatement of
contracts will have to be reviewed in line with HSE
operating procedures. The HSE procedures in place for
the processing of applications for a Community
Pharmacy Contractor Agreement, a process which takes
at least 21 days to complete. A number of checks are
undertaken at each stage of the process, including Data
Protection registration and professional indemnity. The
most important checks involve the Supervising
Pharmacist under whose personal supervision the
responsibility for the operation of the pharmacy lies. At
the HSE inspection stage, the availability of reference
texts, equipment and suitability of the fridge and its
monitoring are reviewed. Following confirmation of
registration with the Pharmaceutical Society of Ireland,
the contract is issued. 
During the coming weeks the HSE will provide
information on pharmacies which have confirmed
that they will continue to participate in the Schemes.
This will be done through the HSE Infoline 1850 24
1850, advertisements and our website: www.hse.ie.
Wednesday 22 July 2009
■ Pharmacists meet in emergency information
session to discuss crisis
■ Warning that HSE contingency plans to supply
medicines are inadequate
■ Pharmacists call on Minister to avert crisis before
August 1st 
Over 1,000 pharmacists from across Ireland have
gathered today at an emergency information session
in Dublin to discuss the crisis in pharmacy. 
The crisis has arisen following a move by the Minister
for Health to cut payments to pharmacists under the
Community Drug Schemes by 34%. Over 1,100
community pharmacists have written to the HSE to
say that they will stop dispensing drugs under the
Community Drug Schemes from 1st August following
the introduction of the cuts by the Minister. As a
result, patients using the Community Drug Schemes
may have difficulty finding a pharmacist to fill their
prescriptions from that date.
Speaking to the Emergency Information Session
today, the President of the IPU, Ms Liz Hoctor, has said
that the crisis could be resolved and the Minister
could still secure her savings if she sat down with the
Irish Pharmacy Union to discuss the matter before 1st
August. She said; “Does the Minister want to destroy
the pharmacy network or does she want to make
savings. Pharmacists want to help the Minister reduce
the national medicines bill, but the way the Minister is
doing this will simply not work. It will undermine
patient services, force thousands of job losses and
widespread closure of pharmacies. We can help the
Minister make her savings but not on these terms.”
The meeting also heard widespread criticisms of the
HSE’s contingency plans to distribute medicines to
patients from 1 August; Darragh O’Loughlin, Galway
Pharmacist and Vice President of the Irish Pharmacy
Union said; “the contingency plans announced by the
HSE will simply not work. The HSE has neither the
experience nor the means to adequately replace the
pharmacy network. It is unrealistic to expect sick and
elderly patients to travel to centralised hospital
dispensaries to get their medicines from people they
don’t know.” O’Loughlin warned that thousands of
patients may not be able to get necessary medicines if
the HSE doesn’t introduce adequate contingency plans”.
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28 July 2009
■ Pharmacist anger over HSE misinformation
■ Inaccuracies in list of pharmacies places huge
question mark over credibility of HSE
■ ‘Plan’ clearly compromises patient care and safety
The HSE contingency plan to supply medicines to
patients on the Community Drugs Scheme has been
totally undermined by inaccuracies in its list of
participating pharmacies according to The Irish
Pharmacy Union, the representative body for
pharmacists. 
Liz Hoctor, President of the Irish Pharmacy Union
said: “Days before the August 1st deadline, patients
anxiety has been increased by the misinformation
contained in today’s HSE newspaper ad. The onus is on
the Minister to provide a safe and workable alternative
to patients to access their medicines, as she and the
HSE assured us would be done. If the HSE cannot get a
list of pharmacies right how can they dispense
medicines safely to people all over the country.”
For example today’s list contains:
■ A pharmacy in Galway which closed 3 months
ago
■ 16 pharmacies in Dublin and the North East
which shouldn’t be on the list 
■ 11 pharmacies in the South East which shouldn’t
be on the list
■ A pharmacy in the midlands which doesn’t have
a contract to dispense on the community drugs
schemes 
■ Dozens of other individual pharmacies all over
the country which shouldn’t be on the list
Given the gross inaccuracies in this list the IPU has
decided – in the interests of patient safety - to put its
list of over 1,100 pharmacies, who have copied the
Union with letters that they have sent to the HSE
indicating that they will not be participating in
community drug schemes, back up on its website.
Liz Hoctor, President of the Irish Pharmacy Union
said: “It is clear the list published in today’s papers is a
smokescreen and confirms the union’s view that the
HSE has no workable contingency plan. In accordance
with our information the list totally overstates the
number of pharmacies who are likely to continue
providing services from August next. The number of
pharmacies appears to be more of the order of 400
rather than the 800 odd claimed by the HSE”.
The IPU understands that the HSE list contains the
names of pharmacies who in the opinion of the HSE
have not given the requisite notice period or where
the HSE has chosen not to interpret the pharmacists’
letter as giving the required notice. IPU head office
has been inundated with calls from angry
pharmacists whose names are on the list despite the
fact that they have given notice of their intention to
withdraw. 
“This is a desperate attempt by a desperate
organisation to hide the fact that they do not have a
workable plan capable of meeting the needs of
patients. Pharmacists have absolutely no faith in the
contingency plan put in place by the HSE. We are
extremely worried about the ability of the plan to
deliver even a basic pharmacy service,” said Ms Hoctor.
After Minister Harney made her announcement to
cut pharmacists payments by 34% on 18 June the IPU
requested a meeting with her. To date there has been
no response.
Friday 31 July 2009
On eve of pharmacy crisis…
■ IPU warns that patient safety will be
compromised by inadequate contingency plans
■ Chaotic service likely in many areas which have
been left without sufficient cover
From tomorrow it now seems likely that many
community pharmacists will no longer supply
medicines under community drug schemes. The Irish
Pharmacy Union (IPU) has warned that patients are
now facing into an intolerable situation as it
becomes clear that the HSE contingency plans are
totally inadequate and in many parts of the country
there is no contingency plan at all in place. 
Liz Hoctor, President of the IPU has accused the HSE
of failing to meet its legal responsibility to patients.
“The Minister assured the Dail that there would be a
workable contingency plan which would ensure that
all patients have access to the medicine they need
including those who cannot afford them. It is clear
that the HSE has failed in this regard and it is now
incumbent on them to admit that there are areas of
this country without adequate pharmacy cover. The
HSE and the Minister should recognise this dangerous
situation immediately as ultimately responsibility for
patients and their care rests with the Minister.”
The IPU believes that under the HSE contingency plan
pharmacy cover in areas such as Waterford, Wexford,
Cavan, Donegal, Kerry, Connemara and Mayo will be
totally insufficient to meet patient demand and that
this could lead to dangerous situations.
Liz Hoctor pointed out that the IPU had raised many
of their concerns with the HSE but had not received
any response. “The HSE says it is setting up a dozen
dispensaries around the country. Will they all be open
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tomorrow? Will there be sufficient staff? Will they have
a full range of medicines? What are their opening
hours? What after hours services will be provided? Will
they be able to deliver medicines to patients/Collect
medicines from surgeries? Will their help line be open on
a twenty four hour basis? Do they have the necessary
equipment such as computer systems, refrigeration
facilities, security systems? Have they been licensed? Will
their staff have the knowledge and experience to spot
mistakes in prescriptions? Will they provide monitored
dosage systems to patients? These are some of the
questions we raised with the HSE on behalf of our
patients but as usual we received no response.”
In response to calls that a mediator be appointed Ms
Hoctor said that “I want to assure patients and their
Associations that the Union is willing to engage in an
attempt to resolve matters.” 
She said she deeply regretted any worry or distress
caused to patients who will be adversely affected by
the current situation. Ms Hoctor said this was a very
worrying time for patients and pharmacists alike and
that she knew the decision by pharmacists to
withdraw from these schemes was taken with the
utmost reluctance.
Ms Hoctor pointed out that given the current
economic situation pharmacists have shown a
commendable willingness to play their part and have
put forward proposals which would bring in €85m
worth of savings, protect patient care and safeguard
jobs. The proposals would also allow pharmacists to
offer patients the choice of cheaper generic
medicines where it is safe to do so.
Ms Hoctor pointed out that community pharmacists
have been forced into this impossible situation by
Minister Harney’s unilateral decision to impose a
disproportionate and unsustainable 34% cut in
pharmacy payments for providing advice and
medicines to patients on community drug schemes.
1.30pm Sunday 2 August 2009
■ Widespread stories of chaos as HSE contingency
plans fail their first test
■ Pharmacists predict much worse problems to
emerge on Tuesday as demand for medicines grows
■ HSE Claims about who’s in and out of schemes is
ridiculed again as Phibsboro pharmacist named
on a HSE list hours after appearing on RTE news
explaining why he quit the scheme! 
Widespread medicine shortages and delays are being
forecast for Tuesday [4th August] by the Irish
Pharmacy Union following the withdrawal of as
many as 800 pharmacists from the Drug Payment
schemes yesterday.
Speaking today the President of the IPU, Liz Hoctor,
said that the Union understood that as many as 800
pharmacists had either closed altogether or were not
dispensing under the state drugs schemes [eg:
Medical Card and Long Term Payment Schemes]. She
said that the HSE contingency plans had failed
dismally on Saturday and widespread shortages and
delays were experienced by patients using the special
HSE dispensary services in Donegal, Kerry and Mayo
and there were no back up facilities operating in
Waterford and Cavan despite the widespread closure
of pharmacies in those areas.
The credibility of the HSE claims about pharmacists
continuing to stay with the schemes has also been
undermined again as its emerged that Phibsboro
pharmacist Richard Collis – who was on RTE last
evening [Sat] as a pharmacist who had quit the
schemes – is today included on the latest HSE list of
pharmacists operating normally. Collis described his
inclusion in this way as an attempt at “intimidation
and bullying” by the HSE.
Speaking on the situation in Donegal on Saturday,
Gweedore Pharmacist, James Cassidy, said; “there is
no semblance of a reliable service available to patients
from the HSE. In Inishowen the HSE actually hired taxis
to transfer patients between the Peninsula and the
contingency site in Stranorlar. Prescriptions were then
to be left for collection after 7.30 [on Saturday evening
last] in Carndonagh community hospital.
In Dungloe, we had several patients who went to the
contingency site requesting medications only to be
told the items were not in stock but to come back on
Tuesday. This is a gross abdication of the duty to
provide safe care to patients who simply cannot wait 3
days for essential medicines.
This is highly dangerous. The contingency site have no
patient records, no contact with patients and are
trusting scripts to pass through several series of
unqualified persons before being left for ad hoc
collection by patients that night.
Ms Hoctor said that the chaos in Donegal was
repeated in many parts of the country; “the HSE
protested for weeks that it’s planned were sufficient.
They are not. And if they failed the test on a quiet
bank holiday Saturday when prescription levels are
always low, then we fear real disasters when demand
picks up on Tuesday of this week.”
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4.00pm Monday 3 August 2009
■ Evidence emerges of potentially serious mistakes
in dispensing from HSE emergency dispensaries
■ HSE’s secret deal with Hospital Pharmacists
revealed 
■ Pharmacists predict chaos [Tuesday] as demand
for medicines expected to grow rapidly 
■ Pharmacists allege HSE intimidation
The Irish Pharmacy Union [IPU] has claimed that it
has seen evidence of clear mistakes and flaws with
the medicines dispensed to patients at some of the
HSE’s emergency dispensaries. The Union has warned
that the likelihood of inexperienced and overworked
staff in these dispensaries making such mistakes
would increase on Tuesday as demand for
prescriptions was expected to rise significantly after
the bank holiday weekend.
One Mayo pharmacist reported his experience in
checking the medicines dispensed by the HSE with
the son of one of his patients who had collected the
medicines from the appointed HSE dispensary. He
said; “The prescription was for 7 items in total but
when the son brought the medicines back to me to
double check what he’d been given, I found that the
HSE had no stock for two of the items…made errors in
respect of 4 of them and only dispensed 1 of the items
correctly.” The pharmacist reported that he rang the
HSE pharmacy on Saturday evening at 6.30pm and
was told that the pharmacist was in a meeting; “The
technician I talked to told me he would ring back but I
did not receive a reply. I rang again and again
requested a reply and got none.” He said that he
regarded the catalogue of events as gross negligence
and a danger to the public.
The IPU has also said that it would write a formal
letter to the Minister for Health expressing its
concern at the poor quality of the HSE’s contingency
planning on Saturday and the danger to public health
which had arisen. President of the Union Liz Hoctor
said; “The HSE was clearly not prepared for the
relatively light volume of patients they saw on
Saturday. I fear for what might happen when the
normal post Bank Holiday surge occurs tomorrow
[Tuesday].”
The IPU has also revealed that the HSE has made a
secret deal with Impact Trade Union [representing
hospital pharmacists] with a view to securing the
service of this group in their contingency plans. The
IPU says the deal with Impact reveals the extent to
which the HSE is trying to go to force through their
agenda. In a letter sent to the HSE by the Union’s
assistant General Secretary, Eugene Donnelly, Impact
has confirmed that Impact –
“can now proceed with contingency plans on the
following basis :
■ HSE to set out a ‘process-map’ for the
procurement of products which would be
supplied to the alternative dispensary services in
the specified critical areas i.e. Donegal, Mayo and
Kerry.
■ Subject to the above being agreed by the
Pharmacists, arrangements will be made to
ensure that sufficient co-operation with same is
forthcoming.
■ Faxing of requisitions, etc can be carried out by
agency staff within the clerical and
administrative field.
■ The HSE must give Pharmacists guarantees
regarding possible risks such as ‘stolen goods at
point of delivery’ and wholesale licensing issues.
■ There will be a review after two weeks
(scheduled for 11th August 2009). In the event of
difficulties, Pharmacists reserve the right to
withdraw from contingency arrangements.
■ As there is a major problem regarding staff
shortages at Hospital Pharmacies and thus, the
limited capacity to cover these extra duties,
IMPACT will set out for you the schedule and
classification of current vacancies for your
consideration.
■ The HSE will formally restate its commitment to
proceeding with the December 2008
Pharmacists agreement.”
Referring to complaints today [Monday] by the HSE
regarding alleged intimidation of staff in dispensaries
by pharmacists, the IPU has again made clear that it
would not condone any intimidation by its members
but it has seen no evidence of any such intimidation.
It was also noted that the letter of complaint from
the HSE to the PSI (The Pharmacy Regulator)
contained no specific details whatsoever of any
alleged incident involving purported bad behaviour
by a pharmacist.
The Union has also criticised the HSE for themselves
seeking to intimidate pharmacists to remain with the
discredited community drug schemes with threats of
legal actions and delays in considering any
application by pharmacists to reengage with the
Drugs Schemes.
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Tuesday 4 August 2009
■ From Donegal to Wexford to Kerry, large areas of
country remain without adequate pharmacy
cover as HSE contingency plan fails dismally.
■ Concern for patient safety increase as litany of
errors revealed at HSE dispensary in Kerry. No
safety warnings being printed on medicines
supplied by HSE dispensary in Mayo
■ New HSE policy bans pharmacists from collecting
prescription for patients
The Irish Pharmacy Union has reported widespread
problems for patients across the country as the HSE’s
contingency plans for dispensing medicines crumbles
under its first real test.
Liz Hoctor, President of the IPU said feedback from
pharmacists show that as forecast there are major
problems in Mayo, Donegal, Carlow, Waterford, North
Dublin, Wexford, Kerry, Offaly, Clare and Galway (See
Editors Note below). ‘We forecast that there would be
huge issues for patient service and care and now
under the first normal day of service the HSE’s plans
have been shown to be totally inadequate.’
Liz Hoctor also pointed out that IPU members have
raised serious concern about the safety of the HSE’s
ten temporary dispensaries set up around the
country. ‘One pharmacist in Kerry who checked the
prescriptions dispensed to 11 of his patients by the
HSE dispensary said 8 of them had been filled
incorrectly. Quite rightly he is horrified at the
standard of service being given by the HSE and has
real concerns for the safety of his patients the longer
this service continues. Another pharmacist in
Limerick was refused permission to collect medicines
on behalf of his patients.’
The IPU has learned that it is now HSE policy
nationally to ban pharmacists from collecting
medicines on behalf of their patients. In another
example of bully boy tactics the HSE has advised
wholesalers not to supply high-tech drugs to
pharmacists who have withdrawn from the
community drug schemes. This action places at risk
an extremely vulnerable group of patients. ‘Together
with their totally inadequate contingency plans these
actions by the HSE show the scant regard they have
for the care and well being of patients all over the
country. If Minister Harney and the HSE is really
concerned about patient care and safety they will
respond to calls by patient organisations for a
mediator to be appointed.’ 
Wednesday 5 August 2009
■ Pharmacists who work in pharmacy chains say
ability to provide medicines in a safe manner is
being severely compromised
■ Failure of HSE contingency plan has put
immense pressure on employee pharmacists
■ Latest reports indicate pharmacies in Wexford,
Waterford and Kilkenny have been forced to turn
patients away
Employee pharmacists (registered pharmacists who
work for pharmacy chains) have expressed grave
concerns about the dramatic increase in prescriptions
presented for dispensing at community pharmacies
continuing to participate in the community drug
schemes. This has occurred due to the failure of the
contingency plan of the HSE to deal with the
withdrawal of hundreds of pharmacies from the
community drug schemes. The statement came as it
emerged pharmacies in Kilkenny, Waterford and
Wexford which are dispensing under the community
drug schemes have been forced to turn patients away.
Bernard Duggan, Chairman of the Employee
Pharmacists Committee, said employee pharmacists
are being placed under unsustainable pressure due to
the huge increase in the workload of the
participating pharmacies. ‘These pharmacies do not
have the resources at their disposal to deal with this.
The ability of employee pharmacists to dispense
medicines in a safe and timely manner is being
severely compromised. Some of these pharmacists
have stopped accepting prescriptions and closed their
doors due to their unacceptable and dangerous
workloads, so as to avoid a serious dispensing error
occurring.’ Duggan said. He cited particular
difficulties in areas such as North Dublin, Kilkenny,
Wexford, Kerry and Waterford.
Duggan said employee pharmacists regretted that
the current situation had come to pass but said
responsibility for this sorry mess rests with Minister
Harney. ‘We are asking for patients’ understanding
during these difficult times. We are in an
unprecedented situation; community pharmacists
have never withdrawn from the community drug
schemes before. The responsibility rests with Minister
Harney and the HSE. The cuts she has imposed have
made it impossible to deliver the high quality,
accessible community pharmacy service that patients
deserve and expect.’
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Thursday 6 August 2009.
■ Pharmacies close to breaking point due to
pressure of HSE’s inadequate contingency plans 
■ Four day delays in Waterford and Kilkenny
■ Medicines being couriered from Dublin to Mayo
at huge expense
■ Serious dispensing error in Tralee – patient given
anti depressant instead of anti inflammatory
■ Cahirciveen HSE dispensary remains closed -
Ballina still to open
The HSE’s inadequate contingency plans are
continuing to unravel causing increasing hardship for
patients all over the country the Irish Pharmacy
Union has said.
The worse affected areas continue to be Donegal,
Waterford, Mayo, Kerry, North Dublin, Kilkenny,
Galway and Limerick.
John Corr, Chairman of the IPU Contracts Committee
said they are continuing to receive reports of long
delays, HSE dispensaries not having commonly used
medicines and prescriptions being incorrectly filled.
‘As we pointed out earlier the situation in Donegal is
dire. There is a four day delay in Waterford city and
one pharmacy that was dispensing has stopped. It is
sending emergency cases to Tramore. There is also a
four day delay in Kilkenny. There are long delays in
North Dublin and we are hearing that several
pharmacies there can’t cope with demand. Most
pharmacies in Limerick and Galway cities were closed
this morning. Pharmacies in Spiddal, Claregalway and
Barna are also closed. The HSE dispensary in
Cahirciveen remains closed while the one in Ballina
still hasn’t opened. The pressure on these
dispensaries and other pharmacies is unsustainable
and could well lead to errors.’
The IPU gave a number of examples:
HSE Dispensary Castlebar, Mayo
Yesterday afternoon this dispensary had no Epilim in
stock for an epileptic patient. The dispensary has
been warned about this dangerous situation by a
local doctor.
HSE Dispensary Tralee, Kerry
A patient was prescribed Difene (Diclofenac – anti-
inflammatory pain relieving medication) was
incorrectly dispensed Affex (Fluoxetine – SSRI anti-
depressant)
HSE Dispensary Dungloe, Donegal
Last Saturday the daughter of a cancer patient went
to the dispensary with a prescription for Forticreme.
She was told to return on Tuesday. The dispensary still
did not have it. Neither did they have it yesterday. A
local pharmacist gave the patient the required
prescription at no cost.
HSE Dispensary Castlebar, Mayo
Four very straightforward prescriptions were
couriered to and from a pharmacy in Monkstown in
Dublin to be dispensed. They were dispensed in a
pharmacy where there were no patient records for
these people and no counselling whatsoever was
offered. Two of the scripts were for antibiotic tablets
and creams.’
‘The HSE is constantly talking about the need to save
money but it seems to have no problem couriering
prescriptions across the country at tremendous
expense. Not alone is this hugely expensive it is also
very poor practise’ Corr said. He pointed out that
medicine supply issues are set to continue. ‘The HSE
cannot order electronically so there is a two day wait
for medicines from wholesalers. The medicines are
going to a central point in Dublin before going to the
dispensaries which takes another 2 days. So patients
are looking at a 4 day wait. As the backlog of
prescriptions builds up this situation will be
exacerbated.’ 
6 August 2009
Statement by the Minister for Health and Children,
Mary Harney TD re Pharmacy Services 
The first priority for everyone working in health at all
times has to be the interest of patients. 
In any commercial or industrial dispute in the health
sector, patients must come first. When there is a
dispute over money, as is the case now, services to
patients must continue safely. This has been the
norm in the health sector and has been properly
followed in almost all disputes. 
The situation now is that, overall, medicines continue to
be provided to the patients of the country as a whole.
But I am very concerned to hear reports of patients
being inconvenienced and facing unfortunate and
avoidable delays in the supply of their medicines, due
to the withdrawal of services by pharmacists.
I am also concerned to hear of medical card patients
being charged for their medicines, in some cases clearly
in contravention of the Community Drugs contract. 
Patients are entitled to receive their medicines safely
and effectively. 
Currently, over 1,100 pharmacists are contracted and
paid to provide drugs free of charge to medical card
patients and to patients covered by the Drugs
Payment Scheme over the €100 a month threshold.
Many pharmacists are continuing to do so fully. 
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But where there are instances of the service not
continuing in full by pharmacists who are in contract,
the HSE must, on behalf of patients, use every
possible means, including enforcement through the
Courts, to ensure contracts are implemented in full, in
every respect. 
I assure patients that this will have the Government’s
full support. We will not allow contracts made for
patients to be ignored or cherry-picked. For
pharmacies in contract, there can be no charges for
medical card patients or inappropriate closing of
pharmacies and refusal to provide medicines under
contracted services in a timely way. 
The Government has brought in new and
strengthened legislation to assure patient safety and
professional standards of pharmacy. I have the
utmost confidence that the regulator, the
Pharmaceutical Society of Ireland, will carry out all its
functions fully. 
Payment for service - €500m in 2009 after changes 
Patients, as taxpayers, are paying for the Community
Drugs Schemes.
This year, even after the changes implemented since 1
July, they will pay half a billion euro to 1,600
pharmacies for the community pharmacy service. 
Next year, leaving aside any growth in numbers of
drugs prescribed, patients, as taxpayers, will be
paying approximately €420m for the service. 
This is a fair payment from the community of
taxpayers and patients for the community services
provided by the pharmacy sector.
It brings remuneration of the pharmacy sector back
to the levels of 2006. This is in the context of fees
having doubled since 2002. In all fairness, and taking
account the financial situation of taxpayers as
individuals and the State as a whole, this is a
reasonable amount to pay for community pharmacy
services.
The new payment rates are now set in law. They have
been in effect since 1 July. It is done. There will be no
policy change, no change in the law to change the
payment rates now.
There can be no case now to divert money needed 
for health services in the autumn back to the
pharmacy sector.
And the financial situation of the country simply
does not permit us to row back on savings that are
now being made.
It is time to move on from the past of pharmacy
remuneration to the future.
Developments in next 12 months
Court case: The measures under the Act are to be
tested in the High Court in late October by one
pharmacy group. These measures were introduced
under law and it is therefore entirely appropriate that
challenges should be heard properly in the Courts. All
sides will keenly await the outcome. In the
meantime, patients are entitled to expect services to
them to continue as normal. 
Discussions on developmental role for pharmacy:
There are many community based health services
where pharmacists can have a greater role. An on-
going process of engagement with pharmacists to
develop this would be useful. I am prepared to meet
and discuss the future of, and developmental role for,
pharmacy services with pharmacists and the Irish
Pharmacy Union. However, as the IPU know, pricing
issues, past or future, cannot be discussed, since no
group of independent contractors may form a
common position to set prices for services. 
Therefore, mediation not possible: Both because of
the clear provisions of competition law and because
of the Courts testing the legislation in autumn, the
issue is not one for mediation. It is not possible to
mediate law, especially as it is to be tested in court.
Second, it is not possible for the IPU to develop an
agreed pricing strategy in conversation with anyone,
mediator or Minister. The Financial Emergency
Provisions legislation was developed in this context
and is the only process available.
Monitoring of savings: We set about to make a
particular level of savings - €55m this year, €133m in
a full year – under the Act. I know that some
pharmacists fear the impact may be greater. We
consulted widely, including with the IPU, and
engaged professional experts in making this
estimate. Now that the measures have commenced,
the actual outturn in savings will be monitored
carefully. As would be appropriate in any case, given
that there is accountability to the Oireachtas for
measures made under law, we will monitor and
report the actual savings in a fully transparent way,
so that the savings objective as planned is achieved,
neither more nor less.
Review of measures: The legislation requires a review
of these measures by 30th June 2010 and annually
thereafter. I will ensure that this review invites all
concerned to make their input in plenty of time on
the basis of the actual outturn of the measures. The
legislation has been enacted by the Oireachtas
fundamentally to deal with the very serious fiscal
situation the country faces and that is the purpose
that has to be achieved.
Additional savings – generics: Pharmacists will not be
alone in adjusting to payment reductions. Other
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measures to reduce costs in the drugs bill to
taxpayers will be advanced this year. For example, we
will bring forward a scheme for reference pricing for
off-patent (generic) drugs in Ireland. This would
mean the State would pay one price for any drug that
is off-patent, whether manufactured and sold as a
generic or a branded drug. I believe this can achieve
significant, predictable cost savings, in a method that
is somewhat different to generic substitution of
branded drugs. I would look forward to pharmacists’
input on the implementation of reference pricing.
Manufacturers’ prices: The agreement with branded
drugs manufacturers (the Irish Pharmaceutical
Healthcare Association) runs out in 2010. For the
period 2005-2010, savings of €250m will be achieved.
We will certainly be looking for more savings from
next year and will conduct those discussions also
within the constraints of competition law and the
fiscal situation. 
Given the current situation and these developments, I
believe patients are justified in expecting normal
community pharmacy services to continue now. 
I would appeal therefore to the pharmacy profession
to ensure that patients continue to be supplied their
medicines in a safe and timely way. 
I acknowledge that pharmacists are having to adjust
their businesses to the new situation and I know that
this can be very challenging.
I want to thank the majority who are continuing to
provide services in sometimes difficult circumstances. 
The Government also appreciates very much the
work of HSE staff at all levels who are working hard
to ensure continuity of supply of medicines to
patients, particularly at the new HSE pharmacy sites
around the country. 
Pharmacy has an important and sustainable role as
part of integrated community and primary care
health services funded by the taxpayer. 
7.00 pm Thursday 6 August 2009. 
Irish Pharmacy Union makes initial response to
statement on dispute by Minister for Health
President of Union:
■ Calls for appointment of Third Party to review
impact of cuts.
■ Expresses belief that majority of pharmacists
would restore full services quickly if the Minister
agreed to such an appointment.
■ Reiterates “grave concerns” that someone may
die in coming days as contingency plans are
clearly inadequate to cope with crisis.
The President of the Irish Pharmacy Union has
responded to the statement on the pharmacy dispute
issued this evening by the Minister for Health &
Children, Mary Harney TD.
Speaking this evening, Ms Liz Hoctor said she was
disappointed that the Minister seemed focused on
justifying the crisis which she had created in the
pharmacy profession; “this week has demonstrated
beyond doubt that the pharmacy profession is a
critical part of the healthcare infrastructure. We have
seen the chaos that arose when pharmacists were
forced to withdraw from the community drug schemes
and we have seen the failure of the HSE’s contingency
plans. The chaos can’t be allowed to continue.”
Ms Hoctor said that while the Irish Pharmacy Union
was dismayed that the Minister continues to rule out
face to face talks or mediation, she believes that
hundreds of pharmacists would re-open their
pharmacies before the weekend if the Minister
agrees to the appointment of an independent third
party to review the impact of the proposed cuts and
the ability of the sector to withstand such cuts this
year and next.
She continued that the Union has always been
prepared to accept a cut that was proportionate to
that being levied on other professionals in the health
services; “we are fast reaching a stalemate. But my
members are telling me that in the present emergency
and in the interests of patient safety they may resume
normal services, if the Minister were to agree to the
appointment of an independent third party to (1)
review and establish the impact of the proposed cuts
on the sector during this calendar year and (2) before
the next budget to assess, in the light of that
information, what would be a reasonable level of
savings that the HSE could expect the sector to
contribute next year in the context of the current
economic crisis and the need to maintain patient
services and jobs.”
Ms Hoctor also said that pharmacists were
increasingly worried about the potential for serious
injury or even death if the dispute goes on into next
week; “the contingency plans have failed. They are not
operating to a proper standard of safety or
professionalism and they must be ended and full
services restored in community pharmacies….the ball is
now in the Minister’s court to see if she will facilitate
that outcome”.
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9.00pm Tuesday 11 August 2009
■ In light of growing risks to patient safety, Irish
Pharmacy Union urges members to resume
normal services across the country
■ Special meeting called for tonight in Dublin to
get support for proposal 
■ Warning that significant issues remain
“unresolved” 
The Executive of the Irish Pharmacy Union [IPU] has
this evening urged pharmacists to resume normal
services immediately in the interests of patient
safety, in order to prevent a recurrence of the chaotic
scenes of yesterday and last week, and in light of
commitments made by the Minister in recent
statements. 
The Executive has called an emergency meeting of
members to take place in Dublin this [Tues] evening
in order to advise them of the reasons for making
this decision and to discuss the continuing dispute
with the Minister for Health and Children.
Speaking today, Ms Liz Hoctor, President of the Union,
made it very clear that some of the issues which
caused this dispute have not been resolved and
warned that further disruption to services was
almost inevitable if they are not. She said; “The
bottom line is that the cuts which the Minister has
forced through will have a very real and detrimental
impact on the quality of patient care which
community pharmacists can provide.” She said; “In this
dispute I hope it was made clear to people that our
ability to continue to provide high levels of service is
threatened by the Minister’s actions. That is a key point
for people to remember long into the future.”
She continued; “We have made progress on some
matters; the Minister has stated emphatically that she
will not seek to remove a cent more than €133 million
from the sector on foot of these cuts – and not the
€169 million that we feared would follow. And the
Minister has agreed to create a dialogue involving
pharmacists on the future and developing the role of
the profession. We will engage vigorously and urgently
with that process.”
Liz Hoctor continued; “the Executive believes that
pharmacists should resume normal services as a
matter of urgency and assist their patients who have
borne the brunt of the total failure of the HSE
contingency plans over the past 11 days. The idea that
the Air Corps would be drafted in to support the HSE in
rural Ireland or that a firm of solicitors paid for out of
taxpayer’s money would be threatening legal action
against pharmacists testifies to the failure of the plan.
That failure also clearly demonstrated to the HSE and
the Minister the importance of pharmacists to the
health services - which they obviously did not
understand or appreciate.
“Pharmacists have made clear over the past 11 days
that the pharmacy profession is united and is prepared
to fight for the right to proper representation and
input into issues that affect our profession and patient
welfare”.
Ms Hoctor also confirmed that, while there had been
some contact between the Department and the IPU
over recent days, no acceptable basis had yet been
found for a meaningful engagement to address the
issues in this dispute.
Ms Hoctor said that she acknowledged the
commitment by the Minister to carry out a Review
before the 30th June 2010 of the operation,
effectiveness and impact of the [fee] amounts and
rates introduced by her on the 1st July 2009. This
Review will also consider the appropriateness and
fairness of those amounts and payments having
regard to all relevant matters. She said; “If
pharmacists are to have confidence in this review, it is
essential that there is scope for meaningful
engagement by the Union in that review and that its
views are fully taken into account and reflected in the
outcome of the review.” 
In order to address pharmacists’ concerns in relation
to this matter, Ms Hoctor said that the Union would
be writing to the Minister setting out its proposals
on how the future relationship between the parties
should be conducted and the Union is prepared to
engage with the Minister on this agenda. She
continued; “The Minister has to recognise that,
irrespective of what legislation she is acting under, she
cannot hope to bring about real and lasting change
without the involvement and participation of all
parties.” The Union has prepared a paper setting out
a process for such an engagement.
Ms Hoctor warned that any attempt by the HSE to
place obstacles in the way of any pharmacist who
decides to resume normal services will be met with a
very swift response. 
Friday 14 August 2009
Pharmacists Thank Patients for Support and
Understanding During Recent Dispute
Express Regret that they were Forced to Take Action
On behalf of pharmacists all around the country, the
Irish Pharmacy Union has expressed its thanks to
patients for their patience, forbearance and support
during the recent dispute.
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Liz Hoctor, President of the IPU said that while
patients had been inconvenienced by the dispute the
feedback pharmacists had received was
overwhelmingly positive.
‘We know that many patients were hugely
inconvenienced when pharmacists were forced to
withdraw from the community drug schemes. And
given the failure of the HSE’s contingency plans we
know that it went well beyond inconvenience in very
many instances. It was extremely difficult for
pharmacists to direct patients to other pharmacies or
the HSE dispensaries, but I think patients appreciated
the fact that their pharmacists continued to care and
advise them. I know of many instances where
pharmacists, their staff or family members collected
and delivered medicines on behalf of their patients.
That’s what community pharmacy is all about and
that is why in the end we called on our members to
resume dispensing under the schemes’.
Ms Hoctor said that while pharmacists had been
forced to take the action by Minister Harney’s
unilateral action of reducing payments by 34% and
her refusal to meet with the IPU she said there had
been a number of positives from the dispute.
“The Minister has now given a commitment to engage
in dialogue on the future role of pharmacists and not
to remove a cent more than €133 million from the
sector on foot of these cuts.”
Ms Hoctor said that while many people have strong
views on pharmacists and the service they provide
she hoped the recent dispute had led to a greater
understanding of the role of community pharmacists.
Local pharmacist X pointed out that pharmacists
went back dispensing because of the mounting
danger to patient safety. ‘Our patients are our main
concern. But people have to remember that in order
to provide the professional and personal service we
want to provide and our patients expect, pharmacists
need to run viable businesses. That is the reality and
one which HSE officials have great difficulty
understanding. We don’t want a service where
pharmacies are forced to close down leaving large
parts of the country and our towns and cities
without an adequate service and up to 5,000 more
people without jobs.’
X said, ‘Hopefully people realize that while
pharmacists were more than happy to take an 8% cut
in payments like other healthcare professionals, a
34% cut is totally disproportionate and will impact
hugely on the ability of pharmacists to deliver the
service people expect. Also I hope people realize that
the price of medicines is completely outside of the
control of pharmacists. That is agreed by the
manufacturers and the government. Similarly while
pharmacists would like very much to offer generic
medicines where appropriate, we are prevented from
doing so by the government.’
In conclusion Ms Hoctor said that undermining the
ability of pharmacists to deliver a proper community
pharmacy service will have severe repercussions in
the future. ‘I hope the Minister, the HSE, will reflect
on that, put aside preconceptions – and indeed
misconceptions – and engage fully with the IPU in
mapping the way forward in a spirit of openness and
partnership.’
Wednesday 20 September 2009
Meetings of Pharmacists hear that cuts are
impacting on patient services
The President of the Irish Pharmacy Union [IPU], Ms
Liz Hoctor has warned that pharmacies are feeling
the impact of the cuts to their payments introduced
by the Minister for Health and Children from 1 July
last.
Speaking at the first of a series of regional meetings
of pharmacists around the country [which took place
in Waterford], Ms Hoctor said that pharmacists
would be facing severe financial problems over the
coming months as the cuts begin to bite; “it’s clear
that pharmacies and patients are beginning to see the
impact of these cuts. Jobs have already been lost and it
is likely more will follow. Some pharmacies have
already reduced their opening hours. This will
ultimately lead to reduced patient access to medicines
through their local pharmacy.”
Ms Hoctor reminded pharmacists that the Minister
for Health had undertaken to review the impact the
cuts on pharmacies before July 2010. Ms Hoctor said
that “It is now our priority to demonstrate to the
Minister the negative impact of the cuts and to seek to
have the cuts reduced in order to maintain quality
patient care in pharmacies.” She said: “This issue will
not go away until it is satisfactorily addressed.” She
also informed members that the constitutionality
and fairness of the legislation (the Financial
Emergency Measures in the Public Interest Act 2009)
and the Minister’s action will be challenged in the
High Court this autumn.
Ms Hoctor also noted the support which the public
had shown to pharmacists during the dispute and
thanked pharmacists for responding to the needs of
their patients during this difficult time. 
Local Pharmacist, X from X said that the recent
dispute between pharmacies and the Minister for
Health had highlighted the vital role played by
community pharmacists. He said that one of the key
challenges for pharmacists would be to expand their
service offering; “the pharmacist has huge potential
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for providing outreach programmes in the community.
Whether it’s managing chronic illnesses like diabetes
or administering vaccinations such as the Swine Flu
vaccination or prescribing for minor illnesses, the
challenge will be to provide additional services which
will benefit patients and provide a more cost effective
solution for the Exchequer.”
Thursday 17 December 2009
Pharmacists Respond to High Court Ruling
The Irish Pharmacy Union (IPU), the representative
body for 1,800 pharmacists, has expressed its
disappointment at today’s High Court ruling on the
use of emergency powers last July by the Minister for
Health and Children to cut payments to pharmacists.
The IPU will review the ruling and its implications
with its legal advisors in due course.
In the course of his judgment, Judge McMahon said
that Financial Emergency Measures in the Public
Interest 2009 Act was “exceptional”. He said: “Clearly
it is capable of affecting persons adversely and that
was one of the objectives of the legislation”. In this
context, the Union will be taking the opportunity of
the forthcoming review of payments by the Minister
to demonstrate the impact of the cuts on members.
It will seek to have this and related issues addressed
in that process.
2. OTHER MATTERS
7 May 2009
■ Students Warned to Protect Against Minor
Ailments as Exam Time Begins
■ Hay Fever Suffers Advised to Take Preventative
Steps before Exams 
■ Pharmacists issue Safe Code to help students
minimise symptoms of common minor ailments 
The Irish Pharmacy Union (IPU) today warned
students taking college, leaving and junior certificate
exams that they should protect themselves from
minor ailments including headaches, stomach upsets,
diarrhoea or constipation and a flare up of certain
conditions such as eczema, asthma and acne which
can, in some cases, be triggered by stress.
The IPU today issued a Safe Code to help students
minimise some of the symptoms that can be
associated with minor ailments associated with
exam stress. They advise parents and children to
discuss forthcoming exams and identify any areas or
subjects causing particular concern or worry.
Pharmacists, who estimate that 1 in 10 people’s lives
will be affected by hay fever at this time of year, warn
that students who may be susceptible to hay-fever
should take preventative steps now to try to ensure
that the ailment does not affect exam performance. 
Keith O’Hourihane, Pharmacy First Plus, Cork, said:
“Hay fever can cause severe deterioration in a person’s
well-being over a number of months as they grapple
with symptoms including blocked and itchy nose
causing frequent sneezing. Other symptoms include
congested or runny nose, itchy skin, itching on the roof
of the mouth, coughing, sneezing or a burning
sensation in the throat. Watery eyes are also a
common symptom of hay fever. Suffering from hay-
fever can add stress to a student who is already feeling
the pressure of exam revision. Prevention is of course
better than cure and students should take steps now
to prevent hay fever ruining their exam preparation.
The IPU highlights that students may experience bouts
of insomnia associated with long hours spent revising
or cramming for their exams and advice that other
ailments associated with long bouts of studying or
‘cramming’ are headache, sore eyes, back and joint
pain.
Mr O’Hourihane continued, “Exam stress can manifest
itself in the body in a number of ways, so we
encourage students and their parents to talk to their
local pharmacist if they have any concerns or want to
take precautions in advance of the exams starting. The
best advice is to be prepared and recognise the triggers
associated with minor ailments, that way you can
treat the ailment as soon as it presents and minimise
its impact.” 
The Safe Guide to Exams is available at www.ipu.ie
“The ailments discussed in our safe guide are just a few
that can arise in the run up to exam times. This advice
is just a guideline on how to prevent illness. A face to
face consultation with a local pharmacist can help to
assess whether a student needs further medical
intervention and can be the first step in ensuring that
a minor ailment does not become a problem during
exam time,” Mr O’Hourihane said.
77
A N N UA L  R E P O RT  2 0 1 0
8 May 2009
■ Rising diabetes crisis – pharmacists urge
Government to introduce screening for patients
through pharmacies 
Pharmacists have today called for the introduction of
a screening programme for diabetes through
pharmacies across the country to counter the
growing incidence of the disease in Ireland. As many
as 200,000 people in Ireland now suffer from Type 2
Diabetes with tens of thousands of people not even
aware that they have the disease. The treatment of
Type2 Diabetes costs the Irish health service €580
million every year and it is being described it as a
silent epidemic.
Liz Hoctor, IPU President, “Early detection of a disease
is naturally better for the patient and is also more cost
effective for the health service. The community
pharmacy network in Ireland is an under-utilised
resource. Because of their extended opening hours,
pharmacists are very accessible healthcare
professionals, which makes the pharmacy the ideal
location for the provision of screening services. This
would make access to healthcare more inclusive,
improve patient care and implement preventative
healthcare interventions which will transform the
management and treatment of chronic diseases in this
country”
The call was made today following news that there is
an extremely high incidence of diabetes in Northern
Ireland. Up to ten people a day are diagnosed with
the condition in the North, and latest figures show
over 62,000 people have the disease. Representing
1,900 pharmacists across the country, the Irish
Pharmacy Union expressed deep frustration about
the lack of political will to expand the role of the
pharmacist to allow them to play a greater role in the
management of chronic diseases like Diabetes.
Ms Hoctor continued, “The introduction of screening
for diabetes, and indeed other chronic diseases through
pharmacies would make significant savings for the
Exchequer by reducing the demand for services in other
parts of the healthcare system, including the already
over burdened A&E departments. If the Government
fails to act, it is a missed opportunity, especially for
patients. The time has come for the powers that be to
think outside the box and recognise this is an obvious
solution for improved healthcare which is practical, and
with long-term benefits to patients.” 
19 May 2009
Local Pharmacists launch Free guide on Common
Ailments in Babies and Young Children 
■ Guide gives practical tips on how to treat
conditions such as Nappy Rash and how best to
administer medicines to children
Babies are born with some immunity from infection
which lasts for about 3 months. After this time, they
begin to suffer from sickness such as colds and sick
tummies. When children get sick it can be a very
worrying and stressful time for parents, especially
first time mums or dads. A simple guide called
‘Common Ailments in Babies and Young Children’,
launched by the Irish Pharmacy Union today, gives a
snapshot of the most common illnesses that children
get and what parents can do to treat their child. It
also gives advice on how to administer medicines
safely to children. The guide is available free in
pharmacies nationwide.
Ailments such as colds, coughs, croup, pain and fever,
teething, colic, nappy rash as well as colic and
diarrhoea are covered in the guide. It lists the
symptoms, the treatment, general healthcare advice
and guidelines on when to see a doctor if conditions
persist or don’t improve. 
The advice from pharmacists in treating nappy rash is
to follow the A,B,C, D method:
A Air the baby’s skin and allow the baby to go
without a nappy when possible.
B Barrier, apply a protective cream to protect the
baby’s skin from excess moisture at each change.
C Cleansing. Change nappies as often as possible
and as soon as they are wet or soiled. Avoid
wipes and products containing alcohol. Pat the
baby’s skin dry after cleaning.
D Disposable. Disposable nappies are less likely to
cause nappy rash.
Pharmacist Aisling Reast says, “Babies and young
children are susceptible to common infections and
bugs, especially when they start mixing with other
children. Most of the time the child is not in danger
however, it is advisable that parents are aware of the
most common conditions and some of the main
symptoms and treatments related to conditions such
as fever, nappy rash, teething and colds. 
In relation to nappy rash for example, if the rash lasts
more than a few days or develops blisters or spots or if
you suspect the baby may have a thrush infection you
should consult your pharmacist who can either help
you treat the baby or advise you on whether you need
to see a doctor.” 
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Pharmacists also give practical advice on how best to
administer medicines to young patients.
■ Always use the 5ml spoon or dosage syringe
provided with medication don’t use household
spoons.
■ Give liquid medicines slowly to avoid choking.
■ Do not give a child any medication without first
consulting a pharmacist or doctor.
■ Stick to the correct dose.
■ Keep medicines out of the reach of children at all
times.
Ms Reast also reiterated the fact that pharmacists are
available at all times to give advice on family
healthcare. “Your local pharmacist is your first port of
call if you are concerned about a child and need to
speak to someone in confidence,” said Ms Reast.
28 July 2009
Pharmacists welcome commencement of
outstanding sections of the Pharmacy Act 2007
The Irish Pharmacy Union (IPU), the representative
body for 1,900 community pharmacists across the
country, has welcomed the commencement of the
outstanding Sections of the Pharmacy Act 2007,
which was announced today by the Minister for
Health and Children, Mary Harney, TD. Ms Liz Hoctor,
President of the IPU said: “We welcome the fact that
the Pharmacy Act is now fully enacted. The Act
recognises the increasingly important role played by
pharmacists in health care delivery.”
The Sections of the Act commenced today provide for
the introduction of a fitness to practice regime for
pharmacists and pharmacy businesses. They also deal
with the prohibition of certain economic
relationships between pharmacists or pharmacies
and medical practitioners or medical practices. 
Ms Hoctor went on to say “The development of
business relationships between GPs and pharmacists
has the potential to put patient safety at risk and
undermine patient choice. I welcome the fact that the
Minister has introduced specific provisions to deal with
this issue in the Pharmacy Act.”
Ms Hoctor referred to the Sixth Shipman Report
which states: “It is now generally accepted that the
involvement of a pharmacist in the process of
providing medication to a patient acts as a safety
check against error. It went on to state that: “where
prescribing and dispensing functions are carried out by
the same person or within the same commercial or
professional entity, there is a potential for the loss of
professional objectivity or even abuse.”
September 2009
Pharmacists recommend festival goers bring tissues
and hand gel.
The Irish Pharmacy Union, the representative body for
1,900 pharmacists, is strongly recommending that
people going to Electric Picnic this weekend bring
adequate supplies of tissues and alcohol-based hand
gel as a precaution against the H1N1 virus (Swine Flu).
Tissues should be placed over the nose and mouth
when coughing or sneezing and disposed of in a bin
straightaway. An alcohol-based hand gel should used
to clean hands frequently and especially after
sneezing and using toilet facilities.
35,000 music fans will make their way to the Electric
Picnic Festival this weekend. With so many fans
attending the festival, the Irish Pharmacy Union (IPU),
which represents 1,900 pharmacists across the
country, today issued some practical tips on health
issues for festival goers to consider while attending
the festival.
Fearghal O’Nia, a Dublin-based pharmacist said:
“Festivals are a time for people to have fun and let
their hair down. Pharmacists are giving some tips on
staying healthy at the festival, especially since we are
in the midst of the Pandemic H1N1.”
Precautions Against the Pandemic H1N1
■ Avoid close contact with people who appear
unwell and have a fever and cough. 
■ Clean hands regularly, especially after sneezing
or coughing or using toilet facilities. Ensure that
they are cleaned thoroughly with an alcohol
based hand cleaner (with at least 60% alcohol) –
ask your pharmacist to demonstrate the correct
technique.
■ Always carry tissues.
■ When coughing or sneezing:
• Turn head away from others.
• Use a tissue to cover nose and mouth.
• Dispose of the tissue immediately
afterwards in a waste bin.
• Clean hands after discarding tissue by using
an alcohol gel for at least 15 seconds.
• If you have no tissues immediately available,
coughing or sneezing into your arm or sleeve
(not into your hand) is recommended.
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Prescription Medication:
■ Make sure to bring along an adequate supply of
any prescription medication you may be taking.
Some medications lose effectiveness or may
cause adverse reactions if mixed with alcohol. If
in doubt consult your local pharmacist in
advance. He/she can inform you of any safety
risks involved. Prescribed medication should only
be taken by the patient they have been
prescribed for.
■ Asthma sufferers should take preventative
inhalers even if they are not showing any
symptoms. Being outdoors and exposed to pollen
and dust may cause asthma to flare up. Carry an
inhaler with you at all times and make sure you
have an ample supply.
■ Anyone with an allergy to any prescription
medicine, such as penicillin, should wear a
bracelet or necklace which states this fact. In the
case of an emergency, medical personnel will be
made aware of your allergy and will know the
correct medication to administer without
putting your life in danger.
Sexual Health
■ If you intend to be sexually active at the festival,
take precautions and practice safe sex. Always
use a condom to protect against sexually
transmitted infections such as Chlamydia or HIV.
■ Remember that vomiting and diarrhoea can
render oral contraceptives ineffective.
Suncare
■ Apply high sun protection factor (SPF). At least
factor 15+ but ideally complete sunblock. Reapply
regularly.
■ Wear a hat and shades.
■ If you suffer from cold sores, wear a lip balm with
high sun protection and carry a cream to treat
cold sores.
30 October 2009
The Elton John AIDS Foundation, Heath Service
Executive and IPU announce a partnership to provide
community needle exchange services throughout
Ireland 
On October 30 2009, the Health Service Executive
announced a new partnership with the Elton John
AIDS Foundation and the Irish Pharmacy Union to
provide additional needle exchange services (NEX)
through Community Pharmacies in 65 new locations
across the country. 
Mr John Curran T.D., Minister of State with
responsibility for the National Drug Strategy 2009-
2016 in welcoming the contribution of the Elton John
AIDS Foundation said that “their partnership with the
Health Service Executive and the Irish Pharmacy Union
will provide a significant additional dimension to the
work of the existing services aimed at preventing the
spread of Blood Borne Viruses. It also increases the
opportunities to persuade this high-risk group of
people to engage with treatment services so that their
health problems can be fully addressed. It is a great
example of how the Statutory sector can work with
the voluntary philanthropic and the private sectors to
impact in a significant way on a public health threat
and fits within the overall direction of the new
National Drugs Strategy”. 
The Health Service Executive is committed under
Action 34 of the National Drugs Strategy [2009-2016]
to extending NEX where they are required. This new
partnership enables the Health Service Executive to
implement this action in a targeted, discreet and safe
way, which not only takes used needles out of local
communities for safe disposal but facilitates injecting
drug users engagement with health services in their
communities and encourages them to give up
substance misuse and take up treatment. This is an
internationally recognised effective method to reduce
heroin injecting and an effective public health
intervention which considerably prevents the spread
of HIV and Hepatitis C viruses. 
Sir Elton John, founder of the Elton John AIDS
Foundation said: “Needle exchange programmes work.
This has been documented around the world and is
the reason why The Elton John AIDS Foundation in the
US is a core member of the Syringe Access Fund. I'm
delighted the Irish government has chosen to promote
proven methods to mitigate the danger of HIV.”
The Elton John AIDS Foundation will play a critical
role in setting up this programme over the next three
years, with the Health Service Executive signed up to
continuing the programme after that. Anne Aslett,
Director of the Elton John AIDS Foundation said: “We
know from our work in Eastern Europe that providing
injecting users with NEX not only prevents
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transmission of HIV and hepatitis but also provides a
critical entry point into health and rehabilitation
services. We wanted to identify a programme that
would have a widespread and lasting impact on the
HIV epidemic in Ireland. This programme can do
exactly that. Our funding can accelerate the roll out of
a network that will benefit anyone in the community
who has to use injecting equipment in the future.”
The Irish Pharmacy Union has been involved in the
development of this work and their members will
provide a discreet and safe needle exchange service
in local communities. The involvement of key
frontline health professionals in this manner will help
not only to address the exchange of needles but will
also provide expert clinical advice and support to
substance misusers on their health risks and health
needs. Pamela Logan, Director of Pharmacy Services
said: “Pharmacists are very supportive of this initiative,
which will help people, who live in the local
community and have a drug addiction problem, to
access healthcare and improve their health. Ultimately,
this will be a first step towards helping these people on
the path to recovery. Pharmacists in the UK and other
countries are already providing this service. We look
forward to discussing and agreeing this programme
with the Health Service Executive.” 
Tony Geoghegan of Merchants Quay said: “I am
totally supportive of the Health Service Executive’s
plan to roll out a national pharmacy based needle
exchange and health promotion programme.’’
16 November 2009
Pharmacists urge caution on introducing 
prescription charge.
The Irish Pharmacy Union has today urged caution in
regard to any attempt to introduce a prescription
charge. The idea of a prescription charge was raised
by the Minister for Health and Children yesterday.
According to the IPU, full consideration must be given
to various issues, such as whether certain patient
groups or those suffering from particularly medical
conditions would be exempted from this charge,
before any changes could be implemented. The IPU
called on the Minister to work with key stakeholders
including doctors and pharmacists on any initiative
of this nature.
The IPU also said that the Minister should
immediately implement previous proposals made by
the Union to maximise the rational and cost-effective
use of medicines, which have the potential to
generate more savings that the introduction of a
prescription charge.
Since 2002, the IPU has made repeated proposals to
reduce overuse and wastage of medicines and to
achieve better value for money for Government and
for patients. 
These proposals, which were never implemented,
include the introduction of Medicines Use Reviews to
make sure the patients were getting the full benefit
from the medicines and to ensure patients were
taking only those medicines which were clearly
necessary for their treatment. 
The IPU has also long called for increased use of
cheaper generic medicines. Pharmacists have sought
to be permitted to offer patients the choice of a
cheaper generic medicine, where it is safe to do so.
This change, which has the potential to save tens of
millions of euro on the state drugs bill, could be
introduced overnight by the Minister and the state
would begin to make savings immediately. 
The IPU believes that the current financial pressures
make these changes more urgent and called on the
Minister to introduce the necessary legislative
changes immediately.
Pharmacists have also argued for more medicines
which have long established safety profiles to be
made available without prescription for the
treatment of minor conditions, as is the case in many
other countries. This would allow patients to obtain
safe and effective treatments for a number of minor
conditions, such as conjunctivitis, thrush, heartburn
and impetigo, directly from their pharmacist, and
would relieve some of the pressure on overworked
GPs and on hospital A&E Departments.
These proposals, which are already in place in other
jurisdictions, would reduce costs and ensure patients
continued to have access to essential medicines. The
proposals would reduce wastage and ensure patients
were taking their medicines correctly, thereby saving
money on hospital care. They would also instantly
afford patients access to cheaper medicines.
9 December 2009
Pharmacists respond to Budget Announcement
The Irish Pharmacy Union (IPU), the representative
body for 1,800 pharmacists, has today warned that
the introduction of prescription charges for medical
card holders could lead to certain patients no longer
taking essential medicines and, as a result, requiring
hospitalisation. 
IPU President, Liz Hoctor, said: “It is ironic that when
prescription charges are being phased out in other
jurisdictions, Ireland is introducing them. Pharmacists
understand the need to tackle medicines wastage,
however, there are better ways to deal with this issue,
which the Union has been advocating for years. These
alternative proposals would not place patients’ health
at risk.”
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Calling on the Minister for Health and Children to
discuss the concerns around the implementation of
prescription charges with key stakeholders, Ms
Hoctor asked: “Has consideration been given to what
happens when a patient is unable to pay these
charges? What happens when a patient with a serious
health condition refuses to pay these charges, but
clearly needs their medication? Will certain patients be
exempt from the charges? Who is going to collect
these charges and what is the cost of collecting them.” 
The IPU had proposed alternative measures to reduce
the overuse and wastage of medicines. The proposals,
which are already in place in other jurisdictions,
include the introduction of Medicines Use Reviews to
make sure patients were getting the full benefit from
the medicines and to ensure patients were taking
only those medicines which were clearly necessary
for their treatment. 
Responding to an announcement in the budget that
the Government planned to enter into an agreement
with the pharmaceutical manufacturers and also
introduce a system of referencing pricing, Ms Hoctor
said that in order to ensure continuity in the supply
of medicines, the implementation of all changes
must be discussed and agreed with the Irish
Pharmacy Union. 
In relation to the proposal to impose further
reductions on the fees paid to health professionals,
Ms Hoctor said: “Pharmacists have already suffered a
massive and disproportionate 34% cut in payments
from the State this year. These cuts are already
damaging patient services and pharmacists cannot
withstand further cuts.” 
21 December 2009
IPU welcomes PSI Guidelines on Codeine Medicines
The Irish Pharmacy Union (IPU), which represents
1,800 pharmacists, today welcomed the
announcement by the Pharmaceutical Society of
Ireland (PSI) that it had published draft guidance for
pharmacists on the safe supply of non-prescription
medicinal products containing codeine. The
announcement comes a few weeks after the IPU and
the Irish Pharmaceutical Healthcare Association
(IPHA) jointly produced a protocol to assist
pharmacists in the sale of codeine-containing
medicines. 
The IPU and IPHA ran a public awareness initiative in
August 2007 highlighting the safe use of pain
relievers and the problems associated with their
overuse or abuse. In particular, people were advised
to speak to their pharmacist on the appropriate use
of codeine, which is contained in a wide range of pain
relievers and available from pharmacies without a
prescription. The campaign recommended that
people always follow the instructions which
accompany the medicines and not use them for
longer than stated on the pack, unless advised to do
so by their doctor. 
“Non-prescription pain relievers can be very effective in
relieving the symptoms of headaches and other forms
of pain when taken correctly,” said Keith O’Hourihane
of Pharmacy First Plus, Cork and Chairman of the
IPU’s Community Pharmacy Committee. “However,
taking medicines which contain codeine for longer than
instructed or misusing them can lead to physical and
psychological dependence and result in withdrawal
symptoms, such as restlessness and irritability once the
patient stops taking the medication.” 
Patients who use pain relievers which contain
codeine for longer than three days at a time or
exceed the recommended dosage could also
experience what is called rebound headaches. Pain
relievers offer quick relief for occasional headaches
but incorrect use may actually contribute to
headaches rather than easing them. 
Pamela Logan, Director of Pharmacy Services in the
IPU, advised: “People who misuse non prescription
pain relievers can become addicted to certain
substances and suffer withdrawal symptoms if they do
not continue to take them. The pattern of usage then
becomes a vicious circle resulting in dependency. We
hope that by highlighting this issue, patients will be
mindful of the problems that can result from the
misuse of such medications and will consult with their
pharmacist who can advise them on appropriate
medical care, which will minimise any potential risks
to themselves or their families.”
8 January 2010
Quitting Smoking? Ask your Pharmacist First
Pharmacist Kathy Maher is currently working with
RTE’s The Afternoon Show to help people to give up
smoking. For the next ten weeks, the Afternoon Show
will track the progress of three volunteers who have
decided to quit smoking. Click on the link below to
see Kathy on the show. 
If you would like to quit smoking, ask your local
pharmacist, who is a healthcare professional and will
be able to provide you with advice, encouragement
and support on quitting and staying off cigarettes. 
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■ Every 6.5 seconds someone in the world dies
from tobacco use = 1.5 million people dying
needlessly each year.
■ Every cigarette a person smokes reduces his/her
life by five and a half minutes.
■ In Ireland, smoking is the leading cause of
avoidable death. Nearly 7,000 people die each
year from the effects of smoking and thousands
of others are ill because of smoking-related
diseases 
Reasons for giving up:
■ Better quality of life, to be fitter/ healthier.
■ To improve lung function
■ To reduce risk of cardiovascular complications in
later life
■ Financial Reasons 
Health Benefits start straight away:
■ Within 20 minutes circulation will improves,
heart rate and blood pressure drop.
■ Within 24-48 hours all the carbon monoxide will
be eliminated.
■ Within a few days sense of smell and taste will
start to improve.
■ After 72 hours breathing will improve and energy
levels will increase.
■ Within 1 year the chance of heart attack drops by
half and within 10 years the risk drops to almost
the same as a non-smoker, or having never smoked
15 January 2010
Cancer Control Programme Welcomed
The Irish Pharmacy Union, the representative body for
1,800 pharmacists, welcomes today’s announcement
on the roll out of colorectal cancer screening and the
cervical cancer vaccine. The President of the IPU, Liz
Hoctor said: “These are very positive developments for
patients and will lead to the early detection and
treatment of colorectal cancer and reduce the risk of
cervical cancer among women.”
31 January 2010
Pharmacists welcome deal with pharmaceutical
manufacturers to lower medicine prices for drug
schemes but warn of transition difficulties.
The Irish Pharmacy Union, the representative body for
1,800 community pharmacists, responded to the
agreement between the pharmaceutical
manufacturers and the Government to reduce the
price of medicines saying that it was good news for
patients, particularly those patients who do not
qualify for a medical card. 
Liz Hoctor, President of the IPU, said that
“Pharmacists repeatedly pointed out that the cost
price of medicines in Ireland is substantially higher
than in many other European countries. This
agreement will bring the cost price more in line with
that being charged elsewhere. This move is too long
overdue and is to be welcomed for patients.
“However, pharmacists have not been allowed to begin
purchasing medicines at the new lower prices in
advance of 1 February, the date on which the changes
come into effect. This means that the medicines, which
pharmacists stock on their shelves for patients on
behalf of the HSE, will now be paid for by the HSE at
the new lower rates, despite having been purchased by
pharmacists at the high prices which were previously
agreed between the HSE and the drug companies. This
discrepancy is yet another severe financial blow for
pharmacists, who have already suffered pay cuts,
which were much greater than were imposed on any
other group.”
The Minister for Health and Children will be carrying
out a review of pharmacy payments later this year
and the IPU will be making a submission outlining
the negative impact of the cuts on patient care and
employment. 
4 March 2010
Minister for Health Launches New Pharmacy
Campaign to Improve Asthma Control
A new campaign to promote asthma control was
launched today by Minister for Health and Children,
Mary Harney TD. The campaign, a joint initiative
between The Asthma Society of Ireland and the Irish
Pharmacy Union, will encourage patients with
asthma to visit their local pharmacist to get advice
on getting the most from their inhaler. The campaign
was prompted by the fact that two out of three
asthma patients do not have their symptoms under
control. Incorrect inhaler technique can result in poor
asthma control and an increase in symptoms. The
campaign is running in pharmacies across the
country and asthma patients are invited to visit their
local pharmacy to have their inhaler technique
checked for free. 
Mary Harney TD, Minister for Health and Children,
said: “I would like to congratulate the Asthma Society
of Ireland and the Irish Pharmacy Union for this
initiative. By spending a few minutes with a
pharmacist, patients could significantly improve the
management of their asthma and reduce their need to
attend hospital. Simple, yet very effective initiatives
such as this, improve patients quality of life. I would
encourage anyone with asthma to avail of this
opportunity.”
Dr Jean Holohan, CEO of the Asthma Society of
Ireland, said: “This campaign is targeting one of the
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common reasons for poor asthma control. Inhaler
medication is the cornerstone of asthma management
but if patients are not using inhalers correctly they are
unlikely to get the full benefit from their medicine. I
would encourage patients, and parents of children
with asthma, to drop into their pharmacist and get
advice on how to use their inhaler. It will only take a
few minutes and could significantly improve their
asthma control, reduce symptoms and improve quality
of life’’
Liz Hoctor, President of the IPU, said: “Community
pharmacists are uniquely placed to advise and support
patients with asthma on how to improve their inhaler
technique so patients get the most from their
medication. We encourage patients to visit their local
pharmacist, bring along their inhaler(s) and the
pharmacist will not only assess their inhaler technique
but will also provide practical advice on living with
asthma. As there are a number of different inhalers
used to treat asthma pharmacists will provide specific
instructions tailored for individual patients needs.’’ 
Poor asthma control is responsible for 5,000 hospital
admissions and 22,000 visits to Accident and
Emergency units every year. Asthma is the most
common respiratory condition in Ireland and the
most common chronic disease in children. The inhaler
technique campaign is one of a number of projects
initiated by the Asthma Society of Ireland to improve
asthma management. 
The campaign is supported by a national radio
advertising campaign. People with asthma are also
encouraged to visit www.asthmasociety.ie for further
information on asthma and videos on inhaler
technique.
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Appendix XII
A SELECTION OF LETTERS PUBLISHED IN NEWSPAPERS
IRISH EXAMINER AND IRISH INDEPENDENT 3 JULY 2009
Health Minister Mary Harney has once again
demonstrated her ignorance and lack of
understanding of her own healthcare system. Instead
she has again bulldozed through half-thought-out
legislation and cuts without a single consideration
for those left to pick up the pieces — no
consideration as to how these cuts filter down the
line or how they will affect the patient. 
Last week Ms Harney announced that she would cut
fees by 35% to pharmacies with less than two weeks'
notice. Since then, neither she nor her department
has been in touch with the pharmacy contractors to
advise them of the cuts. 
Instead, they must rely on what they read in the
press and attempt to rustle up contingency plans to
save their businesses while maintaining their
responsibility to care for their valued patients. In no
way does this foster the vital multidisciplinary
teamwork and communication which our health
service so badly lacks. 
When one examines Minister Harney's performance
as health minister, it’s clear she does not believe in
teamwork. Negotiation is never an option. It seems
communication isn't even an option. She tells no one
of her plans, her reasoning or her justification.
Instead jobs are lost, services are compromised and
patients suffer with very little (if any) savings to the
HSE. 
Now, more than ever before in this crisis, we all need
to get the best minds together, sit around the table
and work out a way to save money, sustain jobs and
services and, most importantly, put the patient first. 
This is called working as a team, Mary. Maybe you
should try it sometime. 
Padraig McGuinness, Pharmacist, Kinlough, Co Leitrim
Irish Times 7 July 2009
Ian O'Mara (July 3rd) castigates pharmacists for
deciding to end our involvement in the medical card
scheme after August 1st. He packs a lot of outrage
into a short letter but completely avoids the obvious
question of what he would have us do instead. Mary
Harney has imposed a 3 per cent cut on our State
income. She has done this using her powers under
the Financial Emergency Measures in the Public
Interest Act 2009 which allows her to ignore any
existing contracts between us and the State; and
offer whatever rate of remuneration she considers
“fair and reasonable”. 
The stark choice we get under this legislation is to
accept the new rates or to withdraw our services.
There is no appeal process open to us. 
This 34 per cent cut will force the closure of up to 300
pharmacies. This figure is not based on spin, hype or
hyperbole but on hard, audited fact. Our decision to
withdraw from all State schemes, not just the
medical card scheme, has not been taken lightly. It is
intended to get us into talks to protect these
pharmacies, their workers and the long-term
interests of the patients they serve, by achieving a
negotiated settlement. We would obviously prefer to
resolve this issue now if we were allowed to do so,
rather than against a backdrop of disruption in
August. However, given that negotiation is not
currently on offer to us, if Mr O'Mara has a better
idea for how we should proceed then I for one would
love to hear it. – Yours, etc, 
Fintan Moore, MPSI, Templeogue, D6W. 
Mary Harney's idea to establish a “tendering process
for the distribution of subsidised drugs by
pharmacist” (“TDs told of EUR1bn in health budget
cuts”, July 3rd) shows the fallacy of having an
individual with no knowledge of health matters in
charge of our health system. 
It also shows that she still believes in the type of
economics that led us into the bubble. 
Pharmacists exist as an essential second check in the
process of providing patients with the medications
(effectively, controlled poisons) that they may need.
Without that second check patients are not
adequately protected. 
Centralising the distribution of medications in the
manner suggested would create the type of
dispensing factory that might sound plausible, but
the need for patient safety would require the
employment of such a large number of pharmacists
that it would in fact cost much more. 
If not, the cost of litigation when things go wrong
with such a system would be unimaginable. 
As a pharmacist, although not employed in the
community sector, I do think that this part of our
health service can be improved and, as a result,
85
A N N UA L  R E P O RT  2 0 1 0
millions saved. However, this will be achieved by
applying knowhow from front line health care
professionals and not by cutting corners. – Is mise, 
Oisin O Halmhain, MPSI, Viking Harbour, Usher's Island,
Dublin 8. 
I am an independent pharmacist who would like to
comment on our current dispute with our
paymasters, the HSE. 
Minister Mary Harney has imposed, without
discussion, a reduction of my HSE fee income (the
bulk of my business) of 42% per cent a year, effective
from July 1st. 
To put this in context, GPs, dentists etc have suffered
an 8 per cent fee reduction (the pharmacist average
is 35 per cent). I fully accept that changes to the
current model of our remuneration are necessary
(and require reduction), but I would have thought
that these changes could be arrived at through
negotiation or talks, as opposed to diktat. 
Maybe I am being unreasonable but I believe that
negotiation is a democratic right. 
All I ask, is that the Minister and her officials
negotiate with the IPU and we will find a resolution
without any negative impact on our customers. Talk
to us. We are reasonable people. – Yours, etc, 
Emmet Feerick, Feerick's Pharmacy, Leixlip, Co Kildare.
Irish Times 9 July 2009
Your editorial (July 6th) states that all groups must be
seen to pull their weight and take their share of the
pain. Of all people in society, pharmacists understand
the seriousness of the country's economic situation. 
My colleagues and I see patients coming into our
pharmacies with a medical card, who never before
needed a medical card. 
The editorial fails to point out that in March of this
year, pharmacists offered to help the Government
make savings of EUR83 million. We offered to take an
8% cut in our fees as other healthcare professionals
were asked to give, in addition we also showed how
EUR30 million could be saved through enabling
pharmacists to offer patients the choice of a cheaper
generic medicine, where it is safe to do so. 
We are currently prevented from doing this through a
clause in an agreement between Government and
pharmaceutical manufacturers. 
The Editorial accused pharmacists of targeting
medical card patients in its dispute with Government
on drug margins. This is simply not the case. 
Historically pharmacists provide an essential service
and support to their patients in their local
community above and beyond mere supply of
medicines. 
I do this on a daily basis on Achill Island and after 18
years here still get immense personal satisfaction
from contributing to our rural community. 
However, the massive cut which is being proposed by
the Minster is unreasonable. 
This cut is four times higher than what is being
imposed on other professionals and will undermine
rural pharmacy services in particular. 
Although I am the only pharmacist here in Achill
Island, I simply cannot afford to maintain pharmacy
services for the people of Achill under the cuts made
by the Minister for Health and regrettably with a very
heavy heart, I have served 30 days notice on the HSE
of my intention to discontinue provide a services on
the community drugs schemes. – Yours, etc, 
Noel Stenson, Pharmacist, Achill Island, Co Mayo. 
Irish Independent 15 July 2009
I wish to congratulate Shane Phelan on his report,
'HSE blows millions on overpriced medicines'(Irish
Independent, July 13). For once someone is prepared
to properly examine the Irish drugs bill and not just
lay the blame at the door of pharmacists. 
The cost price which I or my fellow professionals pay
for medicines is set artificially high and is much
higher than that in Spain or Greece, for example. 
The penetration of cheaper generic medicines is
much lower than other EU countries. 
This is at least partly due to the fact that pharmacists
cannot substitute more expensive medicines with a
cheaper alternative when appropriate. We are one of
only four countries in the EU where this is the case. 
On June 18, Health Minister Mary Harney announced
deep cuts in payments for pharmacy services. By her
own figures the cuts are at least three times those
imposed on other health care professionals or
barristers or government contractors. 
These cuts will decimate the service and place
thousands of jobs in jeopardy. 
The minister is correctly seeking value for money. But
hopefully the solution will not mirror that of the
banking crisis – services bled dry to save a fraction of
what is being squandered elsewhere. 
Des Treacy MPSI, Community Pharmacist, Ballinrobe,
Co Mayo
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Offaly Topic 23 July 2009
Both myself and my staff have worked hard to
provide a service that is highly valued by both my
patients and local health professionals. The meagre
profit I had hoped on making next year will now be
completely wiped out by the HSE cuts. These cuts will
mean at least 30 local jobs will be lost across the nine
pharmacies in Mullingar and the possible closure of
some. Mullingar is quickly turning into a ghost town
with businesses closing each week. The government
have already looked at reducing Gardaí stations, post
offices, now they are talking about closing our A&E
department. If these cuts are implemented,
pharmacies will be next.
Regards, John Keane MPSI Market Point Pharmacy,
Market Point Medical Park, Patrick St Mullingar
Irish Independent 27 July 2009
I refuse to become embroiled in a slanging match
with those responsible for trying to impose cuts in
the pharmaceutical spend in the State. But I would
make a suggestion to them. Seek a 10pc across-the-
board cut in the “factory gate price” of drugs as set
between the HSE and the drug manufacturers. 
Seek a 10pc cut in fees and mark-ups paid to
pharmacists, under State drug schemes. 
Seek a 10pc cut in the monies paid to wholesalers by
the State. 
Allow pharmacist-led generic substitution. The State
strategy? Fair and reasonable. The burden? Shared
equally. The result? Bigger savings than proposed at
present. The figure? EUR200m. Am I wrong in
thinking this is still possible? 
Robert Best MPSI, Tallaght, Dublin 24
Irish Times 29 July 2009
According to your report (Breaking News, July 27th) a
Health Service Executive spokesperson is telling us
that “people should be reassured by the fact that up
to a few years ago, and for more than 30 years before
that, the country was well served by around 1,100
pharmacies”. Actually it was the present Minister
who deregulated pharmacies in 2001, giving rise to
the opening of 300 new community pharmacies
since then. Clearly the Minister believed that
deregulation was necessary to allow additional new
pharmacies to open in order to improve public
services. Why the volte-face now? This week, the HSE
tells us that the old situation was actually a very
good one, and we were “well served by 1,100
pharmacies”. 
Where is the consistency here? Does this
administration have any strategy beyond taking the
next hill, and insulting our intelligence in the
process? The truth is that the Minister and the HSE,
unwilling to challenge more powerful vested
interests in the pharmaceutical supply chain than
independent community pharmacists, are targeting
the weakest player in the most unfair manner. They
could ensure that the burden of medication cost
reduction is shared equally throughout the sector by
a similar cut across the supply chain: 1. In the “factory
gate price” of drugs as set between the HSE and the
drug manufacturers. 2. In fees and mark-ups paid to
pharmacists, under State drug schemes. 3. In the
monies paid to wholesalers by the State. And by one
additional measure already in place in most EU states
– allowing pharmacists to substitute cheaper generic
brands for doctors' brand-name prescriptions. 
These measures would undoubtedly upset the
multinational pharmaceutical industry and the
medical profession. They would also involve
considerable sacrifice by the community pharmacists.
But they would amount to a fair and reasonable
strategy that shares the burden of cost reduction
evenly across the sector, between all players. 
This strategy would avoid alienating the community
pharmacists, whose role in patient safety has
historically been hugely undervalued, if not
completely unrecognised, by the Government. In
addition to sharing the burden equitably among all
players, this plan would yield bigger savings than
proposed at present by the Minister. It would avoid
the negative social consequences of hundreds of
independent rural pharmacies going to the wall, as
will happen if the current proposal is implemented. 
Many of these pharmacies are ones that opened in
the past eight years as a direct result of the decision
by the same Minister to deregulate pharmacy
premises. 
Why are the Minister and the HSE so resolute in their
unwillingness to contemplate this scenario? Could it
be that vengeance for last year's High Court decision
in favour of community pharmacists – the last time
the HSE tried to bully them – takes precedence over
the common good? 
Yours, etc, Tim Delaney, Gordon Street, 
Ringsend, Dublin 4.
Irish Independent 4 August 2009
The HSE spent tens of thousands of euro last week
listing pharmacists who would be dispensing after
August 1 and included 60 for the counties Donegal,
Mayo and Kerry- They then spent tens of thousands
more setting up dispensaries in these counties for
which, if the list were true, there would be no need. 
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The HSE published the list knowing full well the
disinformation would only add to the stress of
patients. 
The HSE mandarins may consider this a clever and
cunning ploy to divide pharmacists but it's a pity they
cannot focus their energies on a really clever ploy – to
sit down with pharmacists and find a solution. 
Yours, etc, Joanne Hynes MPSI, Cornmarket, Ballinrobe,
Co Mayo.
Irish Times 5 August 2009
Our first patient on Saturday morning, the first day of
the pharmacy strike, was a quiet, timid man. He had a
prescription for his elderly mother. He was told that
there was only one pharmacy in Waterford city which
could dispense his prescription. He was totally
bewildered, frightened and confused. He had never
heard of Boots, and despite having lived in Waterford
city all his life, didn't know where it was located. The
second patient returned to us from that pharmacy.
She told us they wouldn't have any of her medication
for treating depression for four days. She was in tears.
The next, a frail lady of over 80 years, on heart and
blood pressure medication, mumbled something
about trying to do without until the dispute was
over. And so it went all day. 
Shame on Minister for Health Mary Harney for
holding the elderly, sick and' vulnerable of this
country to ransom. One phone call to the
pharmacists, who are willing to take fair cuts and
help implement savings over and above what she is
seeking, would end this strike. 
Yours, etc, Margaret Halley, Marlfield, Clonmel, Co
Tipperary. 
The HSE spent tens of thousands of euros last week
listing pharmacists who would be dispensing after
August Ist, and included 60 for the counties Donegal,
Mayo and Kerry. The HSE then spent tens of
thousands of euros more setting up dispensaries in
these counties for which, if the list was true, there
would be no need. 
When the HSE published the list, shouldn't it have
known full well that the disinformation would only
add to the stress of patients? The HSE mandarins
might consider this a clever and cunning ploy to
divide pharmacists, but it's a pity they cannot focus
their energies on the really clever ploy – to sit down
with pharmacists and find a solution. 
Yours, etc, Joanne Hynes MPSI, Cornmarket, Ballinrobe,
Co Mayo. 
There is much confusion regarding the numbers of
pharmacies that have withdrawn from dispensing
medicines under the various State drugs schemes,
with a huge discrepancy between the figures quoted
by the HSE and the Irish Pharmacy Union. This has
arisen from the HSE interpretation of what
constitutes a “valid” 30 days' notice of withdrawal of
service as required under Section 9(8) of the Financial
Emergency Measures in the Public Interest Act 2009. 
The HSE contends that pharmacists who, in letters
sent to the HSE at the beginning of July, used the
expressions “intend to withdraw” or “it is my
intention to withdraw” have not served proper notice.
As a consequence, these pharmacies have been
included in the lists published in the national and
local press and on the HSE website and the HSE has
steadfastly refused to remove these pharmacies from
their lists. 
It seems to me that there are two obvious questions
to be answered by the HSE – if not to serve notice
then for what other reason do they believe these
pharmacies wrote to them in early July, and why,
rather than clarifying the position if they were in
doubt, did they proceed to just include these
pharmacies on their lists published last week? The
upshot of their approach is that in my own county, it
has listed 15 pharmacies as still participating in the
schemes whereas in reality there are only eight. If
this situation is replicated elsewhere in the country,
then frankly the information on their website is
grossly inaccurate. 
I read on your front page on August 3rd about
allegations that staff at the HSE contingency
dispensaries have been intimidated by community
pharmacists. I certainly hope these are not true. For
my own part, as a community pharmacist who has
withdrawn from the State schemes, I have felt
intimidated by the tone and content of letters I have
received from the HSE over these past weeks. I have
yet to receive a formal acknowledgement of my
notice to withdraw and yet I have been threatened
with all forms of repercussions of my actions in their
various “Dear Pharmacy Contractor” letters to me. I
have not received one single letter addressed to me
personally or to my company since the Minister's
announcement on June 18th. 
This dispute will only be resolved by dialogue. The
contingency arrangements in Donegal are
dangerously inadequate. Is the Minister going to wait
until a patient comes to harm before she acts? I
despair of her intransigence. 
Yours, etc, Francis Bonner, MPSI, Main Street, Ballybofey,
Co Donegal.
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Irish Examiner 6 August 2009
The HSE spent tens of thousands of euro last week
publishing lists of pharmacists who would be
dispensing after August 1 and included 60 for
counties Donegal, Mayo and Kerry. The HSE then
spent tens of thousands of euro more setting up
dispensaries in these counties for which, if the list
was true, there would be no need. The HSE published
the list knowing full well the disinformation would
only add to the stress of patients. 
The HSE mandarins may consider this a clever and
cunning ploy to divide pharmacists but it's a pity they
cannot focus their energies on the really clever ploy
— to sit down with pharmacists and find a solution 
Joanne Hynes MPSI, Cornmarket, Ballinrobe Co Mayo
Irish Examiner 12 August 2009
Your editorial (August 8) supports the stance of the
Minister for Health who has implemented cuts to
pharmacists' income far in excess of anything asked
of any other sector — after seven years of refusing to
talk to the representatives of community pharmacy
and after herself being found in breach of contract in
the High Court last year. She implemented these
drastic cuts against the advice of independent
financial consultants who warned her that to do this
would seriously destabilise the community pharmacy
system. You add insult to injury when you go on to
refer to community pharmacists as “sectional
interests who stand between this society and the
possibility of economic recovery”. Community
pharmacies have been one of the few elements of
Ireland's health system that actually works. Typically
open for extended hours, seven days a week, they
provide prompt, efficient service to patients. They
complement the overstretched and under-resourced
urban GP services, providing free advice about minor
ailments. 
Community pharmacists are not merely retailers of
medicines — they provide a professional service
ensuring the prescriptions written for their
customers are correct and appropriate for their
conditions and protecting them from the
unintentional adverse effects of prescribing. 
Poor access for patients, long waiting times, queues
and unpleasant surroundings — the trademarks of
the Irish health service — simply have never existed
in the community pharmacy service. 
The minister's claim that her excessive cuts are
needed in the national financial interest might have
some vestige of respectability had she not already
squandered the entire amount she plans to take from
community pharmacists on pay increases for hospital
consultants. 
Tim Delaney, Gordon Street, Ringsend, Dublin 4
Irish Independent 12 August 2009
I am an angry old retired pharmacist. I am angry
because of the treatment meted out to the pharmacy
profession which has resulted in much suffering to
medical card-holders in some parts of the country.
Despite all the bluster by the HSE, their efforts to
replace the pharmacy service have failed miserably. 
I am angry, too, because of the refusal, up to now, of
the HSE, Mary Harney and the Government to talk to
the Irish Pharmaceutical Union. 
Pharmacists have given an excellent service to
medical card-holders over the years and deserve
better treatment. Pharmacists are prepared to play
their part in the current economic circumstances and
take a cut in their remuneration. Other health
professions saw a cut of 8pc, the cut for the
pharmacists was 34pc (Mary Harney says 24pc). The
minister says she wants to reduce payments to the
pharmacists by EUR133m. 
That is an average of over EUR80,000 per pharmacy
for all 1,660 pharmacists in the scheme. Pharmacists
get no pension, no allowance for premises, no
allowance for equipment (computers etc) and no
allowance for staff. This dispute could be settled by
one phone call, with a reasonable offer that would
avert bankruptcy for vulnerable outlets, and save
jobs. Over to you Mary. 
David Boles, Dublin
Irish Times 4 February 2010
While the recent price reductions of many off-patent
prescription medicines is a move which is widely to
be welcomed, the manner in which it has been done
is not. 
Pharmacists were given 10 days' notice of exactly
which products were to be reduced - 10 days to
dispense everything on their shelves that they had
bought at the previously higher price or dispense it at
a sizeable loss after February 1st. To give one example,
a pack of 30 Zofran 8mg tablets, used for post
chemotherapy nausea and vomiting, cost €208.44
before February 1st. This now costs €125.06 a great
reduction, but what about the pharmacists who had
this product on their shelves before this magical list
was released? They will be dispensing this at a loss.
How many businesses are expected to sell the stock
they paid for at a loss, and one of such magnitude? 
It is a sorry day when pharmacists will have to make
the decision either not to regularly keep items such
as this in stock or to risk having the carpet pulled
from under their feet again. What is the point in
pharmacies opening late to facilitate people who are
working, or who have just been discharged from
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hospital in need of vital medicine, when they cannot
afford to risk keeping any stock? 
Another point which seems to have been missed by
the mainstream media is that the prices on the list
are the prices the wholesaler buys the drugs from the
manufacturer. The wholesaler then adds its mark-up
before selling them to the pharmacist. To say the list
is misleading is putting it mildly. 
Yours, etc, Stella Hancock MPSI, Rockfield Green,
Maynooth, Co Kildare.
Irish Examiner 11 February 2010
While I'm delighted to hear the price of some
medicines is coming down, this is meaningless to
many patients who now have to pay more for their
medicines each month because of the new taxes and
charges brought in by the Minister for Health. The
Minister has increased the monthly threshold on the
Drugs Payment Scheme to a hefty €120. A person or
family whose medicines cost more than €100 last
year, now have to cough up an extra €20 a month or
€240 a year. 
Medical card holders won't benefit either. Before
medical card holders got their medicines without a
charge, they will now have to pay a new prescription
tax — up to €10 a month. The new deal agreed
between the pharmaceutical manufacturers only
applies to approximately 300 medicines out of the
thousands of medicines on the Irish market. 
The manufacturers are still charging top prices for
the majority of medicines. The new deal is not a good
deal for the Irish public. 
Liam Butler, Butler's Pharmacy, Main St, Birr, Co Offaly
Irish Examiner 15 February 2010
While I'm delighted to see that the price of some
medicines is coming down, this is meaningless to
many patients who now have to pay more for their
medicines each month because of the new taxes and
charges brought in by Health Minister Mary Harney.
She has increased the monthly threshold on the
Drugs Payments Scheme to a hefty €120. A person or
family whose medicines cost more than €100 last
year, now need to stump up an extra €20 a month or
€240 a year. Medical card holders won't benefit
either. Before medical card holders got their
medicines without a charge, now they will now have
to pay a new prescription tax which will be up to €10
a month. 
The so-called savings will be largely illusions 
and transient. 
The manufacturers are still charging top prices for
the majority of medicines. 
Jack Shanahan, Pharmacist, Church St, Castleisland, 
Co Kerry
Irish Independent 16 February 2010
Health Minister Mary Harney and the pharmaceutical
manufacturers are patting themselves on the back
for reducing the price of 30pc of the medicines on
the Irish market. However, the taxpayer and the
public are still paying over the odds for 70pc of our
medicines. To make matters worse, 1.5 million medical
card holders will soon have to pay up to €10 a month
for their medicines, due to the new prescription levy. 
Also, the minister has hiked the threshold on the
Drugs Payment Scheme by 20pc, so any person or
family will now have to pay an extra €240 a year if
their monthly medicines bill reaches this threshold. 
The majority of patients in this country will actually
have to pay more for their medicines than they did
last year. 
Rory O'Donnell, Derrybeg, Co Donegal
